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Early development in humans occur in an environment of low oxygen. During the 
first trimester, maternal blood flow into the placenta is blocked by trophoblastic 
plugs; a phase we term ‘pre-flow’. Placental perfusion only  begins upon the removal 
of these plugs, between 10 to 12 weeks of gestation. The sudden presence of blood at 
the end of the first trimester (i.e. post-flow) brings with it oxygenation, drastically 
modifying the uterine environment.
We identified EPAS1 (also known as HIF2α), a transcription factor responding in low 
oxygen and which has been implicated in placental development and function, to be 
pivotal to the placental response to the changing oxygen conditions of its 
environment. Moreover, the EPAS1 gene recently emerged as the gene with the 
strongest signal of natural selection. A SNP was found in native Tibetan highlanders, 
a geographically-isolated population that has survived generations at reduced oxygen 
levels, which appeared to confer not only survivability, but also reproductive fitness. 
Given the rapid enrichment of this particular allele,, we reasoned that natural 
selection could likely be acting in utero, and that EPAS1 was not only instrumental in 
placental development, but that this SNP also effected a profound change in its role.
Using a hESC-derived trophoblast culture maintained at 3% oxygen, I took a three-
pronged approach to this study. I first characterized the SNP found in Tibetan people, 
assessing the impact of a nucleotide change in its position. Molecular analysis of 
EPAS1 transcripts uncovered two cryptic splice sites in close proximity to the SNP. 
Utilization of either cryptic splice site would lead to modification of the adjacent 
exon, likely resulting in attenuation of EPAS1 activity.
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Through ChIP-Seq and preliminary  analysis, I identified 35 potential EPAS1 targets. 
Twelve were found by  global microarray analysis to be upregulated under hypoxia in 
vitro, while eight were confirmed through gene expression analysis of human 
placental samples. From our findings, seven genes had previously been identified as 
HIF targets in a different cell type, including EGFR and ELF3. Strikingly, FLT1 and 
LEP, two genes frequently implicated in preeclampsia were also associated with our 
results. Preeclampsia, a condition of the placenta characterized by  inadequate 
perfusion of the tissue, which likely  leads to dysregulation of oxygen-sensitive gene 
expression, while intensively  studied, remains largely  not well understood. Given the 
oxygen-sensitive nature of EPAS1 and its capacity  in mediating gene expression in 
the trophoblast, there is a likely  role for EPAS1 in the gene dysregulation that occurs 
in preeclampsia. 
Analysis of human placental samples were achieved through RNA-Seq, and by 
comparison between pre-flow and post-flow gene expression. Through this analysis, I 
was additionally  able to explore the global transcriptomic landscape of the early 
placenta, and contrast changes in gene expression across the changing uterine 
environment. Our analysis demonstrated the potential to identify  biological processes 
activated upon placental perfusion, as well as to further our understanding of the 
influence of this developmental milestone on pregnancy outcomes.
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1.1. Understanding placental development in humans.
The fertilized egg, otherwise known as the zygote, undergoes numerous asymmetric 
cell divisions before implantation in the mother’s uterus, during a phase known as 
preimplantation. The zygote forms a spherical structure, the blastocyst, comprising 
two distinct cell populations - the inner cell mass (ICM), and the trophectoderm (TE). 
The TE is the precursor to the placenta, the formation of which marks the first 
differentiation event that takes place in the embryo (Tarkowski and Wroblewska, 
1967; Johnson and Ziomek, 1981; Arnold and Robertson, 2009; Rossant and Tam, 
2009). The TE develops into the extraembryonic tissue which supports the growth 
and development of the embryo, while cells in the ICM give rise to the embryo 
proper. 
Much of what is understood about early  human development is inferred from studies 
in model mammals, primarily  the mouse. Very little has been observed in the first 
weeks of embryonic development in humans; given the limitations of accessing 
human material, very few specimens have been studied and documented. In some 
cases, information about a particular stage of development originates from a single 
specimen (Boyd and Hamilton, 1960). Relevance of information gleaned from animal 
studies remains unclear since cellular interactions that mediate implantation and 
development of the placenta vary  greatly  even amongst primates (Martin, 2008). 
Nevertheless, comparing across species may  be a helpful beginning to elucidating the 
early stages of human embryo development, implantation, as well as placental 
development. 
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1.1.1. From zygote to blastocyst.
Fertilization of the human oocyte takes place in the oviduct, adjacent to the ovary 
(Fig. 1.1). The zygote then makes its way to the uterus, over a period of five to seven 
days. During this time, the zygote divides continuously, with the first cleavage giving 
rise to two identical cells. Upon reaching the 8-cell stage, the early  embryo begins to 
compact, and cells come together in a tight array interconnected by gap junctions. By 
the 16-cell stage, the compacted embryo, now known as the morula, sees the first 
segregation of cells along the basolateral cleavage plane, with smaller inner cells 
forming the ICM, and larger outer epithelial cells forming the TE. The ICM  will 
eventually give rise to all the tissues of the embryo’s body, as well as to the non-
trophoblastic extraembryonic tissues, such as the yolk sac, allantois, and amnion, all 
of which support and protect  the developing embryo throughout gestation. The TE on 
the other hand, will generate the trophoblast cells of the chorion, its contribution to 
the embryo’s extraembryonic tissue, ultimately forming the placenta (Sutherland et 
al., 1990; Gilbert, 2000).
The cell segregation observed in the morula is accompanied by  the formation of a 
fluid-filled cavity called the blastocoel, filled with fluid secreted by  TE cells. As a 
result of cavitation and the accompanying physical separation of the ICM from the 
TE, the morula now becomes a blastocyst, characterized by an outer sphere of 
flattened TE cells around a cluster of small round cells of the ICM  in the fluid-filled 
blastocoel (Gilbert, 2000). The ICM is positioned asymmetrically within the 
blastocoel, attached to TE cells at one end. The outermost layer of cells of the ICM 
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that face the blastocoel is known as the hypoblast, and the remainder of the ICM  is 
known as the epiblast. 
This segregation is followed by the next differentiation event, in which the hypoblast 
form the beginnings of the extraembryonic endoderm, later developing into the outer 
layer of the yolk sac tissue. The epiblast meanwhile harbors pluripotent stem cells, 
which will give rise to the embryo proper (Gilbert, 2000). By definition, pluripotent 
stem cells are self-renewing, and have the ability to generate all three primary  germ 
layers (Evans and Kaufman, 1981; Martin, 1981). 
At this point, three differentiated cell types exist in the embryo - the trophoblast, 
epiblast, and hypoblast, also known as the primitive endoderm (PE). By this time, the 
preimplantation blastocyst  is ready to implant in the uterine wall. During the next 
major phase of development known as gastrulation, the epiblast will give rise to the 
three primary germ layers - the endoderm, or the innermost layer that gives rise to the 
epithelial lining of, for example, the gastrointestinal and respiratory tract; the 
mesoderm, which gives rise to muscles; and the ectoderm, the outermost layer that 
forms the skin and the nervous system.
Human embryonic stem cells.
The pluripotent stem cells harbored within the ICM can and have been, as technology 
has allowed us, harvested for laboratory use. These cells, now known as human 
embryonic stem cells (hESCs), were derived from donated human embryos that had 
been produced by in vitro fertilization (IVF) for clinical purposes (Thomson et al., 
1998). hESCs are self-renewing and have the potential to be expanded limitlessly in 
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vitro. Their innate ability to bear all three germ layers has been replicated both in 
vitro, via directed differentiation or embryoid body formation (Itskovitz-Eldor et al., 
2000), and in vivo, as evidenced by the formation of teratomas in immunodeficient 
mice (Thomson et al., 1998; Stojkovic et al., 2004). They also have the capacity  to 
give rise to germ cells, extra-embryonic tissue, and trophoblast  cells, as demonstrated 
by previous studies (Xu et al., 2002; Hyslop et al., 2005; Babaie et al., 2007). 
In hESCs, the transforming growth factor β (TGFβ) superfamily  signaling plays a 
prominent role in the early cell fate decisions of embryonic development. hESC 
pluripotency  is maintained via the TGFβ or Activin/Nodal signaling pathways, as well 
as the fibroblast growth factor 2 (FGF2)-mediated pathways (Vallier et al., 2004; 
Beattie et al., 2005; Vallier et al., 2005; James et al., 2005; Greber et al., 2007; Greber 
et al., 2008). Both TGFβ and FGF signals synergize to inhibit bone morphogenetic 
protein (BMP) signaling, sustain expression of pluripotency-associated genes such as 
NANOG, OCT4, and SOX2, and promote long-term undifferentiated proliferation of 
hESCs (Xu et al., 2008).
The early trophoblasts; progenitor to the placenta.
Trophoblast or TE formation represents the very first differentiation event and lineage 
restriction that a sub-population of the totipotent cells of the early embryo undergoes. 
The TE gives rise to two main cell types - the cytotrophoblast and the 
syncytiotrophoblast. Cytotrophoblast cells make up the inner layer, and give rise to 
the outer layer of the implanting blastocyst, known as the primitive syncytium, which 
is made up  of multinucleated syncytiotrophoblasts. The primitive syncytium appears 
to secrete enzymes that digest the lining of the maternal endometrium (Fisher et al., 
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1989), allowing expansion of the primitive syncytium into the resultant fluid-filled 
spaces, or lacunae. Processes of the primitive syncytium, referred to as trabeculae, 
advance into the lacunae and as they do so expand the lacunae, which may  go on to 
breach maternal sinusoids (Boyd and Hamilton, 1970; Hertig et al., 1956; Enders, 
1989; Herzog, 1909). 
The trophoblast  cells go on to form the extraembryonic membrane called the chorion, 
ultimately  developing into a large part of the placenta, which is crucial for healthy 
fetal development and protection. Placental development is therefore primarily 
dependent on trophoblast stem cell differentiation (Jurisicova et al., 2005).
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Figure 1.1. Development of the human embryo. The formation of the human embryo 
begins with fertilization in the oviduct. The zygote divides continuously, and at the 8-cell 
stage, the early embryo begins to compact. The first segregation of cells occurs at the 16-cell 
stage, along the basolateral cleavage plane. The smaller inner cells give rise to the inner cell 
mass, and the larger outer epithelial cells form a layer known as the trophectoderm.
© Terese Winslow, 2001. 
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1.1.2. Extraembryonic membranes and the placenta.
While the embryonic epiblast is undergoing gastrulation to form the early  fetal 
structures, the extraembryonic cells proceed to form the distinctly mammalian tissues 
that enable the fetus to survive within the maternal uterus. There are four 
extraembryonic membranes associated with fetal development, namely the amnion, 
allantois, yolk sac, and chorion. The amnion and allantois arise from the epiblast, the 
yolk sac is derived from the PE, and the chorion is formed from the TE (Gilbert, 
2000). 
The amnion is the innermost membranous sac enclosing the embryo. The thin 
amniotic membrane comprises a single layer of extraembryonic ectodermal cells 
lined by a non-vascularized layer of extraembryonic mesoderm. The amniotic 
membrane surrounds the body of the embryo, creating a fluid-filled cavity known as 
the amniotic sac, in which the fetus is suspended for the duration of the pregnancy 
(Fig. 1.2). The amniotic sac not only serves as a buffer against  mechanical injury to 
the fetus, it also accommodates growth and allows fetal movement. Generally, 
amniotic fluid is thought  to be a dilute transudate of maternal plasma, but the origins 
and exchange dynamics of amniotic fluid are complex and not completely understood 
(Carlson, 2007). While the amniotic membrane itself secretes fluids, components of 
maternal serum are also able to pass through the amniotic membrane. As pregnancy 
advances, there are increasing contributions from fetal urine, filtration from maternal 
blood vessels, and possibly filtration from fetal vessels in the umbilical cord and 
chorionic plate. 
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Anatomically, while the amnion appears dorsal to the embryonic disk, which later 
gives rise to the organs and body of the fetus, the yolk sac is formed ventral to the 
embryo. A narrow stalk connects the yolk sac to the forming embryonic gut. As 
pregnancy progresses, the yolk stalk becomes very long and attenuated as it is 
incorporated into the body  of the umbilical cord, while the yolk sac itself moves 
nearer the chorionic plate of the placenta (Fig. 1.2).
The allantois is also embedded in the umbilical cord. The mesodermal wall of the 
allantois gives rise to the blood vessels that form the umbilical circulatory  arc, 
consisting of the arteries and veins that supply the chorion, or placenta. Later in 
development, the proximal part of the allantois becomes continuous with the forming 
urinary bladder.
The chorion too is connected to the embryo via the umbilical cord. It  is the outermost 
protective membrane encapsulating the fetus, and harbors the trophoblast cells. These 
trophoblast cells eventually give rise to numerous, small, finger-like extensions called 
villi that penetrate deeply into the uterine tissue. Although the entire surface of the 
chorion is initially covered by villi, the villi across the cavity  from the embryonic 
pole gradually degenerate, producing the smooth chorion (chorion laeve; Fig. 1.2). At 
the embryonic pole meanwhile, the villi increase in number and branch, forming the 
villous chorion (chorion frondosum), which becomes highly  vascular. As described 
earlier, the fetal vascular compartment that comes in contact with the chorion arises 
from the allantois, and during the course of development, blood vessels grow out of 
the allantois into the chorion.
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It is the chorionic villi which brings maternal and fetal blood into proximity, allowing 
the exchange of nutrients and waste between mother and fetus, yet preventing 
maternal and fetal blood from mixing. Thus, the chorion frondosum ultimately makes 
up the principal embryonic part of the placenta, the structure through which materials 
are exchanged between mother and fetus.
The placenta is the extraembryonic tissue essential for healthy development of the 
fetus during gestation; its malformation can trigger a spontaneous abortion (Trounson 
et al., 2000). The placenta anchors the developing embryo to the uterine wall, and is 
not only responsible for delivering oxygen and nutrition from the mother, but also to 
secrete hormones supporting fetal growth in the uterus, and to produce regulators of 
immune response that prevent rejection of the fetus.
The placenta is a vascular structure with feto-maternal compartments; the chorionic 
villi is fetal, and the maternal portion consists of the area of the endometrium called 
the decidua basalis, into which the villi penetrate. Implantation of the developing 
blastocyst in the maternal endometrium signifies the beginning of the formation of 
the placenta, requiring a cooperative effort between the extraembryonic tissues of the 
embryo and the endometrial tissues of the mother. While the placenta is 
morphologically established early  on, maternal blood supply to the placenta does not 
start until the end of the first trimester of pregnancy  (at approximately  12 to 13 
weeks). As a result, the placenta forms and exists in an environment that is low in 
oxygen during the first trimester. Throughout the rest of pregnancy, the placenta 
continues to grow to keep up with the demands of the developing fetus.
10
Figure 1.2. Development of the extraembryonic membranes during early  pregnancy. 
(A) The amnion appears dorsal to the embryo, while the yolk sac is formed ventral to the 
embryo. The trophoblast forms the beginnings of the chorion. (B) The trophoblasts give rise 
to villi. (C) The villi at the embryonic pole increase in number and branch. (D) The villi across 
from the embryonic pole atrophy, producing the smooth chorion, or chorion laeve. The 
chorion frondosum, or placental villi, make up the embryonic portion of the placenta. (E) As 
pregnancy progresses, the yolk stalk becomes very long and attenuated, while the yolk sac 
moves nearer the chorion. The yolk stalk becomes embedded in the umbilical cord. The fetal 
blood vessels grow out of the allantois, and is carried through the umbilical cord, to supply 
the chorion. 
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1.1.3. Implantation and placentation.
Approximately  one week after fertilization, trophoblasts participate in a complex 
dialogue with maternal cells that enables implantation, a process that quickly 
sequesters the human embryo within the uterine wall. This begins with a phase 
known as apposition, where the blastocyst adheres to the uterine epithelium via TE 
cells (termed “polar”) that  are immediately  adjacent to the ICM at the embryonic pole 
of the blastocyst (Fig. 1.3A; Hertig et  al., 1959). These “polar” cells comprise 
approximately one-third of the TE just prior to implantation, and are morphologically 
different from the remainder of the TE distal to the ICM (termed “mural” 
trophectoderm; Herzog, 1909). The polar TE cells, in the first  hours of implantation, 
proliferate and invade, whereas mural TE cells do not (Fig. 1.3B; Enders, 1976).
In the following hours, the trophoblastic cells proliferate to form a double layer, as 
they  progressively  invade the endometrial epithelium. The inner layer consists of 
cytotrophoblasts, while the outer layer, in contact with maternal tissue, comprises of 
the syncytiotrophoblast, supported by proliferation and fusion of underlying 
cytotrophoblasts. The syncytiotrophoblast is a continuous system, not interrupted by 
intercellular spaces, that  forms branching, finger-like extensions which deeply invade 
the endometrium. Micro-protrusions from the apical surface of the uterine epithelium, 
known as pinopodes, inter-digitate with microvilli on the apical surface of the 
syncytiotrophoblast (Lopata et al., 2002). This first stage, lasting from day 7 to day 8 
post-fertilization, is defined as the prelacunar period (Enders, 1989). 
The next stage is the lacunar or pre-villous stage, characterized by the formation of 
connected syncytial trophoblast-lined lacunae. Small vacuoles appear within the 
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syncytiotrophoblastic mass, and enlarge rapidly, becoming confluent and forming a 
system of lacunae. The separating lamellae and pillars of syncytiotrophoblast are 
called the trabeculae. This stage lasts from day 8 to day 13 post-fertilization (Fig, 
1.3C and D). Meanwhile, by day 12, the blastocyst becomes completely  embedded as 
the uterine epithelium regrows to cover the site of implantation (Hertig et al., 1956).
At about the same time, the cytotrophoblasts beneath the syncytial layer proliferate 
and stream out of the trophoblast layer (Fig. 1.3C; Pijnenborg et al., 1981a). They 
appear as trophoblast cell columns penetrating through the trabeculae, reaching the 
tip, where they extend through the syncytiotrophoblast  and spread laterally, 
coalescing to form a cytrotrophoblastic shell layer, between the syncytium and the 
endometrium. 
The cytotrophoblast cell columns grow into the lacunae, marking the initiation of the 
early villous stage. The cell columns then begin to branch, representing primary  villi, 
which are composed of a cytotrophoblast core with a covering of syncytiotrophoblast. 
Their presence marks the beginning of the villous stages of placentation. Further 
proliferative activity, with branching of the primary  villi, initiates the development of 
primitive villous trees. By the third week of gestation, these villi contain fetal blood 
vessels and occasional macrophages surrounding a core of mesenchymal connective 
tissue (Hertig, 1968).
Villi that maintain contact with the trophoblastic shell are known as anchoring villi. 
Meanwhile, the lacunar system transforms into the intervillous space. 
Cytotrophoblasts at the base of the anchoring villi proliferate outwards from the 
underlying basement membrane, creating the path of migration into the uterine 
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epithelium and ultimately invasion of the maternal spiral arteries. Migrating 
cytotrophoblasts are referred to as extravillous trophoblasts (EVTs). Those that 
infiltrate the entire endometrium and inner third of the myometrium, through a 
process termed interstitial invasion, are known as interstitial EVTs. Endovascular 
trophoblasts are EVTs that penetrate the uterine vasculature, in a process known as 
endovascular invasion (Pijnenborg et al., 1981a; 1981b). 
Endovascular invasion places trophoblasts in direct contact with maternal blood, 
establishing utero-placental circulation. While the basic structure of the definitive 
placenta is complete by the fourth week of gestation, communication with the 
terminal branches of the spiral arteries have not yet been established, and maternal 
blood remains excluded from the intervillous space (Boyd and Hamilton, 1970). At 
eight-weeks gestation, direct channels connecting the maternal spiral arteries with the 
intervillous space are observed, but the path of blood flow remains blocked by 
trophoblast plugs that occlude the spiral arteries (Hustin and Schaaps, 1987; Burton et 
al., 1999). Full blood flow into the intervillous space only takes place upon the 
removal of the plugs, between 10 to 12 weeks of gestation (Hustin and Schaaps, 
1987; Jauniaux et  al., 1992; Jauniaux et al., 1995; Jaffe et al., 1997; Burton et al., 
1999). 
Therefore, during the first trimester, the placenta forms and develops in a low oxygen 
environment. At this time, the conceptus (or the early embryo), is also undergoing 
growth and organogenesis, and therefore derives its required nutrition from secretions 
of the uterine glands, in what is known as histiotrophic nutrition (Burton et al., 2002). 
When the trophoblastic plugs are broken down, the sudden presence of blood 
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drastically modifies the uterine environment; the blood brings with it oxygenation, as 
well as hemotrophic nutrition, which is the exchange of blood-borne materials 
between the maternal and fetal circulations (Wooding and Flint, 1994).
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Figure 1.3. Progression of implantation and invasion of the endometrial lining by 
trophoblasts. Images are from the Carnegie embryo collection hosted by The Virtual Human 
Embryo Project (http://www.ehd.org/virtual-human-embryo/). 
A-B) Sections of a rhesus monkey (Macaca mulatta) embryo (specimen #C 610) initiating 
implantation at Carnegie Stage 4. 
C-D) Sections through human embryos at Carnegie Stage 5a-1 (Panel C: Carnegie embryo 
#8020) and Carnegie Stage 5b  (Panel D: Carnegie embryo #8004) representing 
approximately 0.5 and 2.0 days post-implantation, respectively.
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1.1.4. Molecular basis of trophoblast formation.
Pre-implantation development encompasses a series of important developmental 
events, beginning with fertilization of the oocyte and ending with the formation of the 
blastocyst. The specification of the TE and ICM lineages during blastocyst formation 
represents the first developmental decision during human embryo development, 
paving the way for all subsequent developmental events. The earliest stages of 
trophoblast differentiation are critical for mediating implantation and fostering 
normal placental growth and function during gestation. Moreover, there is growing 
evidence that aberrant trophoblast development is associated with serious pregnancy 
complications, including recurrent miscarriages, preeclampsia, and restricted fetal 
growth. Therefore, a comprehensive understanding of pre-implantation development 
is fundamental.
In the mouse, identification of the determinants of trophoblast  cell fate mainly  stem 
from the analysis of targeted mutations (Rossant and Cross, 2001; Senner and 
Hemberger, 2010). The initiation of TE development in mouse begins with Tead4, 
which controls expression of Cdx2, Eomes, and Tcfap2c. Further downstream, other 
transcription factors essential to normal TE development include Gata3, Elf5 and 
Ets2. However, the relevance of these findings to human TE development are limited. 
The similarities between mouse and human TE development end at the mutually 
exclusive expression of key transcription factors in ICM  (OCT4, SOX2, and NANOG) 
and TE (CDX2; Kimber et al., 2008). 
The molecular basis of human pre-implantation is not well known, owing to a 
scarcity of material, as well as ethical and legal limitations. Most available 
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knowledge is based on mouse (Hamatani et al., 2004; Wang et al., 2004) or bovine 
(Ushizawa et al., 2004; Mamo et al., 2006), and limited data coming from non-human 
primates. Previously, characterization of early pre/post-implantation developmental 
stages of the human placental trophoblast lineage were mainly based on 
morphological studies (Hertig et al., 1956; Enders, 1989). Recently  however, 
technological advances have permitted the exploration of global gene expression 
profiles from limited amounts of material, leading to renewed interest and 
exponential growth of information within the field (Zhang et al., 2009; Vassena et al., 
2011; Bai et al., 2012). 
Generally, pre-implantation development consists of two main phases, governed by 
either maternal or embryonic genes (Zhang et al., 2009; Vassena et al., 2011). The 
timing of the switch from maternal to embryonic gene expression remains unclear. 
Vassena et al. (2011) demonstrated the first  wave of transcriptional activation of the 
embryonic genome at the 2-cell stage, while Zhang et al. (2009) reported expression 
of mainly  maternal genes up to the 4-cell stage, and from 8-cell embryo to blastocyst, 
maternal genes are downregulated while embryonic genes are upregulated. 
The trophoblast  cell lineage is specified early in the blastocyst stage, leading to the 
emergence of the TE surrounding the ICM. Expression microarray analysis of 
mechanically dissected human TE samples revealed a core transcriptional regulatory 
circuitry  of 13 tightly interconnected transcription factors that are expressed during 
TE development, and maintained later in mature placenta (Bai et al., 2012). These 
include CEBPA, GATA2, GATA3, GCM1, KLF5, MAFK, MSX2, MXD1, PPARD, 
PPARG, PPP1R13L, TFAP2C and TP63. The expression profile of these factors 
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suggests a critical role in not only establishing, but  also maintaining the trophoblast 
lineage. 
Moreover, some of these transcription factors have already been reported to be 
important for trophoblast differentiation or placenta formation. For instance, GCM1 is 
a known placenta-specific transcription factor, responsible for inducing ERVWE1 
expression in trophoblast, which cause cell fusion and contribute to the formation of 
the syncytium (Yamada et al., 2000; Rawn and Cross, 2008; Black et  al., 2010). 
GATA2 and GATA3 are known to be expressed in mouse trophoblast, and in placenta, 
for regulation of placenta-specific genes (Ma et al., 1997). In the mouse, GATA3 is 
selectively expressed in the TE of peri-implantation embryo and directly regulates 
expression of trophoblast transcription factor, CDX2 (Home et al., 2009). PPARG, a 
nuclear hormone receptor implicated in the differentiation of various cell types, is 
essential for trophoblast and placental differentiation in mice, as evidenced by 
embryonic lethality in PPARG-null mice, due to defects in these tissues (Barak et al., 
1999). 
Bai et  al. (2012) also demonstrated the TE-associated expression of genes known for 
their role in placenta, namely CGA, PGF, ALPPL2, and ABCG2. An earlier study had 
also confirmed the upregulation of TE-associated genes CDX2 and GATA2, as well as 
pregnancy-associated hormone human chorionic gonadotropin (hCG; encoded by 
genes CGA and CGB) in human blastocysts (Kimber et al., 2008). Studies of human 
embryonic stem cell differentiation also demonstrate that BMP4, GATA2, GCM1 and 
ID2, as well as deficiencies in the polycomb group protein L3MBTL1, are all 
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associated with differentiation into a TE phenotype (Schulz et al., 2008; Hoya-Arias 
et al., 2011). 
Trophoblast invasion and migration, along with formation of the corresponding 
trophoblast cell subtype, are likely  controlled by components of the trophoblast itself 
as well as exogenously by the maternal microenvironment, through molecular and 
cellular interactions. Despite these advances in understanding the genetic regulation 
of the TE lineage, the exogenous regulation of this differentiation process has not 
been well defined. Studies from the mouse have identified a number of exogenous 
factors with the potential to regulate TE lineage formation. Collagen IV has been 
shown to induce TE differentiation from mouse embryonic stem cells, which can be 
further increased by stimulation with basic fibroblast growth factor (bFGF) or FGF4 
(Schenke-Layland et al., 2007). In humans, numerous factors in the extracellular 
microenvironment are thought to be capable of directing TE differentiation, such as 
soluble factors - TGF, platelet derived growth factor (PDGF), leukemia inhibitory 
factor (LIF), macrophage colony stimulating factor (M-CSF), and the chemokines 
CX3CL1, CCL8, and CCL14. Environmental factors include cell–cell contacts, 
extracellular matrix (ECM) composition, oxygen tension, as well as other 
environmental stressors (Suzuki et al., 1999; Hannan and Salamonsen, 2008; 
Dimitriadis et  al., 2010). Indeed, many of these factors have been demonstrated to 
play  an important role in trophoblast differentiation later in the first trimester of 
human pregnancy (Bischof et al., 2000).
Whilst the knowledge of the events underlying cell fate determination in the human 
blastocyst is limited compared to the corresponding events in mouse implantation, 
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even less is known about the events that occur after the initial commitment to the TE. 
Trophoblast lineage formation in the mouse has been mapped from TE to placenta, 
due in large part to the readily available blastocysts and trophoblast stem cells. 
However, this information gleaned from mouse is not entirely  transferable to humans 
as the labyrinthine structure of the murine placenta is quite unlike the villous 
structure of the human placenta. Additionally, maternal exchange in mouse occurs 
across three trophoblast layers, as opposed to the single syncytiotrophoblast layer in 
humans (Carter, 2007).
It is evident that there is much yet to be understood about human implantation during 
early development. The time between formation of the blastocyst and formation of 
the placenta still remains largely unknown given the limitations of accessing material 
for study. The progression of human trophoblast cell types, arising from TE during 
the earliest  days of pregnancy, to the mature trophoblast cell types that constitute the 
placenta and exist throughout pregnancy still remain largely  a “black box” in our 
understanding of early development in humans. Unlike the blastocyst itself, which is 
usually  received from IVF clinics as donations to research, the development of the 
trophoblast and its lineages that follow is mandated by its biological environment and 
ability  to invade and migrate into the uterine epithelium. Moreover, in the earliest 
weeks that follow conception, most women are barely  even aware of the forming 
blastocyst and their pregnancy. As a result, the earliest  that human trophoblast cells 
are normally accessed is at six weeks post-conception. To that end, much work has 
been focused on identifying human trophoblast cell types, and growing these cells in 
the laboratory, in order to understand the development of the placenta.
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1.1.5. Identifying trophoblast cell types.
The human TE differentiates to give rise to the main cell lineages of the villous 
placenta - the cytotrophoblast, syncytiotrophoblast and extravillous trophoblast (EVT; 
Fig. 1.4). As ongoing studies pursue the understanding of how these lineages develop, 
what factors stimulate and regulate this differentiation, as well as when differentiation 
occurs, studies to date have been able to isolate trophoblast cell populations and 
provide markers that identify the trophoblast cell subtypes. 
The human trophoblast stem cell (hTSC) however remains elusive, and hence so does 
its understanding and characterization. Isolation and characterization of the hTSC 
will not only expound the differentiation of the human trophectoderm into 
trophoblast, but will also enable the generation of differentiated trophoblast 
populations in vitro; thereby  allowing a more accurate and detailed study into what 
separates one trophoblast population from another (Hyman and Simons, 2011). On 
the other hand, the stem cell population of the TE lineage has been isolated from 
mouse blastocysts and maintained in vitro in the presence of FGF4, heparin and a 
feeder layer of mouse embryonic fibroblast cells (Tanaka et  al., 1998). These cells are 
found to be immortal in culture and have the potential to differentiate into multiple 
mouse trophoblast cell lineages. However, whilst hESCs can be differentiated to TE 
(see 1.1.6. Modeling human placentation), to date, efforts to isolate true hTSCs from 
human embryos have not yielded an in vitro trophoblast stem cell line comparable to 
those from mice, likely due to differing growth factor requirements and regulatory 
pathways (Douglas et al., 2009).
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While cytotrophoblasts undergo self-renewal and have the potential to differentiate 
down one of two mutually  exclusive differentiation pathways, either the non-invasive 
villous syncytiotrophoblast or the invasive extravillous cytotrophoblast (EVT), they 
are not considered to be the true hTSC. Previous studies have suggested that by  the 
eighth week of gestation, cytotrophoblasts are divided into subpopulations that may 
be committed to differentiation into either the syncytiotrophoblast or the EVT 
(Aboagye-Mathiesen et al., 1996; James et al., 2005; James et al., 2007). This pre-
commitment thus casts a doubt on their previously recognized bi-potent character. 
Nevertheless, cytotrophoblasts have been recognized as specialized cells that actively 
invade the uterus, forming the infrastructure that anchors the conceptus to the 
maternal endometrium and taps the supply of maternal blood. This requires the 
cytotrophoblast to assume highly specialized characteristics; some commonly 
associated with tumor cells, while others are typical of endothelial cells. Expression 
at the mRNA level revealed upregulated levels of EPAS1, a gene primarily expressed 
in endothelial cells and functions in adaptive responses to hypoxia such as in cancer 
(Janatpour et al., 1999).
Interestingly, the isolation of trophoblasts with stem cell-like properties from first 
trimester placentae has been recently reported (Spitalieri et al., 2009; Genbacev et al., 
2011). Spitalieri et al. (2009) claimed to have identified a sub-population of 
cytotrophoblasts in chorionic villus samples that expressed typical stem cell markers, 
and were capable of differentiating into multiple lineages in vitro as well as in vivo. 
OCT4, SSEA4, and alkaline phosphatase, all of which are indicators for pluripotency, 
were expressed in approximately  20% of the cytotrophoblast population, with 
NANOG and SOX2 expression observed in a further subset of these cells. However, 
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the cells isolated in this study could be induced to differentiate into cells with features 
of neuronal, myogenic or pancreatic cells, suggesting they were not true trophoblast 
stem cells. 
In a separate study, Genbacev et al. (2011) identified human trophoblast progenitors 
that predominantly  reside in the chorion of first trimester placenta. In isolated 
colonies, a proportion of these cells expressed markers of trophoblast progenitor cells 
- cytokeratin 7 (CK7), OCT4, tight junction protein ZO-1, and GATA4. Away from 
the original attachment site, these cells expressed markers of trophoblast 
differentiation, like GCM1 (syncytiotrophoblast) and HLA-G (EVT). Single cell 
suspensions isolated from these colonies lost polarity, and did not differentiate in 
culture, suggesting that pure populations of trophoblast progenitors had been isolated. 
These progenitor cells could also be induced to differentiate into cytotrophoblast and 
syncytiotrophoblast lineages, suggesting they could indeed be true trophoblast stem 
cells. However, in order to confirm that these cells are true trophoblast stem cells, it 
would be useful to further characterize for common markers of stem cells, as well as 
those for human trophectoderm and the human equivalents to markers of mouse 
trophoblast stem cells (James et al., 2012).
From second trimester onwards, villous trophoblasts are in contact with maternal 
blood, and mediates nutrient exchange, while EVTs are responsible for invasion of 
the decidua and remodeling of the uterine arteries. In an earlier study which co-
related trophoblast cell type with ability to invade (villous trophoblasts with poor 
invasiveness, and EVTs with high invasiveness), microarray  analysis yielded 991 
invasion/migration related transcripts (Bilban et al., 2009). EVTs were found to be 
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significantly enriched in pathways regulating ECM  synthesis and remodeling, cell 
adhesion, as well as carbohydrate metabolism. Several genes involved in 
physiological and pathological cell invasion, including A disintegrin and 
metalloprotease-12, -19, -28, as well as spondin-2, were upregulated in EVTs. EVTs 
also demonstrated enhanced expression of several collagen or laminin isoforms, the 
predominant matrix proteins in the endometrium (Das et al., 2002), as well as several 
i soforms of lac ta te dehydrogenase , a ldehyde dehydrogenase , and 
phosphofructokinase, all of which are enzymes regulating carbohydrate metabolism. 
Altogether, these observations suggest that EVTs may secrete substrates relevant to 
cell invasion as well as their degrading enzymes.
Additionally, in a more recent whole genome microarray  study examining 
transcriptional changes associated with differentiation from villous to EVT (Apps et 
al., 2011), EVTs were found to be associated with genes involved in migration (ECM 
proteases such as PAPPA, ADAM-19, laeverin, TIMP2, and SERPINE2), immune 
modulation (HLA-G, TAP1 and -2, CFB, PVR), and cytokine or angiogenic factor 
secretion (CTGF, PGF, FGF1, GKN1, VGF, and CXCL16, and its receptor CXCR6). 
Cytokine/chemokine receptors such as CCR1, IL1R2, IL1RAP, IL2RB, ACVRL1 and 
ACVR1B are all increased, suggesting EVT acquires an enhanced ability to respond to 
the wide range of cytokines secreted in the decidua. Adhesion molecules regulating 
cell migration were also upregulated, including integrins α-1, -2 and -5, as well as 
ESAM, and JAM2, both of which are involved in regulating the adhesion of 
leukocytes to endothelium. Their up-regulation by EVT suggests trophoblast may 
utilize these molecules to interact  with decidual leukocytes during invasion 
(Wegmann et al., 2006).
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Meanwhile, villous trophoblasts (or cytotrophoblast) were significantly enriched in 
genes implicated in stress response, signal transduction, and gene regulation, among 
others (Bilban et al., 2009), which is unsurprising given their vulnerability to 
maternal blood supply. Genes regulating response to heavy metals, oxygen species, 
and DNA damaging agents, including SOD2, HO-1, and several heat shock proteins 
were upregulated in these cells. Furthermore, several signal transduction pathways 
are modulated, including glucocorticoid-, cAMP/Ca2+-, and G protein-coupled 
receptor signaling. Interestingly, there was also enhanced expression of a large group 
of gene sets regulating the nuclear import/export and translation factor activity, which 
may be tied to the potential of the cytotrophoblast to progress down the 
differentiation pathway. Additionally, in demonstration of the validity of their 
findings, Bilban et al. (2009) showed an inverse relationship of HO-1 expression with 
trophoblast migration, acting via upregulation of PPARG.
The other study by Apps et al. (2011) reported upregulation of human endogenous 
retroviruses HERV-FRD and ERVWE1, as well as transcription factor ELF5, in 
villous trophoblasts, indicating its potential to generate the syncytiotrophoblast cell 
type. 
Overall, these studies cumulatively present a yet unfinished picture of trophoblast  cell 
type markers. While all-encompassing, the contents of these preliminary  lists must be 
validated before a definitive list  can be issued as the gold standard for identifying the 
specific trophoblast  cell type. Nevertheless, these studies provide a good starting 
point for the search of defining trophoblast traits.
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Figure 1.4. Trophoblast lineage cell types and proposed markers. Formation of the 
trophectoderm (TE) marks the first differentiation event in the development of the embryo. 
The self-renewing human trophoblast stem cells (hTSCs) have yet to be definitively isolated 
and characterized. Several genes identified in mouse models to have limited expression in 
the TE and found to be essential for proper trophoblast formation are proposed for the 
identification of hTSCs (adapted from James et al., 2012).
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1.1.6. Modeling human placentation. 
The human implantation process is unique, as exemplified by the placenta 
representing the most  structurally and morphologically diverse organ found in 
mammals (Mossman, 1991). As such, animal models are subpar estimates at best. 
While knock-out studies in mice have provided insight on the possible roles of 
various factors in the implantation process, differences in reproductive physiology 
between species limit the relevance. Non-human primates, representing our closest 
cousins on the evolutionary  scale, provide a more physiologically  relevant model, 
thus in vivo and in vitro studies in baboons have contributed to the current 
understanding. 
Ethical restrictions and limited availability of human placental tissue prohibit  human 
implantation studies. Where practical and ethical considerations prevent the use of 
human blastocysts, cells that closely  represent  the trophectoderm have been used as a 
model in its stead. Studies have shown that hESCs can be induced to differentiate into 
the trophoblast lineage via three different mechanisms: 1) The transgenic knockdown 
of pluripotency  genes OCT4, NANOG, and SOX2 result in the expression of 
trophoblast markers (Matin et al., 2004; Babaie et al., 2007); 2) Spontaneously 
differentiating trophoblasts have been collected from embryoid bodies formed in the 
absence of growth factors that support pluripotency. The trophoblasts are purified 
from these embryoid bodies either by  clonal selection for hCG production (Harun et 
al., 2006) or by  their adhesive properties (Peiffer et al., 2007); 3) Feeder-free hESCs 
can be cultured in the presence of BMP4, leading to an upregulation of transcription 
factors linked to trophoblast differentiation. These cultures are able to give rise to 
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syncytiotrophoblast-like cells when dissociated and re-plated at low density, forming 
multinucleated hCG positive patches of cells (Xu et al., 2002). Regardless of their 
method of differentiation, the apparent  mix of villous (hCG-expressing) and 
extravillous (HLA-G-expressing) cell types derived from hESC colonies suggest that 
multipotent trophoblast progenitors or individual progenitors of both trophoblast cell 
types arise during differentiation (Xu et al., 2002; Udayashankar et al., 2011). 
A range of trophoblast  cell lines is also widely available. These lines are derived from 
differentiated trophoblast, or from highly invasive choriocarcinomas, and therefore 
are likely  to have key phenotypic differences from TE and the primitive trophoblast. 
While terminally  differentiated trophoblasts are not  able to illustrate the transition 
from hTSC to terminally differentiated cell type, EVTs provide a look at an 
intermediate state due to their functional similarity  to the implanting TE, denoted by 
their invasion through and direct  interaction with decidual stromal cells. Some studies 
have used EVT cell lines to model the cell-cell interactions that occur in the initial 
stages of blastocyst implantation (Genbacev et al., 2003; Hannan and Salamonsen, 
2008; Stoikos et al., 2010; Robins et al., 2011). However, it has yet to be established 
how closely these differentiated trophoblasts represent the implanting polar TE and 
primitive cytotrophoblast (James et al., 2012). The ability  to pick an appropriate 
trophoblast cell line is confounded by the limited understanding of the adhesion 
molecule and cytokine repertoires of the implanting TE, as well as the time line of 
differentiation into various trophoblast lineages from the TE. 
Lastly, in an attempt to further improve the accuracy of models used to study early 
placentation, trophoblast cell lines have been maintained in three-dimensional 
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cultures, successfully generating embryo-free trophoblast vesicles (Robins et al., 
2011). This exciting development may well hold great importance, as TE lineage 
differentiation is dependent upon the position of each trophoblast cell with respect to 
the ICM, as seen in both mouse and primate models (Dickson, 1963; Enders, 1976; 
Maltepe et al., 2010). 
1.1.7. Preeclampsia: A multi-factorial pregnancy complication.
The need to understand human placental development is not without purpose. 
Without  comprehensive fundamental understanding of the progression of the early 
trophoblasts of the trophectoderm to ultimately, the placenta, the pathogenesis of 
many pregnancy complications remain puzzling. Pregnancy complications are 
commonly associated with placental dysfunction, some even resulting in early 
termination of the pregnancy. These complications not only affect the viability and 
health of the fetus, they also endanger the mother’s life. 
Preeclampsia is one of the most common and dangerous pregnancy-disorder, and 
represents the principal cause of maternal morbidity, accounting for 15-20% of 
pregnancy-related mortalities (Sibai et al., 2005). Preeclampsia is diagnosed when the 
mother, more than 20 weeks along in the pregnancy, develops both hypertension and 
proteinuria, which is characterized by significant  amounts of protein in the uterine. It 
is a complex disorder involving multiple organ failure including that of the liver, 
kidney, lung, and the coagulatory and neural systems. If left untreated, it  can develop 
into eclampsia, the life-threatening occurrence of seizures during pregnancy.
The prognosis for both the mother and fetus in severe preeclampsia is particularly 
poor in early onset cases (<34 weeks of gestation; Hall et  al., 2000). Patients are 
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generally  treated for prevention of seizures and control of hypertension, but the lack 
of understanding of the precise etiology of the condition has hindered the 
development of preventive and therapeutic measures to effectively treat this disease 
based on its etiology (Nishizawa et al., 2011). The consensus now is that 
preeclampsia is a complex polygenetic disorder in which maternal and fetal genes, as 
well as environmental factors, are involved. While it is recognized that its 
pathogenesis involves numerous processes, such as oxidative stress, endothelial 
dysfunction, vasoconstriction, metabolic changes, thrombotic disorders and 
inflammatory responses, the precise underlying mechanisms have remained elusive 
(Roberts and Cooper, 2001; Nishizawa et al., 2011). 
Preeclampsia is considered a two-stage disease (Redman and Sargent, 2005; Roberts 
and Hubel, 2009). The first stage is characterized by inadequate placentation, 
resulting from shallow invasion of the trophoblasts into the maternal spiral arteries, 
underscoring the need to understand trophoblast progression in early pregnancy. 
Instead of the low-resistance, high-flow system seen in the normal placenta, the 
preeclamptic placenta is associated with increased resistance with accompanying 
decreased blood flow, and uneven perfusion, leading to hypoxia, ischemia, and 
reperfusion injuries in the placenta (Redman and Sargent, 2005; Roberts and Hubel, 
2009; Centlow et al., 2011). The second stage of preeclampsia is characterized by 
general vascular endothelial damage, which eventually affects all maternal organs. 
The transition from the first stage to the second is typically  seen before 35 weeks of 
gestation, in early  onset preeclampsia. Placentae from early onset preeclampsia more 
often show histological pathological findings associated with poor placental 
perfusion, such as infarcts and chronic inflammation (Salafia et al., 1998). In contrast, 
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those from late-onset preeclampsia rarely present these pathological findings. 
Unfortunately, placental factors linking the two stages are not well understood. 
The placenta is implicated as the primary player in the etiology of this disorder. 
Moreover, patients with preeclampsia recover from the associated clinical symptoms 
after delivery  of the placenta. The gene expression profile of the placenta is also 
consistently altered in preeclampsia, as reported by multiple microarray studies 
(Enquobahrie et  al., 2008; Founds et al., 2009; Sitras et al., 2009; Centlow et al., 
2011; Meng et al., 2012). While substantial progress has been made in identifying 
genes involved in the pathogenesis of preeclampsia, there is still considerable debate 
on the significance of the role of the candidate genes (Chappell and Morgan, 2006). 
Additionally, placental gene expression reflects feto–maternal interaction, and could 
potentially contribute to the maternal phenotype (Oudejans and Dijk, 2008). To that 
end, several placental factors that may participate in the progression to the second 
stage have been identified, including soluble fms-like tyrosine kinase 1 (sFlt1) and 
endoglin (Maynard et al., 2003; Venkatesha et al., 2006).
Preeclampsia has been strikingly associated with a fetal disorder known as 
intrauterine growth restriction (IUGR), commonly described as poor growth of the 
fetus while in the uterus. IUGR is a result of heterogeneous causes, including 
maternal, fetal, and placental factors (Bernstein and Divon, 1997), and has an 
increased risk of perinatal morbidity and mortality (Bernstein and Gabbe, 1996). 
IUGR may be caused by maternal malnutrition or fetal chromosomal abnormalities, 
which lead to inhibited growth, but it can also strike with an unknown cause. Reviews 
of current literature indicate that preeclampsia and unexplained IUGR have a 
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common etiological background (Gerretsen et al., 1981; Bernstein and Divon, 1997; 
Aardema et al., 2001; Kaufman et al., 2003; Baschat  and Hecher, 2004), although this 
assertion has remained controversial (Villar et al., 2006; Burton et al., 2009). In any 
case, little is known about their involvement at the molecular level. Nonetheless, a 
recent microarray study by Nishizawa and colleagues (2011) showed strong 
correlation between IUGR and preeclampsia; many genes that are known to be 
upregulated in preeclampsia are also upregulated in IUGR, including anti-angiogenic 
factors. Moreover, a failure of trophoblast invasion leading to abnormal shallow 
vascularization and impaired remodeling of the spiral arteries appears to be common 
ground for these two disorders (Kaufman et al., 2003). It has been posited that such 
placental defects, as seen in preeclampsia, may thus inhibit the materno-fetal 
transport of nutrients and oxygen. 
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1.2. EPAS1 and the HIF family.
The EPAS1 gene encodes for the human endothelial PAS-domain containing protein, 
better known as HIF2α. It is a member of the hypoxia-inducible factor (HIF) family 
of proteins. This family of proteins is responsive to changes in oxygen levels in the 
cellular environment. 
Oxygen is essential for the survival of all aerobic organisms and is required for 
aerobic metabolism in order to maintain intracellular energy  balance. Aerobic energy 
metabolism is dependent on oxidative phosphorylation, through which the oxido-
reduction energy of the mitochondrial electron transport is converted into the high-
energy phosphate bond of ATP. In this process, oxygen serves as the final electron 
acceptor. 
Hypoxia has conventionally been defined as a state of reduced oxygen level, one that 
is below normal values (Table 1.1A; Koh and Powis, 2012). Since molecular oxygen 
is essential for the development and growth of multicellular organisms, the ability to 
sense and respond to low oxygen conditions is critical to survival. When oxygen 
tensions fall below the normal physiological range, the function of organs, tissues, or 
cells are restricted, a condition referred to as pathological hypoxia. Pathological 
hypoxia may occur at high altitude, or due to localized ischemia as a result of 
disrupted blood flow. On the other hand, the hypoxic environment or hypoxia in first 
trimester placenta, is normal, and not considered pathological. Nonetheless, 
physiological oxygen tensions are actually significantly lower than ambient oxygen 
tensions as a result of the dramatic decrease in blood oxygen content as blood travels 
throughout the body’s circulation (Table 1.1B; Carreau et al., 2011). Oxygen 
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gradients have many important  and beneficial roles in mammalian physiology; 
hypoxia provides the required extracellular stimulus for proper embryogenesis and 
wound healing, and helps maintain pluripotency  of stem cells (Ezashi et al., 2005; 
Dunwoodie et al., 2009; Patterson and Zhang, 2010). Numerous adult stem cell types 
are in fact maintained in their niche environments at oxygen concentrations between 
<1% and 8% (Fig. 1.5; Mohyeldin et al., 2010). 
Viewed from a molecular perspective, physiological hypoxia illicits a conserved 
molecular response. Cells utilize a number of oxygen-sensing pathways, including 
those that involve the energy and nutrient sensor known as mammalian target  of 
rapamycin (mTOR), the endoplasmic reticulum stress response, the nuclear factor 
(NF)-κB transcriptional response, as well as the hypoxia-inducible factor (HIF)-
mediated transcriptional response (Lai et al., 2007; Perkins, 2007; Wouters and 
Koritzinsky, 2008; Koh and Powis, 2012). These mechanisms promote hypoxia 
tolerance by  activating transcription and inhibiting translation. The HIF-mediated 
response in particular switches on a large number of genes including those promoting 
angiogenesis, anaerobic metabolism, and resistance to apoptosis (reviewed by Kaluz 
et al., 2008; Yoon et al., 2011; Koh and Powis, 2012). 
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Table 1.1 (A) Frequently  used definitions describing low oxygen. Ambient oxygen level, 
termed normoxia, is defined as 20% oxygen concentration. Because physiological tissue 
oxygen tensions are lower than ambient oxygen tension, this condition is referred to as 
physiological hypoxia. Extreme hypoxia is known as anoxia, with <0.1% oxygen 
concentration. (B) Physiological oxygen tensions in a selection of normal human tissue 
types. Oxygen tension in physiology is lowered as a result of the dramatic decrease in blood 
oxygen content as it travels throughout the bodyʼs circulation. As a result, multiple tissue 
types exist and function under physiological hypoxia.
(A) Condition pO2 
(mmHg)
%O2 (B) Organ Normal pO2 
(mmHg)
%O2
Normoxia (ambient) 159 21 Trachea 150 19.7
Physiological 
hypoxia
15-68 2-9 Alveoli 110 14.5
Mild hypoxia 8-38 1-5 Arterial blood 100 13.2
Hypoxia <8 <1 Pulmonary arterial blood 40 5.3
Anoxia <0.08 <0.1 Brain 35 4.4




Bone marrow 49 6.4
36
Figure 1.5. Oxygen tension measurements in various stem cell niches. Adult stem cell 
types that are maintained in their niche environments at physiological hypoxia include the 
mesenchymal stem cell, neural stem cell, as well as the hematopoietic stem cell. Schematic 
models are depicted based on current available data for the adipose tissue, subventricular 
zone, and the bone marrow (adapted from Mohyeldin et al., 2010).
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1.2.1. The canonical HIF pathway: Oxygen-dependent regulation.
The hypoxia-inducible factor (HIF) is a DNA-binding transcription factor that 
associates with specific nuclear cofactors under hypoxia to transactivate a myriad of 
genes, triggering various adaptive responses to inadequate oxygen tension. The HIF 
complex forms through the interaction and heterodimerization of the oxygen-labile 
HIF-α subunit and the constitutively expressed HIF-β/ARNT subunit, the aryl 
hydrocarbon receptor nuclear translocator. Both subunits are part of the basic helix–
loop–helix PER-ARNT-SIM  (bHLH-PAS) family  of transcription factors. Three 
genes encoding distinct HIF-α isoforms exist in humans: HIF1A, encoding HIF1α; 
EPAS1, encoding HIF2α; and HIF3A, which is expressed as multiple HIF3α splice 
variants (Table 1.2A; Wang et al., 1995; Makino et al., 2002; Maynard et  al., 2003). 
All HIF-α isoforms possess one oxygen-dependent degradation domain (ODD), as 
well as one N-terminal transactivation domain (TAD), but only HIF1α and -2α 
possess an additional transactivation domain at the C-terminal. HIF1α dimerizes with 
HIF-β/ARNT forming the HIF-1 transcription factor, and HIF-2 is formed similarly 
via the association of HIF2α and HIF-β/ARNT. While both HIF-1 and HIF-2 activate 
transcription, HIF3α has been found to negatively  regulate HIF-1 and HIF-2 activity. 
Two of the HIF3α isoforms achieve this indirectly by competing for available HIF-β/
ARNT and then only weakly activating transcription, while a third HIF3α isoform 
inhibits HIF-1 and -2 activity  by binding HIF1α and -2α, therefore preventing their 
heterodimerization with HIF-β/ARNT (reviewed by Greer et al., 2012; Table 1.2B).
Under normal oxygen tension (>5%), prolyl-hydroxylase domain proteins (PHDs) 
hydroxylate two proline residues within the ODD of HIF-α (Fig. 1.6; Epstein et al., 
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2001; Ivan et al., 2001; Jaakkola et  al., 2001; Masson et al.; 2001). This 
hydroxylation is recognized by  the von Hippel-Lindau tumour suppressor protein 
(pVHL) and is subsequently  ubiquitylated by the Elongin BC/Cul2/pVHL ubiquitin–
ligase complex, thereby marking HIF-α for degradation by the 26S proteasome 
(Maxwell et al., 1999; Ohh et al., 2000; Ruas and Poellinger, 2005; Schofield and 
Ratcliffe, 2005). PHDs require oxygen for catalytic activity; thus, prolyl-
hydroxylation of HIF-α is abrogated under hypoxia (<5% oxygen), allowing HIF-α to 
escape recognition by  the pVHL ubiquitin–ligase complex and accumulate in the 
nucleus. Similarly, biallelic inactivation of VHL (VHL−/−) has a profound stabilizing 
effect on HIF-α protein levels, thereby implicating pVHL as a predominant  HIF-α 
antagonist. Additionally, in the presence of oxygen, another hydroxylase-domain 
protein termed factor inhibiting HIF (FIH) participates in the negative regulation of 
HIF-α by hydroxylating an asparagine residue in the C-terminal activation domain, 
sterically inhibiting interactions between HIF-α and transcriptional co-activators (Fig. 
1.6; Arany et al., 1996; Lando et al., 2002; Lisy and Peet, 2008).
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Table 1.2. (A) Members of the HIF family. There are 3 HIF-α and 1 HIF-β proteins in the 
HIF family. (B) Associations as well as transcriptional activity  of the HIF complexes. 
The α subunits heterodimerize with the β  subunit (ARNT) to form the respective HIF 
transcription factor complex. HIF-1 and HIF-2 have 2 TADs each, while HIF-3 and HIF-3NEPAS 
only have 1. IPAS does not activate transcription, but instead prevents transcription by 
binding HIF1α and -2α thus preventing their dimerization with ARNT (adapted from 
Dunwoodie, 2009). 
         
A Member Gene Protein
Hif1α HIF1A hypoxia-inducible factor 1, alpha subunit
Hif2α EPAS1 endothelial PAS domain protein 1
Hif3α HIF3A hypoxia-inducible factor 3, alpha subunit
Hif1β ARNT aryl-hydrocarbon receptor nuclear translocator
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Figure 1.6. HIF regulation under aerobic and hypoxic conditions. Under normoxic 
conditions, Hif-α is hydroxylated by PHD1-3 and FIH, which targets it for degradation and 
inhibits its transcriptional activity. In hypoxic conditions, Hif-α heterodimerizes with Hif-β/
ARNT, and binds CBP/p300 to form the HIF transcriptional factor complex; which 
translocates to the nucleus and binds HREs to activate transcription of target genes (adapted 
from Dunwoodie, 2009).
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1.2.2. HIF target genes.
In hypoxic conditions, stable HIF-α dimerizes with HIF-β/ARNT before binding to 
hypoxia-responsive elements (HREs) comprising a core 5′-[A/G]CGTG-3′ consensus 
sequence and highly variable flanking sequences in the promoters of HIF-responsive 
genes (Wenger et  al., 2005). FIH-mediated hydroxylation is also reduced when 
oxygen is depleted, thereby allowing HIFα to interact with the transcriptional co-
activators p300/Creb-binding protein (Fig. 1.6; Arany et al., 1996). This 
transcriptional complex transactivates a specific subset of genes that regulate the 
cellular adaptive response to hypoxia, including, but not limited to, SLC2A1 (solute 
carrier family 2, facilitated glucose transporter membrane 1), VEGF (vascular 
endothelial growth factor), and EPO (erythropoietin; Wang and Semenza, 1993; 
Forsythe et al., 1996). SLC2A1 encodes glucose transporter 1 (GLUT1), a transporter 
protein facilitating the movement of glucose across the plasma membrane in 
mammalian cells. VEGF is a signaling protein produced by cells that stimulates 
vasculogenesis and angiogenesis, while EPO is a glycoprotein hormone that controls 
erythropoiesis, or red blood cell production. These genes, as well as others activated 
by HIF, are involved in energy  metabolism, autophagy, translation inhibition, 
erythropoiesis and angiogenesis, all of which help promote a tolerance of hypoxia by 
decreasing the cellular requirement for oxygen and increasing the supply  of oxygen to 
tissues (Kaelin and Ratcliffe, 2008; Anderson et al., 2009). 
Historically, HIF target genes have been identified on the basis of one or more of the 
following strategies: 1) Identification of a functional HRE containing a HIF-binding 
sequence (HBS); 2) Comparison of patterns of gene expression in HIF-α wild-type 
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and null cells (through genetic knockout or siRNA knockdown); 3) Screening for 
increased gene expression using VHLnull cells or cells transfected with a HIF-α 
expression vector (Kaluz et al., 2008). Expression profiling experiments indicated the 
heterogeneity of gene subsets induced by hypoxia; tumor cell lines as well as normal 
stromal and epithelial cells display distinct hypoxic profiles (Semenza, 2003). The 
consensus from various studies is that  there is a core set of genes consistently induced 
by hypoxia, and other variable genes that exhibit cell-type specific induction. This 
conclusion underscores the importance of studying hypoxic gene expression in a cell-
type-dependent context. Hypoxia induces HIF activity in almost all cell types and 
therefore, HIF alone cannot  account for the cell-type specific gene expression. 
Instead, the cell-type specific induction by hypoxia appears to be determined by 
functional interactions of HIF with other type-specific transcription factors (Semenza, 
2003; Wenger et al., 2005).
Estimates of the total number of HIF target genes induced by  hypoxia, in one or more 
cell types, vary from more than two hundred (Wenger et al., 2005) to as many as 5% 
of all human genes (Semenza, 2003). However, not all of them may be regulated 
directly  through HREs, and other transcription factors have been implicated in 
hypoxia-inducible gene expression as well. HIF-activated transcription factors such 
as DEC-1 and -2, and ETS-1 also contribute to the pool of hypoxia-induced genes 
(Oikawa et al., 2001; Miyazaki et al., 2002). In general, HIF induces expression of 
proteins that  specifically help meet the metabolic and survival needs of hypoxic cells. 
Table 1.3 lists representative HIF target genes, grouped according to function 
(adapted from Kaluz et al., 2008). 
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Table 1.3. Selected HIF target genes grouped according to their function. HIF induces 
expression of proteins that specifically help  meet metabolic and survival needs of hypoxic 
cells (adapted from Kaluz et al., 2008).
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1.2.3. HIF1α vs. HIF2α: Are they redundant?
The existence of three HIF-α isoforms raises questions about the role of each 
individual isoform in regulation of transcription under hypoxic conditions. While the 
α subunits are highly  conserved at the protein level, domain structure, and hypoxia-
dependent mechanisms of regulation, distinct patterns of cellular expression appear to 
be responsible for the respective physiological roles of HIF1α and HIF2α (Huang and 
Bunn, 2003). For example, both isoforms are abundantly expressed in the kidney but 
in different cell types; HIF1α is predominantly expressed in epithelial cells whereas 
HIF2α is predominantly  detected in interstitial fibroblast and endothelial cells 
(Rosenberger et al., 2002). 
Furthermore, studies have found differences in the phenotypes of HIF1αnull mice and 
HIF2αnull mice strains, both of which are embryonic lethal. HIF1αnull mice suffered 
from cardiac malformations, severe vascular defects, and impaired erythropoiesis, 
and did not survive beyond embryonic day 11 (Iyer et al., 1998; Kotch et al., 1999; 
Yoon et al., 2011). HIF2αnull embryos mostly die by embryonic day 13.5 due to 
vascular defects (Peng et al., 2000), or bradycardia as a result of deficient 
catecholamine production (Tian et al., 1998). Some embryos survived gestation and 
died either as neonates due to impaired lung maturation (Compernolle et al., 2002), or 
several months after birth due to multi-organ failure mediated by the reactive oxygen 
species (Scortegagna et al., 2003). This suggests that HIF1α and 2α are functionally 
non-redundant and are unable to functionally complement each other. 
Moreover, several studies have suggested that  HIF1α and HIF2α differ in their 
capability to transactivate hypoxia-inducible genes. While both isoforms regulate the 
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expression of many common genes, HIF1α is found to preferentially activate genes 
involved in the glycolytic pathway  (Hu et al., 2003; Wang et al., 2005), whereas 
HIF2α is involved in the regulation of genes important for tumor growth, cell cycle 
progression, and maintaining stem cell pluripotency, like the proto-oncogene C-MYC 
(Gordan et al., 2007) and the stem cell factor OCT4 (Covello et al., 2006). The VEGF 
receptor 2 gene known as FLK-1 has also been reported to be specifically  regulated 
by HIF2α, although comparison of the FLK-1 HBS with HBSs of HIF1α target genes 
revealed no obvious difference (Elvert et  al., 2003). Intriguingly, while HIF-1 was 
originally  identified by affinity purification with EPO HRE (Wang and Semenza, 
1995), recent studies indicate that HIF-2 is the physiological regulator of EPO 
production (Gruber et al., 2007; Kojima et al., 2007; Kapitsinou et al., 2010). A 
linkage of familial erythrocytosis further supports this notion with a gain-of-function 
mutation in HIF2α (Percy et al., 2008).
While a study by  Hu and colleagues (2007) has indicated that it is the N-TAD that 
contributes to target-gene specificity  of HIF1α and HIF2α, other factors should be 
noted in the transactivation of hypoxia-inducible genes. For example, preferential 
cooperation between the HIF transcription factor complex with certain subsets of 
transcription factors, co-activators, or co-repressors, as well as tissue-specific 
expression of HIF-α isoforms may affect the differential gene activation by HIF1α 
and -2α respectively. Promoter analysis of a subset of genes preferentially  regulated 
by HIF2α revealed a commonality  in binding sites for the ETS family of transcription 
factors. Correspondingly, the knockdown of ELK-1 (the most abundant member of 
ETS family) significantly  reduced hypoxic induction of the HIF2α-responsive genes 
(Aprelikova et al., 2006). Similarly, a separate study found that ELK-1 is required for 
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HIF2α to activate specific target genes such as CITED-2, EPO, and PAI-1 (Hu et al., 
2007). These results demonstrate the need for interaction between the HIF 
transcription factor complex and appropriate transcriptional cofactors in order for 
comprehensive expression of hypoxia-inducible genes. 
Altogether, a review of the current literature indicates that not only are HIF1α and -2α 
functionally non-redundant, but are also expressed in a cell-type specific manner, 
resulting in regulation of differential suites of target genes. Type specific expression, 
with functional interaction of cooperative factors, determine the consequent 
activation of their respective target genes, and hence the individual contribution of 
HIF1α and HIF2α to overall health and development. 
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1.3. Role of hypoxia and HIF in development.
Much of mammalian embryogenesis occurs at oxygen concentrations of 1-5%, and 
the role of hypoxia during this time is found to be central to proper embryonic 
development (reviewed in Dunwoodie, 2009). This hypoxic environment is necessary 
for the appropriate development of the embryonic vascular system as well as for 
endochondrial bone formation in the developing embryo (Harvey, 2002; Christoffels 
et al., 2004; Dai and Rabie, 2007; Hutson and Kirby, 2007; Karsenty, 2008; Patterson 
and Zhang, 2010). HIF-mediated response to hypoxia is responsible for the regulation 
of morphogenesis of the developing heart; loss of HIF leads to defective development 
of the myocardium and adversely affects the vascular endothelium of the heart (Ryan 
et al., 1998; Compernolle et al., 2003; Krishnan et al., 2008; Ream et al., 2008). 
During endochondrial bone formation, HIF is required for chondrogenesis and is a 
key regulator for mesenchyme condensation and chondrocyte formation (Schipani et 
al., 2001; Amarilio et al., 2007; Provot et al., 2007). 
Apart from embryogenesis, HIF activity also mediates development of the placenta, 
and is essential for proper trophoblast maturation and activity. One of the main 
functions of the placenta is to bring oxygenated maternal blood into proximity with 
deoxygenated fetal blood. Paradoxically, the placenta develops in a low oxygen 
environment during the first trimester of pregnancy, as a result of trophoblastic 
plugging of spiral arteries of the endometrial lining (Hustin and Schaaps, 1987). 
During this period, oxygen concentrations in the uterine environment range from 
1-5% (pO2 0.5-30 mmHg; Okazaki and Maltepe, 2006) allowing for the extensive 
proliferation of cytotrophoblasts, which upon increased oxygen concentrations, form 
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the invasive cells that give rise to the architecture of the placental vasculature 
(Genbacev et al., 1997; Robins et al., 2007). Impaired placental formation and 
function have been implicated in several pregnancy complications, such as 
unexplained miscarriage, preeclampsia, IUGR, placental abruption, pre-term labor 
with intact membranes, premature rupture of the membranes, and stillbirth (Khong et 
al., 1986 & 1987; Dommisse and Tiltman, 1992; Kim et al., 2002 & 2003; Smith et 
al., 2004). The changing oxygen environment of the endometrium is thus a key 
regulator of placental development. Therefore, the ability to sense these changes and 
to respond appropriately are essential for proper placental function. To this end, there 
is a large body of work that indicates that HIF is central to this system. 
1.3.1. Placentation begins in an environment of physiological hypoxia.
In the early days of placentation and pregnancy, endovascular cytotrophoblasts 
invade and plug the uterine spiral arterioles, effectively  blocking the flow of maternal 
blood into the intervillous space (IVS). Hustin and Schaaps (1987) first reported that 
maternal blood flow to the IVS was not  fully  established until approximately 11 to 12 
weeks of gestation, which was later confirmed through Doppler ultrasound (Foidart et 
al., 1992; Coppens et al., 1996). At about 11 weeks of gestation, the arteriole plugs 
are displaced and blood flow commences (Hustin and Schaaps, 1987; Burton et al., 
1990). The onset of maternal blood flow is progressive, beginning from the periphery 
of the placenta and gradually extending towards the centre (Jauniaux et  al., 2003a). 
The oxygen tension within the IVS thus rises, from 2.5-3% at 8 weeks, to 8.5% at 12 
weeks, leading to a burst of oxidative stress in the placenta (Rodesch et al., 1992; 
Jauniaux et al., 2000; Jauniaux et al., 2001). Early onset  of maternal blood flow into 
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the IVS results in a premature increase in placental oxidative stress, and is associated 
with early  pregnancy loss (Hustin et al., 1990; Jauniaux et al., 2003a & b). This 
premature onset of blood flow occurs prior to the establishment of robust mechanisms 
to ameliorate oxidative stress, therefore adequate trophoblast  invasion and plugging 
of the spiral arterioles in early pregnancy are essential for healthy  embryonic and 
placental development. 
EPAS1 is expressed most abundantly in the human placenta.
The expression of EPAS1, the gene for HIF2α, across a variety  of human tissues has 
been reported in a study  that used whole-genome gene expression arrays to measure 
the expression of transcripts across a diverse panel of human and mouse tissues. This 
study therefore presents a gene atlas that describes the normal transcriptome (Su et 
al., 2002). The tissue-specific pattern of mRNA expression derived from such an atlas 
could offer important clues about gene function. 
Using this tool, it is evident that there is a huge disparity between EPAS1 and HIF1A 
expression pattern across human tissues (Fig. 1.7). The expansive reach of HIF1A 
expression is starkly  different from the distinct localization of EPAS1 expression to 
the placenta and lung, suggesting a deviation in role. HIF1A may have a function 
common to multiple tissues and organs, while EPAS1 has a specialized function 
unique to placenta and lung. Moreover, while EPAS1 demonstrated its highest 
expression levels in these two tissues, HIF1A is conversely very lowly  expressed in 
these tissues.
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EPAS1 displays a substantial expression level in the placenta, and to a lower degree, 
lung. In comparison, EPAS1 expression in the other human tissues is negligible. For a 
gene closely  tied to oxygen homeostasis, to find it expressed in the lung, a major 
channel for gas exchange is unsurprising. Similarly, given that the placenta is the 
major organ through which fetal gas exchange takes places, it  is reasonable to find 
such strong expression of EPAS1. Moreover, EPAS1 has been implicated in regulating 
trophoblast differentiation as well as proper placental development (see next section). 
In a microarray study assessing global gene expression in 8-week placental villi, 
EPAS1 was found to be remarkably abundantly expressed, emerging with the 57th 
strongest signal, out of a total of 48,803 probes (Apps et al., 2011). Similarly, in our 
lab, previous data from global transcriptome analysis (mRNA-Seq) revealed the 
strength of EPAS1 expression in hESC-derived trophoblast culture (Fig. 1.8). It 
emerged as the 70th most abundantly expressed mRNA transcript, and represented the 
most highly expressed transcription factor, suggesting its involvement in trophoblast 
and/or placental formation and function. The strength of expression, coupled with the 
specificity of its tissue localization, strongly indicate a unique function of EPAS1 in 
the human placenta.
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Figure 1.7. Expression pattern for EPAS1 and HIF1A across different human tissues. 
EPAS1 gene expression is by far the highest in the human placenta, followed by the lung, 
whilst in other human tissues, its expression is negligible in comparison. In contrast, HIF1a is 
lowly expressed in the lung and placenta, and is instead expressed across a variety of other 








































































































































































































1.3.2. HIF activity impacts placental development.
Previous work in mouse has shown that HIF activity  is required for normal 
development of the placenta, with loss of HIF1α, both HIF1α and -2α, or HIF-β/
ARNT causing catastrophic failure in placenta formation, resulting in embryo 
lethality early on (Table 1.4; Kozak et  al., 1997; Abbott and Buckalew, 2000; 
Adelman et al., 2000; Cowden Dahl et al., 2005). Key features of placental defects in 
mouse models include reduced interaction between the embryo and forming placenta 
(chorioallantoic interaction), reduced development of the labyrinthine layer (a feature 
of the mouse placenta not found in humans), limited vascularization of the placenta, 
overarching disruption of trophoblast differentiation (including the absence of 
syncytiotrophoblasts), dramatic reduction in spongiotrophoblasts (a mouse 
trophoblast cell type), and greater numbers of trophoblast giant cells (another mouse 
trophoblast cell type). These resulting placental defects offer an insight to the current 
understanding of how oxygen gradients affect  trophoblast  proliferation, 
differentiation, and gene expression. 
Cowden Dahl et al. (2005) demonstrated that HIF activity is required for effective 
chorioallantoic interaction and branching morphogenesis of the mouse placental 
vasculature. No overt morphological deficiencies were observed in the allantois or 
chorion, suggesting that HIF might be affecting molecular components of the 
interaction itself, such as integrins and their ligands (Watson and Cross, 2005). In 
cases where chorioallantoic interaction does occur, the vascularization of the 
developing placenta was reduced, thus suggesting that branching morphogenesis of 
the trophoblasts is impaired and/or that angiogenesis by fetal vascular endothelial 
54
cells is defective (Dunwoodie, 2009). Moreover, Abbott and Buckalew (2000) found 
that HIF-β/ARNTnull mice had a reduced expression of genes involved in the 
angiogenesis pathway, namely Vegfr2, Ang-1, and Tie-2. However, since the 
molecular mechanisms by  which HIF affects chorioallantoic fusion and fetal 
vascularization remain unclear, further investigation is necessary to determine 
whether either or both of these pathways are involved in mediating the role that HIF 
plays in placental angiogenesis. 
In humans, both HIF1α and -2α proteins are constitutively  expressed in the placenta. 
In the first trimester, HIF1α and -2α have been identified in the syncytiotrophoblast, 
villous cytotrophoblast, as well as the fetoplacental vascular endothelium (Rajakumar 
and Conrad, 2000; Genbacev et al., 2001). Their localization is consistent with the 
low oxygen environment of the placenta during this time, with their abundance 
decreasing significantly  with gestational age (Caniggia et al., 2000; Caniggia and 
Winter, 2002; Ietta et al., 2006). Additionally, Ietta et al. (2006) described in detail the 
dynamic expression of HIF and HIF regulators during placental development; HIF1α 
and VHL mRNA and protein are present throughout gestation, peaking at 7 to 10 
weeks of gestation when the oxygen tension is low, and declining thereafter. The 
expression of HIF-β/ARNT and HIF2α mRNA and protein are also present and found 
to be stable throughout gestation, while PHD is dynamically  expressed in an oxygen-
dependent manner, peaking at 10 to 12 weeks gestation (Ietta et al., 2006). Others 
report slightly  different results, that HIF1α mRNA levels in the placenta does not 
change across gestation, while HIF2α mRNA abundance increases as gestation 
progresses (Rajakumar and Conrad, 2000). 
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Meanwhile, comparing placentae from healthy pregnancies at low altitudes (i.e. 
normoxia) with preeclamptic placentae as well as placentae from pregnancies at high 
altitudes (i.e. hypoxia) have revealed differences in the abundance of, and presumably 
activity of HIF proteins. In a study examining pregnancies at high altitude, HIF1α and 
VHL mRNA and protein levels were found to be significantly increased in the 
placentae, whereas HIF2α and HIF-β/ARNT levels were unchanged (Zamudio et  al., 
2007a & b). Likewise, HIF1α and HIF2α were over-expressed in the villous placenta 
of women with preeclampsia compared to normal term pregnancies (Rajakumar et al., 
2001; Rajakumar et al., 2004). Another report by Helske et al. (2001) showed 
enhanced placental expression of HIF target  genes, including VEGF, in pregnancies 
complicated by preeclampsia and IUGR, which maybe suggestive of a vasculo-
adaptive response to chronic hypoxia at the fetoplacental-maternal interface. These 
results indicate that HIF1α and HIF2α are well placed to regulate placental 
development throughout gestation in both normal and pathological pregnancies. 
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Table 1.4. Placental defects in mice lacking in components of the HIF transcription 
complex. Loss of HIF1α, both HIF1α and -2α, or ARNT in the mouse leads to failure in 
proper placenta formation, resulting in embryo lethality. Key features of placental defects 
include reduced interaction between the embryo and forming placenta (chorioallantoic 
interaction), reduced development of the labyrinthine layer, limited vascularization of the 
placenta, and disrupted trophoblast differentiation (Dunwoodie, 2009).
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1.3.3. EPAS1 as a candidate gene that confers reproductive success. 
The conditions at high altitude present a hypoxic environment, prolonged exposure to 
which normally results in chronic mountain sickness. When the human body is 
subjected to low oxygen conditions, it  acclimatizes to allow the sustained delivery of 
normal amounts of oxygen to the organ systems. This involves an increase in 
hematocrit, through excessive erythrocytosis, to compensate for the insufficient levels 
of oxygen from the surroundings. However, chronically elevated levels of hematocrit 
eventually leads to increased blood viscosity, precipitating increased vascular 
resistance and ultimately  compromised tissue oxygenation; a condition known as 
chronic mountain sickness. Individuals from low-altitude populations who move to 
live at high altitude thus suffer from a number of potentially lethal diseases 
specifically related to the low oxygen levels (León-Velarde et al., 2005; Zubieta-
Castillo et al., 2006).
Additionally, residence at high altitude has been shown to have an impact on 
pregnancy outcomes. Fetal growth is affected; birth weight is reduced by more than 
100g per 1,000m elevation gain as a result of slowed fetal growth, or IUGR, rather 
than shortened gestation (Lichty et al., 1957; Unger et al., 1988; Jensen and Moore, 
1997; Lees et  al., 2002). Consequently, gestation at  high altitude increases the 
likelihood of infants being born small-for-gestational age (SGA; Julian et  al., 2007). 
Chronic hypoxia is postulated to be the main cause for such IUGR incidences at high 
altitude, as birth weight is reduced in animals exposed to hypoxic gas mixtures 
(Gilbert and Leturque, 1982). Moreover, other studies also found decreased birth 
weight in babies born to women with conditions limiting fetal oxygen supply (Novy 
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et al., 1968), as well as greater growth retardation in babies born to women with 
lower levels of arterial oxygenation and/or uterine blood flow (Moore et al., 1982a & 
b; Zamudio et al., 1995).
Apart from reduction in birth weight, studies across different populations have found 
that infant mortality is also affected by altitude. Neonatal mortality rates in Colorado 
were almost doubled, at an altitude of 2,740m relative to lower altitudes (<2,130m; 
McCullough et al., 1977). Furthermore, infants of low birth weight born above 
2,730m had higher mortality  rates relative to infants of normal birth weight 
(McCullough et al., 1977), indicating that low birth weight is not advantageous at 
high altitude. Similarly  in Peru, Mazess (1965) demonstrated that neonatal mortality 
rate was nearly  twofold greater for infants born at high altitude (3,030m) relative to 
low altitude (338m). More recent studies in Bolivia also show that intrauterine and 
infant mortality increases with altitude (Giussani, 2002; Keyes et al., 2003). 
Likewise, available data indicate that neonatal mortality is higher in highland 
populations compared with lowland Himalayan regions. 
Taken together, these data report that residence at high altitude might be a challenge 
for reproductive success. It is associated with lower reproductive fitness, evidenced 
by greater infant mortality  rates and/or morbidity  in the form of reduced infant birth 
weight (Julian et al., 2009). It would therefore seem that long-term habitation of high 
altitude terrain would be challenging, if not  fatal, but contrary to that, the high 
plateaus of Central Asia and the Andes have been inhabited by native populations for 
generations under hypobaric hypoxia (hypoxia of altitude). Tibetan highlanders, a 
geographically and genetically distinct population native to the Himalayan range, are 
59
in fact particularly  resistant to developing chronic mountain sickness (Pei et al., 1989; 
León-Velarde et al., 2005). They exhibit little or no increase in hemoglobin 
concentration with increasing altitude, even as high as 4,000m, and only  show 
moderate increases beyond (Beall et al., 1998). Tibetan women are also less afflicted 
by pregnancy complications, compared to non-native pregnant women (i.e. Han-
Chinese) living at high altitude - fetal mortality is reduced for the former, and 
newborns are protected from altitude-associated IUGR (Moore et al., 2001; Tripathy 
and Gupta, 2005; Yangzom et al., 2008). Moore et al. (2001) found that  Tibetan 
newborns weighed more than Han-Chinese newborns living across the same 
2,700-4,800m altitude gradient in the Tibetan Autonomous Region of southwestern 
China. Likewise, Yangzom et al. (2008) reported that Tibetan infants weighed more 
and were less often classified SGA than non-Tibetans (i.e. Han-Chinese and Hui 
Muslim) infants born in Lhasa, Tibet. 
In trying to understand this ancestrally  conferred protection, EPAS1 emerged as the 
leading candidate gene. Coming from a landmark discovery only two years ago, a 
variant of the EPAS1 gene in the Tibetan population was postulated to confer fitness 
to the native highland population (Beall et al., 2010; Simonson et al., 2010; Yi et al., 
2010). In their study, Yi et al. (2010) used exomic sequencing of 50 ethnic Tibetans in 
order to identify genes showing population-specific allele frequency  changes, 
representing strong candidates for altitude adaptation. EPAS1 emerged with the 
strongest signal of natural selection, in the form of a single-nucleotide polymorphism 
(SNP; C-to-G substitution), which presented at 78% frequency difference between 
the Tibetan population (87%) and their most recent divergent neighbors, the Han-
Chinese (8.75%). In contrast, the G allele is completely absent in the Danish 
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population, a far removed subset of people. The Tibetan population are thought to 
have diverged from the Han-Chinese as recently as <10,000 years ago (Aldenderfer 
and Zhang, 2004), making this SNP the fastest allele frequency change observed in 
any human gene to date (Yi et al., 2010). 
The hypoxic environment at high altitude therefore acts as a selection pressure. An 
advantageous mutation evolved to confer reproductive success to a sub-population 
(i.e. Tibetans) living in a harsh chronic hypoxia environment. In contrast, the Han-
Chinese represents the lowland population most closely  related to the Tibetans, but 
has not undergone selection for altitude-associated hypoxic adaptation. 
Impact of SNP on gene expression.
A single-nucleotide polymorphism (SNP) is defined as a variation in the DNA 
sequence between members of a biological species at a single nucleotide position. 
Generally, SNPs occur at a frequency of >1% in a population (Wang et al., 1998). The 
International HapMap Project has characterized over 3.1 million human SNPS, 
indicating a SNP density of approximately one per kilobase (Morizono et al., 2007).  
SNPs are not evenly distributed across the genome, but SNPs that affect gene 
expression occur in all regions of the genome. Generally, SNPs occur much less 
frequently in coding regions than in non-coding regions of the genome. SNPs found 
within coding regions of genes have been extensively  studied, primarily those 
resulting in amino acid codon alterations which can lead to variable protein levels and 
stability  (Salavaggione et al., 2005; Beluzic et al., 2006), protein misfolding (Komar 
et al., 1999), altered protein binding affinities and catalytic properties (Koyano et al., 
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2004; Kimchi-Sarfaty et al., 2007), improper post-translational modifications (Gentile 
et al., 2008), and other functional consequences (Gupta and Lee, 2008; reviewed by 
Chamary et al., 2006). SNPs in mRNA sequences may also influence mRNA folding 
and stability (Duan et al., 2003; Capon et al., 2004; Boffa et al., 2008), changing 
levels of mRNA available for protein translation. Additionally, altered mRNA 
structure can impact protein synthesis rates (Nackley et al., 2006), and 
correspondingly affect protein levels.
SNPs located within non-coding regions of the genome are less well understood, and 
while mostly regarded as non-functional, these variations can alter gene regulatory 
sequences such as promoters, enhancers, and silencers (Ponomarenko et al., 2002; 
Tokuhiro et al., 2003; Wang et al., 2005; reviewed by Knight, 2003 & 2005). SNPs of 
this kind may alter affinity  with the regulatory protein, resulting in differential gene 
expression (Giacopelli et al., 2004; Egli et al., 2009; Landa et al., 2009), as well as 
alter efficiency of translation initiation, leading to differential protein expression 
(Jacobson et al., 2005). In the most extreme scenario, a gain-of-function SNP 
conferred promoter-like activity to a non-coding region between the α-globin genes 
and their upstream regulatory elements (Gobbi et  al., 2006), which then interfered 
with normal activation of downstream genes, consequently  leading to a variant form 
of α thalassemia.
Additionally, SNPs occurring either within splice sites or their auxiliary  elements, 
such as exonic splicing enhancers (ESE), intronic splicing enhancers (ISE), and 
exonic/intronic splicing silencers (ESS, ISS), can alter or abolish splicing (Krawczak 
et al., 1992 and 2007), and in doing so, alter the balance of alternative splice forms 
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(Garcia-Blanco et al., 2004). Table 1.5 lists the varying outcomes from modifications 
of splicing regulatory  elements. For example, Pagani et al. (2003) reported that 
substitutions in a novel regulatory element, described as composite exonic regulatory 
element of splicing (CERES), of the CFTR gene led to alternative splicing of exon 
12, resulting in variable degrees of exon skipping. Skipping of this exon removes part 
of the first nucleotide-binding domain of CFTR, rendering the protein non-functional.
As another example, a mutation that inactivates an ESE in exon 5 of the MCAD gene 
causes exon skipping and MCAD deficiency, resulting in a disease that affects 
mitochondrial function (Nielsen et al., 2007). However, the severity of this disease is 
alleviated in the presence of a silent  A/C polymorphism in the same exon, located 11 
bases upstream of the ESE mutation. This is achieved by  the C variant which 
inactivates an adjacent ESS, therefore preventing exon skipping. This particularly 
revealing example demonstrates the complexity  and commonality of the splicing 
code, and the intricate relationships between disease-causing splicing mutations and 
disease-modifying natural variants that affect splicing (Wang and Cooper, 2007). 
When splicing is altered or abolished, mature mRNA sequence and structure is 
consequently affected, leading to aberrant protein synthesis. A SNP at a splice donor 
site of the human MYH genes results in reduced translation efficiency of its 
transcripts (Yamaguchi et al., 2002). In a splice-site genetic polymorphism of the 
KLK12 gene, individuals with the affected genotype have no substantial expression of 
the KLK12 protein with serine protease activity (Shinmura et  al., 2004). Both cases 
exemplify  single nucleotide variations, within splice sites, that cause modifications in 
translation initiation sites and translation efficiency. 
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Fundamentally, the overall effect of SNPs in splicing regulatory regions basically 
modulates splice-site and/or splicing efficiency (Pagani and Baralle, 2004). In some 
cases, this translates to SNPs serving as modifiers of disease severity  (Nissim-Rafinia 
and Kerem, 2005; Wang and Cooper, 2007), much like the earlier described example 
of MCAD deficiency. SNPs can also impact disease susceptibility; an A/G splice site 
SNP in the OAS1 gene, a key antiviral enzyme, is associated with basal enzymatic 
activity, influencing susceptibility to Type I diabetes (Field et al., 2005). Similarly, an 
A/C splice site polymorphism in the first intron of the P2X(7) gene, important for 
innate immune response, gives rise to a null allele in 1-2% of the Caucasian 
population (Skarratt  et al., 2005), ultimately affecting susceptibility  to environmental 
exposure.
When the natural splice site is altered, the splicing machinery may employ the next 
available legitimate splice site, leading to a phenomenon known as exon skipping. 
Alternatively, the spliceosome may opt for the next best, although illegitimate, splice 
site in the vicinity, in which case utilizing a cryptic splice site (Krawczak et al., 
2007). For example, intronic mutations in ABCC8 and HADH were identified to 
create cryptic splice donor sites, leading to the inclusion of an out-of-frame 
pseudoexon, which eventually resulted in a frameshift and premature termination 
codon (Flanagan et al., 2013). While the differences between natural and cryptic 
splice sites have been studied in vitro (Roca et al., 2003 and 2005), it remains largely 
unclear precisely which properties of the local sequence environment influence the 
choice of mRNA splicing phenotype.  
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The advent of genomics has led to great leaps in the study of human evolution, 
unveiling genomic variation through genome-wide scans. In recent years, genome-
wide scans for selection have been frequently reported, uncovering several hundred 
loci which show patterns of variation characteristic of new beneficial mutations that 
have spread through the population (Bustamante et al., 2005; Sabeti et al., 2007; 
Akey et al., 2009;  Pickrell et al., 2009; Grossman et al., 2013). Sabeti and colleagues 
(2007) showed evidence of selection, within an African population, for a gene linked 
to the Lassa fever virus. This disease is endemic in Lassa, Nigeria, where 21% of the 
population show signs of exposure (Richmond and Baglole, 2003). The LARGE gene 
codes for a glycosylase responsible for post-translational modification of the Lassa 
fever virus receptor, which has been shown to be critical for virus binding (Kunz et 
al., 2005). 318 SNPs were found in this gene, 35 of which were common only to the 
African population, and a further 3 of that have been identified as functional by 
current annotation (Sabeti et al., 2007). The authors thus posit that Lassa fever 
created selective pressure at LARGE. 
While most genetic variation has little impact on health, certain variants lead to a 
myriad of phenotypic effects, and within the right context, can strongly impact 
disease susceptibility  (Sachidanandam et al., 2001). SNPs increase gene diversity, and 
it is evident that particular SNP alleles confer protection from disease manifestation 
or progression, whether they are the major allele or variant/minor allele in a 
population. A SNP that enhances survival will emerge in the population when faced 
with specific selection pressures, and in this manner, SNPs are contributors to the 
evolutionary process. 
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Table 1.5. SNPs/Mutations in splicing regulatory elements and resulting outcome. 
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1.4. Experimental hypothesis and approach.
EPAS1 emerged as a subject of interest when it was recently  cited as the fastest 
evolving gene observed in humans to date (Yi et al., 2010). A variant of the gene, 
containing a SNP, exists in native Tibetans; a population that is protected from 
chronic mountain sickness despite inhabiting a highland environment low in oxygen, 
and has been tied to lowered hemoglobin production (Beall et al., 2010; Simonson et 
al., 2010). While these findings explain why Tibetans are protected from chronic 
mountain sickness, they also raise the question of how these people compensate for 
the lack of oxygen if not through increased erythropoiesis. 
More strikingly  however, the postulated rate of evolution of this gene implied a 
remarkable population bottleneck, in which a significant percentage of a population 
that migrated to the highlands must not have survived, or were prevented from 
reproducing, due to harsh selection pressures. Since the gene in question has been 
implicated in placental development, it raised the possibility that selection pressure 
could be acting in utero. I therefore hypothesize that - 
A) EPAS1 has a significant role in the development of the human placenta, and that
B) the variant EPAS1 gene contributes to reproductive fitness of the Tibetan 
population at hypoxic conditions.
We sought to prove this by  studying targets of the EPAS1 transcription factor protein 
in the context of the human trophoblast cell type, the precursor to the placenta. This 
was achieved through a hESC-derived trophoblast cell culture, maintained under 
hypoxia (3% oxygen). Targets of EPAS1 were then identified via chromatin 
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immunoprecipitation and sequencing (ChIP-Seq). Bearing in mind that presence of 
oxygen impacts HIF activity, we validated those targets by  studying their in vivo 
transcriptomic expression in human placental biopsies derived from high and low 
oxygen uterine environments. These clinical samples were through a collaboration 
with investigators at the Center for Trophoblast Research, University of Cambridge. 
To investigate the role that the variant EPAS1 gene might have in contributing to 
reproductive fitness at hypoxic conditions, we first characterized the SNP uncovered 
by Yi et al. (2010), to look for clues as to how it may affect  expression of the EPAS1 
gene and protein. This was done by inspecting the position of the SNP in relation to 
splicing regulation as well as assaying for alternatively spliced transcripts. 46 human 
cell lines, 30 of which were induced pluripotent stem cell lines derived from ethnic 
Han-Chinese, were also screened in search of a human cell line with the variant 
EPAS1 gene that contains the aforementioned SNP. This would thus enable us to 
compare expression and activity of the EPAS1 gene with and without the SNP. Hence, 
we hope to understand how the presence of the SNP might confer reproductive fitness 






Human embryonic stem cell line H1 (WA01, WiCell) was maintained in feeder-free 
culture using commercially available cell culture media (mTeSRTM1, StemCell 
Technologies). Growth media was changed daily, and the volume of media was 
gradually increased across the days as cells grew more confluent. Upon reaching 80% 
confluency, cells were passaged at a ratio of 1:12. To dissociate cells, they  were 
incubated with Dispase (1mg/ml; StemCell Technologies) at 37°C for seven minutes. 
Dissociation was quenched by flushing with Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 Media (DMEM/F-12, GIBCO). Cells were then collected by 
centrifugation at 500rpm for three minutes. Resulting cell pellet was resuspended in 
mTeSR to remove cell clumps, and cells were seeded onto tissue culture plates coated 
with BD MatrigelTM Matrix Basement Membrane (BD Biosciences). For maintenance 
and propagation, cells were grown at 37°C, at 20% oxygen concentration.
Cells were induced to differentiation into the trophoblast lineage two days post-
passage, to allow for cell recovery after the passaging procedure. Differentiation 
media comprised of 20uM  SU5402 (fibroblast growth factor receptor [FGFR] 
inhibitor; Calbiochem) and 100ng/ml rhBMP4 (recombinant human bone 
morphogenetic protein 4; R&D Systems), in DMEM/F-12 supplemented with 4ng/ml 
recombinant human basic fibroblast growth factor (bFGF, GIBCO), 20% 
KnockOutTM Serum Replacement (GIBCO), 1mM L-Glutamine (GIBCO) with 35nM 
β-mercaptoethanol (GIBCO), and MEM  Non-Essential Amino Acids Solution 
(GIBCO). Before differentiation media, referred to as BMP4/SU henceforth, was 
applied to cells, culture was flushed with DMEM/F12 to remove remnants of growth 
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factors present in mTeSRTM1. Cells were incubated in differentiation media for no 
longer than eight days. For hypoxic treatment, filtered nitrogen gas was piped into 
cell culture incubators to maintain oxygen at 3% concentration. 
For storage of hESCs, confluent cell cultures were dissociated as described above, 
and centrifuged at  500rpm for three minutes. The cells were resuspended in 
cryofreezing media mFreSR™ (StemCell Technologies) in the manner recommended 
by the manufacturer, and aliquoted into cryotubes at 1ml per vial. The cryotubes were 
placed in “Mr Frosty” containers (Nalgene) buffered with isopropyl alcohol and 
stored at -80°C overnight, before being transferred into liquid nitrogen for long-term 
storage. When necessary, cells are taken out of long-term storage and rapidly thawed 
in a 37°C water bath. Cells were transferred into 10ml of pre-warmed DMEM/F12, 
and centrifuged at 500rpm for three minutes. The cell pellet was gently resuspended 
in mTeSR and seeded onto tissue culture plates prepared as previously described.
2.2. Gene expression assay. 
2.2.1. RNA extraction.
To extract RNA from cells, 500ul of TRIzol® Reagent (Ambion) was applied to one 
well of a 6-well culture plate, enough to cover the surface. The reaction was left at 
room temperature for five minutes, for cells to be lysed and detached from plate 
surface. Cell lysate was collected in 1.5ml Eppendorf tubes, and 200ul of chloroform 
was added. Tubes were vortexed until a homogeneous cloudy  solution was obtained, 
and then spun at 13,000rpm for ten minutes. The resulting upper aqueous phase, 
containing RNA, was transferred to a new tube, and then processed with the RNeasy 
Mini Kit (Qiagen) for RNA purification. RNA was resuspended in nuclease-free 
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water (Ambion), and quantified on Nanodrop2000 (Thermo Scientific). For 
downstream processing, amount of total RNA used from each sample was normalized 
at 1ug. 
2.2.2. Complementary DNA synthesis.
Complementary DNA (cDNA) was synthesized from purified RNA with the High 
Capacity  cDNA Reverse Transcription Kit (Applied Biosystems). This protocol 
quantitatively converts total RNA to cDNA, generating single-stranded cDNA 
suitable for quantitative PCR. The reaction begins with binding of random primers to 
RNA, at  25°C for ten minutes. This is followed by reverse transcription by the 
proprietary MultiScribeTM Reverse Transcriptase at 37°C for two hours. The final step 
quenches the reaction by heating to 85°C for five minutes. The resultant single-
stranded cDNA can be stored long-term at -20°C. For downstream processing, an 
aliquot of the cDNA is diluted in nuclease-free water to one-twentieth the original 
concentration. 
2.2.3. Quantitative real-time polymerase chain reaction.
The TaqMan® platform (Applied Biosystems) was used for real-time detection of 
quantitative polymerase chain reaction (qPCR) product. Using the TaqMan® 
Universal PCR Master Mix (Applied Biosystems), reactions were set up with 1ul of 
cDNA template, along with readily available TaqMan® probes (Applied Biosystems) 
for the respective human genes. Probes used are included in the Appendix. Reactions 
were run on the Applied Biosystem ViiA7 thermocycler. The geometric increase in 
fluorescence signal detected corresponds to the exponential increase of the product, 
and is used to determine the threshold cycle (Ct) in each reaction. 
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To check for changes in gene expression upon treatment with BMP4/SU, level of 
expression in treated cells was compared to that of undifferentiated hESCs grown at 
the same corresponding oxygen concentration. Expression in treated cells grown at 
20% oxygen concentration (treated sample) were compared to that of undifferentiated 
cells (reference sample) also grown at 20% oxygen concentration, and so forth for the 
3%-oxygen sample set. GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was 
used as the reference gene for normalization, since BMP4/SU treatment affects cell 
morphology  and therefore cytoskeletal gene expression, including the common 
reference gene, β-actin. Although GAPDH is involved in the glycolytic pathway, 
which is affected by oxygen availability, expression was compared between samples 
kept at the same oxygen concentration, and not across differing oxygen 
concentrations. 
To derive change in expression level, Ct values from qPCR were analyzed as follows: 
ΔCt1 = Ct (target gene in treated sample) - Ct (GAPDH in treated sample)
ΔCt2 = Ct (target gene in reference sample) - Ct (GAPDH in reference sample)
ΔΔCt = ΔCt1 - ΔCt2
2-ΔΔCt = Fold-change in expression
2.3. Assay for alternative transcripts.
To determine transcript sequence generated from EPAS1 in the region of the 
identified SNP, I screened the EPAS1 mRNA transcripts from H1 hESC-derived 
trophoblast in the region between exons 2 and 7, within close proximity  to the locus 
of the SNP (located in intron 5). 
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RNA extraction and cDNA synthesis were conducted as previously described. 
Primers flanking exons 2 to 7 of the EPAS1 mRNA transcript were designed on CLC 
Main Workbench. Primer sequences are included in the Appendix. I amplified this 
sequence via high fidelity  PCR, using the KAPA2G Robust  PCR Kit (Kapa 
Biosystems). The reaction was initiated at  95°C for three minutes, and was then 
cycled through 20 seconds at 95°C, 20 seconds at 64°C, and 30 seconds at 72°C, for a 
total of 35 cycles. PCR products were separated on a 1% agarose gel (UltraPure™ 
Agarose, Invitrogen) by  electrophoresis at 90V for 30 minutes. DNA bands were 
excised from the gel and purified using QIAquick Gel Extraction Kit. 
The resulting DNA was cloned into pCR® 2.1-TOPO® vector (TOPO TA Cloning® 
Kit, Invitrogen) and propagated with MAX Efficiency® DH5α™ Competent Cells 
(Invitrogen). Colonies were screened and selected for on LB agar using ampicillin-
based resistance and IPTG/X-gal-blue/white selection. Positively-transformed 
colonies were expanded overnight at 37°C in LB broth, and plasmid was purified 
using Plasmid Mini Kit (Qiagen). 
Plasmid DNA was amplified in the same PCR set up as previously described, in 
search of the sequence between exons 2 and 7 of the EPAS1 transcript. PCR product 
was again resolved by  gel electrophoresis to check for size. Plasmid DNA was 
sequenced for further analysis. Sequence analysis was performed on CLC Main 
Workbench, and sequences were mapped back to the human genome (hg18 assembly, 
NCBI Build 36.1).
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2.4. Screen of human cell lines for presence of SNP.
To aid our search for a human cell line carrying the target EPAS1 SNP, I screened 16 
cell lines received from the International Stem Cell Initiative (2011) and another 30 
from the laboratory of Lawrence Stanton (Genome Institute of Singapore). DNA, in 
solution, from the first 16 cell lines were already available in the lab, from an earlier 
project. The 30 cell lines were received in induced-pluripotent stem cell (iPSCs) 
form. Coming originally from patients of known Han-Chinese ethnicity, the cells had 
been reprogrammed to the induced pluripotent stem cell state, in order to generate 
patient-specific cell lines. For these samples, genomic DNA was harvested from iPSC 
culture using the DNeasy Kit (Qiagen). 
Primers for the regions flanking the SNP were designed on CLC Main Workbench. 
Primer sequences are included in the Appendix. High fidelity PCR was performed as 
previously  described, to amplify the sequence within this region. PCR products were 
separated on 1% agarose by gel electrophoresis at 90V for 30 minutes. Bands of the 
appropriate size were excised and purified using QIAquick Gel Extraction Kit. DNA 
was resuspended in nuclease-free water.
All genotyping was conducted on PCR-amplified fragments derived from genomic 
DNA, using the BigDye® Terminator v3.1 cycle sequencing kit (Applied 
Biosystems). Direct sequencing was performed for all samples on an automated 
sequencer 3730XL Genetic Analyzer (Applied Biosystems). Sequence analysis was 
performed on FinchTV (Geospiza Inc.), a DNA sequence chromatogram trace viewer.
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2.5. Microarray.
RNA extraction was performed as previously described, and assayed for quality 
(RNA integrity number, RIN>8.0) using Agilent  2100 Bioanalyzer (Agilent RNA 
6000 Pico Kit, Agilent Technologies) in accordance with the manufacturer’s protocol. 
300ug of total RNA was processed using Illumina® TotalPrep™ RNA Amplification 
Kit (Ambion). This yielded ample synthesized RNA, or cRNA, which was again 
assayed for quality on the Agilent Bioanalyzer platform. 1ng of cRNA was loaded per 
lane of the microarray (HumanHT-12 v4 Expression BeadChip Kit, Illumina), and 
allowed to hybridize for 18 hours at 58°C. Arrays were washed according to the 
manufacturer’s protocol, and scanned for single-color gene expression signal on 
BeadArray  Reader (Illumina). Microarray analysis was performed on GeneSpring GX 
(Agilent Technologies), using the unpaired student's t-test to determine statistical 
significance with Benjamini-Hochberg multiple-testing correction (FDR<0.05), and 
genes demonstrating ≥ 1.5-fold change were reported as statistically significant.
2.6. Immunocytochemistry. 
Cells were immuno-stained to confirm protein expression. Since the target proteins 
are degraded in presence of oxygen, cell culture was harvested on ice to limit 
enzymatic activity. Cells were fixed in the dish using cold 4% paraformaldehyde 
(Sigma-Aldrich) for 30 minutes, and were then washed thrice with phosphate-
buffered saline (PBS). Cells were permeabilized using 0.3% Triton X-100 in PBS for 
five minutes at room temperature, and were then rinsed thrice with blocking buffer 
comprising 1% bovine serum albumin (Sigma-Aldrich) in PBS. 
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The next step was incubation, with mild agitation, in blocking buffer for 30 minutes 
at room temperature, to limit non-specific immuno-binding by  antibodies. Incubation 
with primary antibodies was performed for one hour at room temperature, also with 
mild agitation. Antibodies were used at 1:1000 dilution - EPAS1 (sc-28706, Santa 
Cruz Biotech) and HIF1α (sc-13515, Santa Cruz Biotech). Prior to incubation with 
fluorescent-conjugated secondary antibodies, cells were washed thrice with blocking 
buffer. 
Secondary  incubation was then performed for 30 minutes at room temperature, with 
mild agitation and away from light, due to the light-sensitive nature of the 
fluorescence conjugates. Secondary antibodies (Molecular Probes®) were used at 
1:5000 dilution - Fluorescein Goat Anti-Rabbit IgG (H+L; F-2765) and Alexa Fluor® 
488 Donkey Anti-Mouse IgG (H+L; A-21202). 
In the final step, cells were stained with 1ug/ml DAPI (4',6-diamidino-2-
phenylindole), a nuclear dye, for three minutes at room temperature. Cells were 
washed thrice with PBS before visualization on the AxioObserver.D1 microscope 
(Carl Zeiss International). 
2.7. ChIP-Seq. 
2.7.1. Chromatin immunoprecipitation.
Cell culture was scaled up  to 10-cm dishes to accumulate the necessary number of 
cells. Cells were harvested on ice and rinsed with cold PBS. To cross-link protein-
DNA complexes, cells were fixed in the dish with 1% formaldehyde (VWR 
International), on a shaker at 100rpm for ten minutes at room temperature. Cross-
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linking reaction was quenched using 375mM  glycine. At the end of the reaction, cells 
were washed twice with cold PBS and scraped off the surface of the dish with a cell 
scraper. Cells were collected by centrifugation at 3,000rpm for ten minutes. 
Lysis was next performed with mild agitation for 30 minutes at 4°C in Cell Lysis 
Buffer comprising 10mM  Tris-HCl pH8.0, 0.25% Triton X-100, 10mM EDTA pH8.0, 
0.1M NaCl, and protease inhibitors. Cellular debris was collected by centrifugation at 
2,000rpm for ten minutes. Nuclei were next lysed for 30 minutes at 4°C, also with 
mild agitation in Nuclear Lysis Buffer comprising 50mM HEPES-KOH pH7.5, 
150mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate (NaDOC), 
1% SDS, and protease inhibitors. Chromatin pellet was obtained by centrifugation at 
20,000rpm for 30 minutes at 4°C. 
Chromatin pellet was then resuspended and washed twice by incubating for 30 
minutes at  4°C in 0.1% Reduced SDS Buffer (0.1%RSB) comprising 50mM  HEPES-
KOH pH7.5, 150mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% NaDOC, 0.1% 
SDS, and protease inhibitors. Chromatin pellet was finally  resuspended in 0.1%RSB 
and sheared to 200-500bp  fragments in a water bath sonicator. Debris was removed 
from solubilized chromatin extract by centrifugation at 13,000rpm for 20 minutes at 
4°C. 
Chromatin extract was immunoprecipitated with primary antibodies adsorbed on 
magnetic beads (Dynabeads® Protein G, Invitrogen). 5ug of respective primary 
antibodies were used per 100ug chromatin extract - EPAS1 (sc-28706x, Santa Cruz 
Biotech), HIF1α (PA316521, Pierce), and isotype control rabbit IgG (sc-3888, Santa 
Cruz Biotech). Beads were primed with antibodies for two hours at 4°C. Chromatin 
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extract was first pre-cleared by  incubation with clean (non antibody-bound) beads for 
two hours at 4°C. An aliquot of pre-cleared chromatin was set aside as ‘INPUT’ for a 
quality check procedure, described in detail later. 
Pre-cleared chromatin extract was then incubated overnight (<16 hours) with 
antibody-bound beads at 4°C. At the end of incubation, beads were pelleted on a 
magnetic stand, and supernatant from each immunoprecipitation reaction was 
collected, for quality  check by Western blot. Immunoprecipitated beads were washed 
thrice with 0.1%RSB by  incubation with mild agitation for five minutes, then rinsed 
once with Reduced NP40 Wash Buffer (10mM Tris-HCl pH8.0, 0.25M  LiCl, 1mM 
EDTA, 0.5% NP40, 0.5% NaDOC), and finally with TE Buffer (10mM  Tris-HCl 
pH8.0, 1mM EDTA). 
Protein-DNA complexes were eluted from the beads in Elution Buffer (50mM  Tris-
HCl pH7.5, 10mM EDTA, 1% SDS) at 68°C for 30 minutes, with agitation at 
1,400rpm. Cross-linking was reversed with Proteinase K (Fermentas) in equal parts 
of Elution Buffer and TE Buffer, at 50°C for four hours, followed by 68°C for six 
hours. Contaminating RNA was removed using 10ug RNase A (Qiagen) in a 30-
minute reaction at 37°C. 
DNA precipitation was achieved through phenol/chloroform extraction. Dissolved 
DNA was mixed thoroughly  with phenol/chloroform/isoamyl alcohol (Calbiochem) 
by vortexing. The suspension was centrifuged at 13,000rpm for ten minutes. The 
supernatant was collected, to which chloroform was added. The suspension was again 
mixed thoroughly by  vortexing, followed by  a second centrifugation step. To 
precipitate DNA, the supernatant was mixed with glycogen, 3M sodium acetate, and 
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ethanol, and incubated at -80°C for two hours. DNA precipitate was collected by 
centrifugation for 30 minutes at 13,000rpm. The pellet  was washed once with 75% 
ethanol, then spun again and finally air dried. The final product, referred to as ChIP-
DNA, was resuspended in nuclease-free water and quantified using the Qubit® 
dsDNA High Sensitivity Assay Kit (Invitrogen). 
2.7.2. Quality check of ChIP-DNA: Western blot and qPCR.
To determine if immunoprecipitation had been successful, the samples were assayed 
by Western blot. ‘INPUT’ sample from pre-cleared chromatin represents total protein 
content prior to immunoprecipitation, whereas supernatant from respective 
immunoprecipitation reactions (IP S/N) would have been cleared of the target protein, 
as it would have been bound by the respective antibody. If the ChIP had been 
successful, the target protein would be present in ‘INPUT’, but absent in its 
corresponding IP S/N. 
Protein samples were prepared with NuPAGE® LDS Sample Buffer (Invitrogen) and 
denatured with 50mM dithiothreitol (DTT; NuPAGE® Sample Reducing Agent, 
Invitrogen) at 70°C for ten minutes. Protein gel electrophoresis was carried out on 
NuPAGE Novex® 4-12% Bis-Tris gels, at 200V for 50 minutes, using NuPAGE® 
MOPS SDS Running Buffer (Invitrogen). Protein standards used were MagicMark™ 
XP Western Protein Standard (Invitrogen) and SeeBlue® Plus2 Pre-Stained Standard 
(Invitrogen). Protein was transferred onto PVDF membranes (Invitrolon™, 
Invitrogen) using NuPAGE® Transfer Buffer (Invitrogen), at 25V for 90 minutes. 
Protein blots were blocked and washed in 0.1% TWEEN® 20 Tris-buffered saline 
(TBS) supplemented with 5% milk (Blotting-Grade Blocker, Bio-Rad). Primary 
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antibodies were used at 1:1000 dilution - EPAS1 (sc-28706x, Santa Cruz Biotech) 
and HIF1α (PA316521, Pierce). Horseradish peroxidase-linked secondary antibody 
was used at 1:5000 dilution (anti-rabbit  IgG; NA934V, GE Healthcare). Blots were 
washed once with stringent buffer (0.3% Triton™ X-100 TBS) and rinsed with PBS 
before visualization using Amersham ECL Prime Western Blotting Detection Reagent 
(GE Healthcare).
Another quality  check for ChIP is to assay by qPCR for the captured DNA fragments. 
Primers for putative HIF binding sites were derived either through a review of the 
literature or by  independent primer design. Four pairs of primers were used in qPCR 
on the SYBR Green platform. Three of them have been identified to bind to promoter 
regions of the genes CA9, PHD3, as well as to a putative binding site referred to as 
Bind ID 17 (Lau et al., 2007; Schodel et  al., 2011). As a negative control, a primer 
pair binding to the region 1kb upstream of Bind ID 17 was designed. Primer 
sequences are included in the Appendix. 
The template for qPCR was ChIP-DNA from the ‘INPUT’ sample as well as ChIP-
DNA from the immunoprecipitated samples. The binding sites, as specified by the 
primers, would be enriched in the ChIP-DNA from immunoprecipitated samples 
when compared to that of the ‘INPUT’. In order to be comparable, amount of 
template per reaction was kept consistent at 0.1ng DNA. The reaction was set up 
using SYBR® Green Real-Time PCR Master Mix (Life Technologies), with 0.2uM 
primer. Real-time detection of the reaction was achieved in the Applied Biosystem 
ViiA7 thermocycler. To calculate enrichment, Ct values from qPCR were analyzed as 
follows: 
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ΔCt1 = Ct (in EPAS1/HIF1α-IP sample) - Ct (Rabbit IgG-IP sample)
ΔCt2 = Ct (INPUT) - Ct (Rabbit IgG-IP sample)
ΔΔCt = ΔCt1 - ΔCt2
2-ΔΔCt = Fold-enrichment
2.7.3. Sequencing.
This protocol describes the preparation of a library of ChIP-DNA in a format 
compatible with Illumina’s cluster amplification and sequencing platforms. The 
objective of the protocol is to add a sequencing primer to the 5’-end, as well as 
adapter sequences to both ends of the DNA fragments. The adapter sequences 
correspond to the two surface-bound amplification primers on the flow-cells used in 
the cluster amplification platform, and the sequencing primer corresponds to the 
primer used in the sequencing-by-synthesis reaction. 
15ng of DNA from the EPAS1 ChIP was processed using a modified version of the 
ChIP-Seq DNA Sample Prep Kit (Illumina). The first step involves DNA end-repair 
using components of the kit as recommended by the manufacturer’s protocol. Prior to 
the following step, DNA was purified using the QIAquick PCR Purification Kit 
(Qiagen). The next step  was to synthesize an adenine-overhang at the 3’-ends of the 
DNA fragments, as described in the kit. The DNA product from this reaction was then 
purified using the MinElute Reaction Cleanup Kit (Qiagen). 
This was followed by ligation of adapters to the ends of the DNA fragments, again as 
recommended by the manufacturer. As in the previous steps, DNA was again purified, 
using the QIAquick PCR Purification Kit. Adapter-ligated DNA was next enriched 
via PCR using the Platinum® Pfx Amplification Kit  (Invitrogen). PCR primers were 
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provided in the ChIP-Seq DNA Sample Prep Kit. The reaction was first incubated at 
94°C for five minutes, and then cycled through 94°C for 15 seconds, then 55°C for 
30 seconds, and 68°C for 60 seconds, for a total of 15 cycles. The DNA product from 
this reaction was then purified using the MinElute Reaction Cleanup Kit. 
The resulting DNA was resolved for size by  electrophoresis on a 2% agarose gel 
(UltraPure™ Low Melting Point Agarose, Invitrogen) in Tris-acetate buffer (TAE, 1st 
Base). The sample was loaded with one lane spacing from DNA ladders (50bp  DNA 
ladder, Invitrogen) to prevent cross-contamination. Electrophoresis was carried out at 
120V for 60 minutes. 
The gel was next stained with SYBR Green I Nucleic Acid Gel Stain (Invitrogen). 
The gel was immersed in a solution of TAE with the gel stain, in a dark box. The set 
up was incubated at  room temperature for 30 minutes, with mild agitation to ensure 
homogeneous staining of the gel. Visualization was achieved using a UV-
transilluminator. The 200bp-300bp section of the DNA smear was excised and 
weighed. DNA was purified from the gel using the QIAquick Gel Extraction Kit, and 
eluted in 20ul of elution buffer provided in the kit. 
DNA was lastly assayed for quality and quantity using the Agilent 2100 Bioanalyzer 
(Agilent DNA 1000 Pico Kit, Agilent Technologies). The sample was diluted to a 
final format of 15ul of 5nM DNA for sequencing on the Illumina HiSeqTM 
Sequencing System. 
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2.7.4. Bioinformatics analysis of ChIP-Seq targets.
Sequences were mapped to reference genome Homo sapiens hg19 (GRCh37) and 
analyzed using an in-house software package “Control based ChIP-Seq Analysis 
Tools” (CCAT; Xu et al., 2010), followed by the Model-based Analysis of ChIP-Seq 
(MACS; Zhang et al., 2008). 
At the time of writing, peaks were manually identified by viewing sequence tracks on 
the UCSC genome data browser, and genes in proximity, or with known associations 
to peak loci, were annotated for binding.
2.8. RNA-Seq.
We interrogated the transcriptomic landscape within the early human placenta to 
study the in vivo expression of HIF-associated target genes, in the context of differing 
oxygen levels in the uterine environments. 
We received total RNA derived from placental tissue biopsies at the Centre for 
Trophoblast Research, University of Cambridge. Prior to the biopsy, gestation age 
was confirmed by ultrasound. Biopsies are from otherwise normal pregnancies, 
obtained through chorionic villus sampling (CVS) in the central region of the 
placenta. Biopsies were immediately preserved cryogenically upon extraction.
In total, 14 samples were grouped into two subsets based on their gestational age. The 
first subset comprises of 8 samples, collected from 7- to 9-week old placentae. The 
second subset comprises of 6 samples, collected from 13- to 15-week old placentae. 
Since maternal blood flow and the corresponding onset of oxygenation normally 
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begins at 12 weeks, the first subset is referred to as ‘pre-flow’, and the second as 
‘post-flow’. 
Upon receipt of samples, RNA was assayed for quality  using Agilent 2100 
Bioanalyzer (Agilent RNA 6000 Pico Kit, Agilent Technologies) in accordance with 
the manufacturer’s protocol. 2ug of good quality RNA (RIN>7.0) was processed in 
96-well format using TruSeq™ RNA Sample Preparation Kit v2 (Illumina). Samples 
were multiplexed, or barcoded with unique adapters provided by the manufacturer. 
Paired-end sequencing on Solexa Genome Analyzer (Illumina) generated 101-base 
reads, which were then mapped to reference genome Homo sapiens hg19 (GRCh37). 
Bioinformatics analysis was performed by Dr. Li Juntao. Sequence reads were 
aligned using TopHat, and transcript assembly and annotation was performed using 
Cufflinks, of the Tuxedo Suite (Trapnell et al., 2012). Differential expression analysis 
was conducted using edgeR (Robinson et al., 2010). Cluster analysis and 





OF THE TARGET EPAS1 SNP
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3.1. Introduction.
To investigate the role that the variant EPAS1 gene might have in contributing to 
reproductive fitness at hypoxic conditions, I first characterized the locus of the target 
SNP as defined by Yi et al. (2010). I inspected the position of the SNP in relation to 
sequence conservation across species, as well as across the genome. 
Since the SNP was found in close proximity  to a splice site, I speculated that there 
might be effects on splicing of the mature transcript, and began investigating this by 
screening the exon-exon junctions of the EPAS1 transcript. This was made possible 
through the use of RNA-sequencing data established previously  (Herath, 2011). In 
this technique, poly-adenylated mRNA transcripts are captured to analyze expression 
at the transcriptomic level (mRNA-Seq). These mature transcripts are used to 
generate smaller fragments known as sequencing reads, which are then mapped to the 
human genome (hg18 assembly, NCBI Build 36.1). To quantify  gene expression, the 
density  or frequency at  which reads map to the genome is calculated as ‘reads per 
kilobase per million mapped reads’ (RPKM). RPKM  values of mapped reads can be 
charted against the genome, and is generally indicative of the expression level for a 
particular (exon) sequence in the genome. From the mRNA-Seq analysis, I found 
discrepancies in exon-exon junctions of the EPAS1 mRNA transcript. 
This then prompted me to test for alternative splicing, by assaying for alternatively 
spliced transcripts. Using robust, high fidelity  PCR and cloning techniques, I captured 
three differently spliced transcripts. However, in order to confirm functionality of the 
SNP, in perhaps repressing the natural splice site, it was necessary  to conduct the 
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assay in a cell line with the SNP. For this purpose, I screened 46 human cell lines for 
the target G-allele SNP. 
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3.2. Characterizing the locus of the EPAS1 SNP. 
The EPAS1 gene comprises 16 exons altogether, with the aforementioned SNP 
located in the intronic region upstream of the sixth exon. As the precise location of 
this SNP was not characterized in the original publication (Yi et al., 2010), I 
investigated this further. Interestingly, I found it to be at chr2:46,441,523; the fifth 
nucleotide upstream of the 5’ splice site of the sixth exon. Such proximity to the 
splice site implies it  may influence splicing of EPAS1. Moreover, given the C-to-G 
substitution, there is likely  interruption of the pyrimidine-rich tract, usually located 
about 5 to 40 nucleotides before the 3’ end of the intron (Breathnach and Chambon, 
1981; Mount, 1982; Freyer et al., 1989). 
At this and immediately  adjacent  positions, there is sequence conservation as 
evidenced from cross species comparisons, for the C allele, as well as the T allele 
(Fig. 3.1). The genomes of the rabbit (Oryctolagus cuniculus), rat (Rattus 
norvegicus), mouse (Mus musculus), and the rhesus monkey (Macaca mulatta) have 
the C allele in this position. The genomes of the elephant (Loxodonta africana), dog 
(Canis lupus familiaris), and cow (Bos taurus) have the T allele. This is in contrast to 
the G allele found in the Tibetan population. 
Genome-wide analysis showed that this particular position (five bases 5’ to the start 
of the exon) has specific base preferences. Base preference indicates the likelihood 
that any  one of the four nucleotide bases adenine, thymine, cytosine, and guanine (A, 
T, C, G) occupies a particular position in the genome. Searching across all exons 
from RefSeq genes in the human genome, we tabulated the occupancy of each 
nucleotide at positions relative to the 3’ splice acceptor sites. This lead to the 
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observation that at the position of the EPAS1 SNP, the strongest base preference is for 
T at 51.1%, followed by C at 31.5%, then A at 8.8%, and finally G at 8.6% (Fig. 3.2). 
This thus adds further credence to the idea that the observed C-to-G switch affects 
splice site function.
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Figure 3.1. Locus of EPAS1 SNP shows some sequence conservation. The SNP is at 
position chr2:46,441,523; 5th nucleotide upstream of the 5ʼ  splice site of the 6th exon, 
indicated by the green arrow. The C allele is found at this position in the genomes of the 
rabbit (Oryctolagus cuniculus), rat (Rattus norvegicus), mouse (Mus musculus), and the 
rhesus monkey (Macaca mulatta). The T allele is found at this position in the genomes of the 
elephant (Loxodonta africana), dog (Canis lupus familiaris), as well as the cow (Bos taurus). 
In contrast, the Tibetan population has the G allele in this position.
91
Figure 3.2. Locus of EPAS1 SNP has specific base preferences. Analysis of genomic 
sequence of all internal exons (i.e. those with an intron on either side) represented in RefSeq 
showed that the 5th position upstream (indicated by position -5) has highest base preference 
for T at 51.1%, followed by C at 31.5%, then A at 8.8%, and finally G  at 8.6%. Position 0: 3ʼ 
splice acceptor sites. 
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3.3. Alternative splicing between exon 2 and 7.
With the locus of the SNP in such close proximity  to the 5’ splice site of the adjacent 
exon, it seemed reasonable to check for exon-exon junctions, as preliminary evidence 
for alternative splicing. I next analyzed mRNA-Seq data previously generated in the 
lab of hESC-derived trophoblast (8 days post-BMP/SU induction). Specifically, I 
examined reads that map to the 3’ ends of the preceding exon and 5’ end of the 
following exon. These reads represent those that span exon-exon junctions. The 
junction between exons 5 and 6 were under-represented compared to that of exons 6 
and 7 (Fig. 3.3). More significantly, the junction between exons 4 and 5 was found to 
be severely under-represented, showing up  in only two instances. Lastly  but most 
intriguingly, there was one instance of an exon-exon junction that  spanned the 3’ end 
of exon 4 and the 5’ end of exon 6, altogether skipping exon 5 (indicated by  the 
asterisk; Fig. 3.3). Despite the H1 hESC line used to generate this mRNA-seq data set 
being homozygous for the C or ‘low altitude’ allele, these read profiles suggested 
alternative splicing.
To investigate the quality  and sequence of EPAS1 transcripts being generated, the 
region of the EPAS1 transcript between exon 2 and exon 7 was amplified using 
robust, reverse transcription and high fidelity PCR, and resolved by gel 
electrophoresis. This resulted in two fragments of distinct sizes; the expected 1,142bp 
fragment and another fragment approximately 500bp  long (Fig. 3.4A). The two 
fragments, deemed fragment a (1,142bp) and fragment b (~500bp), were extracted 
from the gel and individually  cloned into vectors for propagation. Their DNA was 
amplified using the same primers as before, in search of the sequence between exons 
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2 and 7 of the EPAS1 transcript. All plasmid clones derived from fragment a 
presented with a DNA band of approximately 1.1kbp (Fig. 3.4B). Clones derived 
from fragment b yielded bands of varying sizes, between 400bp to 500bp. Clones 
were also sequenced for further analysis. Sequences are included in the Appendix. 
Analysis of sequences revealed that all clones generated with fragment a yielded 
canonical transcripts that had been appropriately spliced (i.e. identical to the RefSeq 
transcript), with no evidence of exon skipping (Fig. 3.4C). In contrast, clones 
generated with fragment b yielded a variety of alternatively-spliced transcripts. These 
transcripts differed in the position of their splice junctions, indicating novel splice 
sites. Two populations of transcripts featured prominently; one in which exon 2 had 
been spliced to exon 6, and another in which exon 3 had been spliced to exon 6 (Fig. 
3.4C). In each of these populations, a novel splice junction had been generated. More 
pertinently, both scenarios featured a novel splice acceptor site within exon 6, 
indicating the presence of cryptic splice sites. 
Since the SNP was found just five bases upstream of exon 6, I reasoned that, by 
proximity, it  would affect splicing at the exon 5-6 junction more so than it would 
upstream splicing. Nevertheless, this reasoning would be verified when testing the 
functionality of the SNP. At this juncture, using synthesized exon 2-7 transcript 
sequences, splice acceptor sites within exon 6 were mapped back to existing mRNA-
Seq data. In the region of an exon, the detected level of expression is represented as a 
histogram, and is referred to as the mRNA-Seq footprint  of the exon. Within the 
footprint of exon 6, I mapped the loci of the novel splice acceptor sites (Fig. 3.5). 
Both novel splice sites featured the invariant dinucleotide AG, characteristic of the 3’ 
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splice acceptor site. The loci of the splice sites were marked with relatively strong 
peaks downstream, indicating stable and/or strong expression of the following 
sequence (Fig. 3.5A). Additionally, one of the splicing scenarios preserved the 
original reading frame of the codons (Fig. 3.5i), while the other did not (Fig. 3.5ii). In 
the case of (i), 50 codons/amino acids were shaved off the original 68 specified by 
exon 6. As for (ii), an additional 6 codons were fully  omitted, with the 7th only 
partially removed, leading to a frameshift.
Next, I examined the mRNA-Seq data from chorionic villus samples (see Chapter 5), 
to assess the expression of the EPAS1 transcript, and any variant isoforms. Bearing in 
mind that none of the samples were positive for the G allele, it  was unsurprising that 
EPAS1 expression remained orthodox, with no evidence of variant isoforms, as 
visualized through de novo transcript assembly, an analysis performed by Dr. Li 
(Computational and Systems Biology, GIS).
Lastly, in order to functionally characterize the SNP, the next logical step was to 
obtain a human cell line with the G-allele SNP, so that we may analyze splicing of 
EPAS1 in the presence of the SNP.
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Figure 3.3. Screening of exon-exon junctions in the EPAS1 mature transcript showed 
under-representation of exon 4-5 junction and exon 5-6 junction. Pink peaks depict 
exons 5 and 6 expression, as derived from mRNA-Seq of the EPAS1 transcript. Red bars 
represent connections between exons as detected through the mapping of sequencing reads 
to the genome. Red bars between exon 5 peak and exon 6 peak thus represent reads that 
map  to exon 5-6 junction. Exons 4 and 7 are not included, but red bars extending to the right 
from exon 6 represent reads that map  to exon 6-7 junctions, and those that extend to the left 
from exon 5 represent reads that map  to exon 4-5 junction. The number of red bars 
presented thus indicate the frequency of detection of these exon-exon junction-spanning 
reads. Exon 5-6 junction was found to be under-represented compared to that of exon 6-7. 
Exon 4-5 junction was found to be far more drastically under-represented, coming up  in only 
two instances. The red bar marked by the asterisk represents an exon 4-6 junction.
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Figure 3.4. Alternative splicing between exons 2 and 7 of the EPAS1 gene. (A) The 
region between exon 2 and exon 7 of the EPAS1 gene was amplified by PCR, and two 
fragments of distinct sizes were found. The larger fragment was at the expected size of 
1,142bp, and the smaller fragment was ~500bp  long. (B) When individually cloned and 
propagated, the larger fragment a yielded clones carrying the full-sized ~1kb  fragment, while 
fragment b yielded varying clones carrying fragments of varying sizes (400bp  - 500bp). (C) 
Upon sequencing, clones that had been transformed with fragment a presented canonical 
transcripts, with no evidence of exon skipping. On the other hand, clones that had been 
transformed with fragment b presented a variety of alternatively spliced transcripts. “Other 
aberrant splicing”  represents transcripts that were detected but with no reproducibility. Two 
populations of alternatively spliced transcripts were found in significance; one at 21%, in 




































































































































































































































































3.4. Screening of human cell lines for the target EPAS1 SNP.
As reported by Yi et  al. (2010), the SNP in question exists in the Tibetan population at 
a frequency of 87%, and in the Han-Chinese population at a frequency of 8.75%. 
Based on this statistical probability, I sought to screen 30 locally derived Han-
Chinese cell lines for the presence of the target SNP. I also screened 16 other cell 
lines, of various ethnic backgrounds, from a collaborative study with the International 
Stem Cell Initiative (ISCI). 
Having identified the locus of the SNP, primers were designed to flank the intronic 
region containing the SNP. This region was amplified from genomic DNA of 
respective cell samples and sequenced to check for the presence of the G allele at the 
noted SNP position. 
All 16 of the ISCI samples were negative for the G allele, and although there was an 
expected yield of two to three cell lines, out of the 30 Han-Chinese samples (8.75% 
of 30 samples), none of the samples yielded the targeted SNP. All the cell lines 
examined had the C allele in the position of the SNP, as opposed to the G allele as 
found in the Tibetan population. Figure 3.6 illustrates the typical sequencing 
chromatogram generated from the samples. 
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 Figure 3.6. Representative sequencing chromatograms from screened samples. None 
of the samples yielded the target SNP with the G allele. -5 denotes the position of the SNP, 
and 0 denotes the 5ʼ  splice site of the exon. All the samples had a clear peak for the C allele 




As a start to studying the target EPAS1 SNP, we inspected its locus within the gene. 
The SNP is found at the fifth nucleotide upstream of the 5’ splice site of the sixth 
exon. At this locus, there was sequence conservation across some species for the C 
allele, as well as the T allele, but not the G allele as found in the Tibetan population. 
Universally across all RefSeq introns, this position has a ranked preference for bases; 
T (51.1%), C (31.5%), A (8.8%), then G (8.6%). Additionally, when I examined 
occurrence of alternative splicing in proximity to the SNP, we found evidence of 
cryptic splice acceptor sites within exon 6, just  downstream of the SNP. While this 
finding was promising, I next needed to conduct the same studies in the presence of 
the G allele, to prove the functionality of the SNP. To that end however, I have been 
unsuccessful in our search for a human cell line with the target SNP. 
3.5.1. Significance of the locus of the SNP.
Based upon the sequence conservation observed at the locus of the SNP, it appears 
that the C allele is important, whereas the presence of the G allele is novel and unique 
to the Tibetan population (Fig. 3.1). It is widely accepted that sequence similarities 
serve as evidence for structural and functional conservation, as well as of 
evolutionary  relationships between the sequences (Kimura, 1979; Cooper and Brown, 
2008). Generally, nucleotides with important molecular functions evolve more 
slowly. Active sites of enzymes, DNA-binding domains of transcription factors, and 
residues essential for structural maintenance constitute some of the most highly 
conserved sequences, as changes in amino acid residues are particularly deleterious 
(Suckow et al., 1996; Simon et al., 2002). Correspondingly, within cis-regulatory 
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elements of the genome, sites that have a stronger role in regulation accumulate fewer 
substitutions than those that contribute less (Brown et al., 2007).
Based on our genome-wide analysis, a hierarchy was determined for the base that 
occupies the position of the SNP. This analysis was done by  tabulating the occupancy 
of a particular nucleotide at positions relative to the 3’ splice acceptor sites. Relative 
to this position, exonic sequences are found downstream. Exons specify  codons for 
amino acids, and ultimately the nucleic acid sequence for primary protein structure. It 
stands to reason that if all exonic sequences were compared and tabulated, each 
position has an equal likelihood of being occupied by any  of the four nucleotide 
bases. This pattern is thus evident in our results (Fig. 3.2). Moreover, it is also evident 
that just upstream of 3’ splice acceptor sites, there is a greater propensity for T and A 
nucleotides (>50%) compared to C and G nucleotides, reflecting the region for the 
pyrimidine-rich tract. A region with a specified recognition or functional motif would 
indicate explicit base preferences. For example, the consensus sequence of 3’ splice 
sites has been reported as “(C or A) A G | G T (A or G) A G T” where “|” represents 
the boundary between intron and exon (Mount, 1982). To that end, the findings of this 
analysis corroborate fairly  well (Fig. 3.2); the consensus sequence at the 3’ splice site 
is “(C or T) A G | G T (A or G) A G T”. This thus serves to validate our analysis. 
Examining the position of the EPAS1 SNP, it was evident that the highest base 
preference is for T (51.1%), followed by C (31.5%), then A (8.8%), and finally G 
(8.6%). The C-to-G switch in this position goes against expectations; a base switch 
for the least  preferred nucleotide could possibly influence splicing, although still 
speculative at this juncture. 
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Nevertheless, the locus of the SNP is at the 3’ end of what could likely be the 
pyrimidine-rich tract of that intron (Fig. 3.5). A change to the purine base G as in the 
SNP disrupts the pyrimidine sequence, and would likely impact binding by  U2 small 
nuclear ribonucleoprotein (snRNP) auxiliary factor 65 kDa (U2AF65). Meanwhile, 
cross-species comparison indicates that  even with random genetic drift (C/T), the 
pyrimidine nature of this locus has been preserved (Fig. 3.1). 
U2AF65 mediates the first step in splicing, and has been found crucial for vertebrate 
development (Golling et al., 2002). Deficiencies in this factor are associated with 
cystic fibrosis (Zuccato et al., 2004), myotonic dystrophy (Tiscornia and Mahadevan, 
2000), and some cancers (Davies et al., 1998; Fay et al., 2009; Chen et al., 2011). 
Splicing involves a number of trans-acting factors, like the snRNPs, as well as cis-
acting determinants, including the splice donor site (5’ end of intron), the splice 
acceptor site (AG at 3’ end of intron), the branch point  sequence (BPS) some 20-35 
bases upstream of the splice acceptor site, and also the pyrimidine-rich/
polypyrimidine tract  (spanning 4-24 bases) between the BPS and splice acceptor site 
(Gao et al., 2008). Pre-mRNA splicing complex assembly is mediated by  two specific 
pre-mRNA-snRNP interactions; the U1 snRNP binds to the splice donor site, and U2 
snRNP binds to the BPS. However, prior to these interactions, during the early  stages 
of pre-mRNA splicing, U2AF65 is able to universally recognize and bind degenerate 
pyrimidine tracts (Ruskin et al., 1988; Zamore et al., 1992), via independent binding 
ability  of two central RNA recognition motifs (Zamore et al., 1992; Banerjee et al., 
2004; Jenkins et al., 2013). U2AF65 then facilitates the ATP-dependent association of 
U2 snRNP with pre-mRNA at the branch point (Ruskin et  al., 1988). In this way, 
U2AF commits the pre-mRNA to the first critical ATP-dependent step  of splicing, 
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and its binding is thus often regulated during alternative splicing (Smith and 
Valcarcel, 2000).
Although degenerate sequences (splice site signals) mark intron boundaries, U2AF65 
is able to recognize these diverse pyrimidine tracts via the action of RRMs. While the 
exact mechanism remains unclear, it was recently  found that RRM1 was more 
promiscuous for cytosine-containing tracts, and RRM2 was more stringent (Jenkins et 
al., 2013). This thus implies that while U2AF65 binding may be forgiving  (RRM1) to 
certain alterations in pyrimidine tract sequence, there are some changes that may not 
be tolerated due to the stringency of RRM2. 
It has been shown that interruption of the polypyrimidine tract affects splicing (Freyer 
et al., 1989; Zuccato et al., 2004), and therefore may also impact phenotypes. A 5-
base (CTTCT) deletion polymorphism in intron 3 of TNNT2, one of the genes 
responsible for hypertrophic cardiomyopathy, has been associated with a 
predisposition to prominent left ventricular hypertrophy (Komamura et al., 2004). 
The deletion allele significantly affected mRNA expression pattern, by skipping exon 
4 during splicing, leading the authors to postulate that the five bases were likely part 
of the intronic polypyrimidine tract, the loss of which therefore impacted splicing. 
In the case of the EPAS1 SNP, a G substitution just upstream of the splice acceptor 
site (region for pyrimidine-rich tract), in a position that  was also conserved across 
species for pyrimidine, could possibly impact U2AF65 binding and consequently 
splicing. Precisely how this is achieved cannot yet be determined with the current 
analysis. Although the samples used in this study were derived from the C-allele 
genotype, the sheer strength of EPAS1 expression in the hESC-derived trophoblasts 
104
meant that EPAS1 mRNA was in abundance, and thus brought to light low-level 
alternative splicing scenarios, including the utilization of cryptic splice sites. 
Cryptic splice sites resemble natural splice sites, but are illegitimate, and emerge as 
the dominant site when the natural splice site has been compromised. According to a 
hypothesis originally put forth in 1992, the “probability of cryptic splice site 
utilization is an increasing function of the saturation of the local DNA sequence 
environment with such motifs” (Krawczak et al., 1992) While one coping mechanism 
is to opt for the next legitimate splice site and skip exons, in the presence of relevant 
splicing motifs, cryptic splice site utilization becomes more prevalent (Krawczak et 
al., 2007). Although the study asserted that  this trend was more evident in splice 
donor sites than in acceptor sites, cryptic splice acceptor sites are not altogether 
foreign in eukaryotic splicing systems (Roshon et al., 2003). A mutation in the first 
intron’s splice acceptor site of the SHOX gene, controlling long bone growth, 
activated a cryptic splice acceptor site in exon 2 (Danzig and Levine, 2012). A study 
with an approach similar to ours, using reverse transcription and PCR analysis, 
identified 2 alternative splicing products of the CFTR gene, produced by the 
activation of two different cryptic acceptor splice sites (Costantino et al., 2013). In 
contrast to our exon 6 partial exclusion, these cryptic splice acceptor sites resulted in 
pseudoexon inclusions. 
In our analysis, two cryptic splice sites marked by  the invariant dinucleotides AG 
emerged in exon 6, downstream of the natural splice acceptor site (Fig. 3.5). Within 
the vicinity of the cryptic splice sites (~10 bases upstream), there were clear 
polypyrimidine tracts (>4 pyrimidines) as well, strengthening the overall splicing 
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motif. Overall, I conclude that should the natural splice acceptor site of intron 5 be 
compromised, the cryptic sites defined in this study will be utilized in splicing. What 
remains to be seen however, is if the EPAS1 SNP does indeed compromise the natural 
splice acceptor site of intron 5, given its proximity. This however requires 
examination of splicing events in the context of the G-allele SNP.
3.5.2. Impact of cryptic splice sites in exon 6.
Our analysis revealed three differently spliced transcripts; the canonical one that 
utilized the natural splice acceptor site, and two others which had utilized cryptic 
splice sites within the adjacent exon. In the non-canonical scenarios, at least 50 
codons were omitted from the original 68 specified by exon 6 (Fig. 3.5). The 
utilization of one of the cryptic splice sites uncovered in this study would lead to a 
frameshift (Fig. 3.5ii), likely resulting in missense and/or premature termination. In 
the alternative scenario (Fig. 3.5i), a significant portion of the exonic sequence (50 
out of 68 codons) would be removed. When EPAS1 mRNA sequence (as identified on 
RefSeq) was mapped using CLC Main Workbench, it was found that exon 6 lay  in 
between two functional domains of the EPAS1 protein; PAS and PAS3 (Fig. 3.7A). 
The PAS domain, while first recognized as a signaling module responsible for sensing 
oxygen, amongst other stimuli (reviewed by Taylor and Zhulin, 1999), is also 
required for structural integrity  of the eventual functional complex (Chapman-Smith 
et al., 2003). The PAS3 domain of EPAS1 has been found to bind the analogous HIF-
β/ARNT domain, disruption of which interferes with the ability  of full-length HIF to 
respond to hypoxia in living cells (Erbel et al., 2003). In a follow-up study, the 
authors proposed a new model for the interaction of EPAS1 and HIF-β/ARNT PAS 
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domains in the context of the functional transcription factor (Card et al., 2005). The 
visualization shows a “potent cooperative interaction” between the PAS domains of 
both proteins, which may provide additional affinity and/or specificity for the 
complex (Fig. 3.7B). It also demonstrates the role of linkers between PAS domains in 
accommodating the associations to form the heterodimer. The authors posit that the 
PAS domains form a co-operative, intermolecular tetramer of PAS components that 
serve to “convert an inherently  weak set of protein/protein and protein/DNA 
interactions into a stronger binding force that permits the formation of a functionally 
viable complex.” 
Should the frame-preserving cryptic splice site defined in this study be utilized during 
pre-mRNA processing, it would lead to a major loss of the linker region between the 
PAS domains of EPAS1. This would presumably lead to inefficient, if at all, 
association of the PAS domains in forming the heterodimeric HIF transcriptional 
complex, and could likely inhibit or impede binding to HREs and further gene 
regulation of downstream targets. 
In light of the EPAS1 SNP in the Tibetan population, I now hypothesize that  the C-to-
G substitution interferes with U2AF65 binding, altering splicing with the utilization of 
cryptic splice acceptor sites. At this juncture, two possibilities arise; utilization of the 
frame-shifting splice site, resulting in a missense protein, or utilization of the frame-
preserving splice site, resulting in partial exon-exclusion in the region linking two 
functional protein domains. Either situation would likely  lead to, at best, a 
compromised ability of the transcription complex to respond to hypoxia. This 
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hypothesis would be verified through assessment of EPAS1 splicing in the context of 




                               
Figure 3.7. Exon 6 as the spacer/linker between two functional domains of EPAS1. (A) 
EPAS1 mRNA and coding region as identified by RefSeq; 16 exons in EPAS1 mRNA, CDS 
denotes the coding region. Upstream of the CDS would be the 5ʼ untranslated region (5ʼ 
UTR), and downstream would be the 3ʼ  UTR, followed by the poly-A tail. Within the CDS, four 
conserved domains have been mapped; PAS, PAS3, HIF-1, and HIF-1a CTAD. Exon 6 
mostly makes up  the space/linker between the two PAS domains. (B) A model of interaction 
between HIF-α and HIF-β/ARNT PAS domains, as proposed by Card et al. (2005). Linkers 
between functional domains accommodate the associations to form the complex. Pre-α 
refers to α-helical elements that are predicted to form to the N-terminal side of the ARNT and 
HIF-a PAS-A domains.
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3.5.3. The SNP screening process.
The search for a human cell type inherently  carrying the target SNP fell short. In a 
study conducted early last year by Buroker et al. (2012), they used a similar 
genotyping technique, by direct sequencing of PCR-amplified genomic DNA. Their 
samples were obtained from 162 Han-Chinese and 79 Tibetan patients, of which they 
successfully  identified 2% of the Han-Chinese subgroup and 28% of the Tibetan 
subgroup  to be homozygous for the G-allele SNP. Since the methodology is thus 
validated, the fruitless search could be attributed to the unfortunately  conservative 
sampling size. 
Based on the sequencing chromatograms, all our samples had strong clear peaks for 
the C allele at  the specified position. However, sample P10 represents a typical 
sample where there was a background peak for another allele, which can be attributed 
to leaky signaling across the read for the sample (Fig. 3.6.). Overall, the background 
trace for sample P10 is not as clean as that of the other samples shown. Apart from 
that, the results clearly  indicate that  none of the cell lines available were positive for 
the G-allele.
Alternative methods to overcome this obstacle would be to engineer site-directed 
mutagenesis, to knock-in the desired gene variant, or to silence the inherent gene and 
induce artificial expression of the variant gene via a BAC (bacterial artificial 
chromosome) system. However, these steps are notoriously  time-consuming, and not 
to mention, challenging (Zwaka and Thomson, 2003). For these reasons, I chose not 
to further pursue this investigation of the SNP. Instead, efforts were focused on 
elucidating the functional role of EPAS1/HIF2α within the human trophoblast.
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3.6. Conclusion.
This study had set out to prove the functionality  of the C-to-G SNP in the EPAS1 
gene. A striking characteristic of this SNP was its prevalence in Tibetan highlanders, a 
geographically-isolated population that have survived generations of hypobaric 
hypoxia courtesy of their native habitat. The emergence of the SNP is testimony for 
the functionality of the sequence element. While studies have associated this SNP 
with decreased hemoglobin concentration phenotypically (Beall et al., 2010), none 
have shown the molecular interactions involved in achieving the resultant phenotype. 
As a start, this study assessed the likelihood for alternative splicing in the vicinity  of 
the SNP locus. It was evident, through genome analysis across species, as well as 
genome-wide analysis of base preferences, that this locus was preserved for 
pyrimidine. Analysis of mRNA-Seq data then unveiled the discrepancies in exon 
junctions, which led to the search of alternatively-spliced EPAS1 transcripts. This 
culminated in the discovery  of two cryptic splice sites in proximity to the locus of the 
SNP. Despite conducting studies in the context of the C-allele SNP, the significant 
expression of EPAS1 in the hESC-derived trophoblast culture meant that EPAS1 
mRNA was in abundance, therefore enabling the identification of the lesser-used 
cryptic splice sites. Nevertheless, examination of splicing in the presence of the G-
allele SNP was necessary to confirm the functionality  of the SNP in abolishing the 
natural splice acceptor site five bases downstream of its position, and the emergence 
of either or both cryptic splice sites as the default splice acceptor site. Alternatively, 
in order to investigate if splicing at the cryptic sites does result  in phenotypic 
changes, a functional assay involving the (partial) deletion of exon 6 would be useful.
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Both possibilities predicted from the cryptic splice sites involve modifications of the 
affected exon, and either situation would result in attenuation of HIF activity and 
response to hypoxia. Since the Tibetan population do not display symptoms of 
altitude sickness, one of which is increased hematocrit, and since the SNP has been 
associated with decreased hemoglobin (Beall et al., 2010), it could be likely that the 
SNP, by compromising HIF activity, in effect serves to mitigate this debilitating 
condition in the Tibetan population. Hence, these native highlanders are able to 
escape the dire symptoms. While that may  be so, the question still remains: how then 







This study sought to identify  the binding targets of EPAS1/HIF2α in the human 
trophoblast, in an effort to understand its role in the development of the human 
placenta and the oxygen-modulation of the uterine environment. As an oxygen-
sensitive protein, EPAS1/HIF2α is thought to be a key contributor to the progression 
of trophoblast cell types, which is modulated by  oxygen levels within the uterine 
environment. The initial climate of physiological hypoxia allows for extensive 
proliferation of cytotrophoblasts, which upon increased oxygen concentrations, form 
the invasive cells that give rise to the placental villi (Genbacev et al., 1997; Robins et 
al., 2007). 
Our in vitro system was an hESC-derived trophoblast culture, as previously 
established in the lab (Luo, 2008). hESCs were induced to differentiate into the 
trophoblast lineage through the use of growth factor BMP4 and fibroblast growth 
factor receptor (FGFR)-specific tyrosine kinase inhibitor, SU5402. Luo (2008) 
presented an extensive list of trophoblast-associated genes, including transcription 
factors as well as placental genes, that were upregulated within hours of treatment, 
exemplifying the sensitive nature of the treatment. Additionally, Luo’s work in 
profiling the transcriptome of the resultant culture showed the lack of expression of 
genes that mark the ectoderm (SOX1, PAX6, GFAP and NEUROD1), mesoderm (T/
BRACHYURY, PECAM1, MYF5, and MYOD1), endoderm (SOX17, GATA4) and 
germ cells (SYCP3), this time exemplifying the specificity of the treatment. 
Moreover, in a separate thesis, Herath (2011) analyzed the protocol designed by Luo 
through transcriptome sequencing, and compared the profile of gene expression with 
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published microarray datasets derived from a range of tissue and cell types. 
Unsupervised hierarchical clustering indicated that 6-day old cultures from the in 
vitro differentiation protocol was most similar to the placenta as a tissue type, and 
most similar to EVTs and cytotrophoblasts, as a cell type. Altogether, much of the 
earlier work provide evidence in support of our in vitro system as representative of 
the true trophoblast. 
The protocol, like most standard culture protocols, was designed for 20% oxygen 
conditions. However, since EPAS1/HIF2α is at risk of oxygen-dependent degradation 
at normoxia, the protocol was modified and subjected to 3% oxygen instead, which 
also mimics the in vivo uterine environment (Rodesch et al., 1992; Rodesch et al., 
1992; Jauniaux et al., 2000; Jauniaux et al., 2001; Okazaki and Maltepe, 2006). 
However, there was a need to first verify  and profile the gene expression of the 
resultant culture at 3% oxygen. This was done by global microarray analysis, with 
further verification of gene expression by qPCR. 
After establishing the trophoblast lineage of the cells, EPAS1/HIF2α protein 
expression and nuclear localization were first confirmed via immunocytochemistry. 
Western blot then verified the ChIP protocol, demonstrating the presence of the target 
EPAS1/HIF2α protein in the pre-immunoprecipitation lysate, and the efficient 
clearing of the target protein from the supernatant of the immunoprecipitation 
reaction. ChIP-DNA extracts were interrogated by qPCR for putative binding targets 
of EPAS1/HIF2α, drawn from existing literature (Lau et al., 2007; Schodel et al., 
2011), before being sequenced for physical binding targets. These targets are 
indicative of the HIF-transcriptional response in the trophoblast cell type, offering 
insight to the role of EPAS1/HIF2α in placental development.
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In vitro as well as in vivo expression and upregulation of genes associated with these 
targets were then assessed. In vitro samples were obtained from 6-day BMP4/SU-
treated culture grown in 3% oxygen, and upregulation was assessed by comparison 
with that cultured in 20% oxygen. In vivo expression was verified by RNA-Seq of 14 
chorionic villi samples obtained from collaborators in Cambridge (see Chapter 5). 
Samples were categorically  split by gestational age; 7- to 9-week old and 13- to 15-
week old. Given the understanding that maternal blood perfusion of the placenta 
occurs between 10 to 12 weeks of gestation (Hustin and Schaaps, 1987; Jauniaux et 
al., 1992; Jauniaux et al., 1995; Jaffe et al., 1997; Burton et  al., 1999), the former was 
deemed pre-flow, and the latter post-flow. The implication therein was that pre-flow 
samples were indicative of gene expression in low oxygen (therefore HIF activation), 
and consequently in post-flow, EPAS1 targets would be downregulated. 
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4.2. In vitro differentiation into trophoblast lineage at 20% and 3% oxygen. 
Cell culture, and BMP4- and SU5402-directed differentiation (BMP4/SU) were first 
observed for variability in growth and maintenance between 20% and 3% oxygen. 
hESCs were able to proliferate fairly efficiently in 3% oxygen, comparable to that in 
20% oxygen. hESCs when grown in culture form circular colonies (Fig. 4.1A). In 
cultures kept at 20% oxygen, masses of cells were occasionally  found growing out 
from the centre of the colonies after several days, indicative of spontaneous 
differentiation (Fig. 4.1A[iv]). hESCs cultured in 3% oxygen exhibited far less 
spontaneous differentiation. 
Upon BMP4/SU treatment, cell differentiation began at the periphery of the colony, 
evidenced by morphology  (Fig. 4.1B). Cells take on a flattened form, with increased 
cell area as well as increased cytoplasmic-nuclear ratio. Over several days, 
differentiation proceeded in a radial fashion toward the centre of the colony (Fig. 
4.1B[ii] & [iv]). Overall, based on morphology, maintenance of cells in culture as 
well as differentiation ability of cells were observed to be similar at 20% and 3% 
oxygen. 
Since the BMP4/SU treatment had been previously established for 20% oxygen 
conditions, it  was necessary to determine if the treatment would be compatible in 3% 
oxygen. I determined this by global microarray analysis for gene expression in cells 
treated for 2 days and for 6 days, in either 3% or 20% oxygen, with biological 
duplicates, and compared expression with untreated cells grown in 3% and 20% 
oxygen respectively. Each array had a coverage of 47,323 probes.
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Upregulated genes (>1.5-fold, p-value<0.05) were examined by Venn analysis to 
derive overlapping sets of genes that have been upregulated due to hypoxia and/or 
BMP4/SU treatment  (Fig. 4.2). After subtracting genes upregulated as result of the 
change in oxygen level, 2,312 genes were found commonly  upregulated in 3% and 
20% oxygen conditions, after 2-day treatment. Similarly, after 6-day treatment, 3,654 
genes were commonly upregulated between the two conditions.
Of the 2,312 genes upregulated at 2 days, many  were known trophoblast-associated 
genes, such as GCM1, CK7, ID2, DLX3, TFAP2C, and TFAP2A. Interestingly, 
TFAP2A was found to be also upregulated in untreated hESCs grown in hypoxic 
culture. By 6 days of treatment, this list  grew to include genes for hCG (CGA, CGB, 
CGB1, CGB5, and CGB8), syncytin (ERVWE1), the marker for EVTs (HLA-G), and 
placental growth factor (PGF). In the case of ID2 and TFAP2C, they were no longer 
found to be upregulated by  6 days, in 20% oxygen, but remained upregulated in 3% 
oxygen (Fig. 4.2). 
To validate the microarray, it was imperative to assay by  qPCR for the expression of 
specific genes. Moreover, this would further establish that BMP4/SU treatment under 
hypoxia was effectively inducing the trophoblast lineage. Gene expression profiles 
were also compared to that of normoxic BMP4/SU treatment.
Expression of the pluripotency  markers OCT4, SOX2, and NANOG, along with a 
panel of trophoblast and placental genes were examined (Fig. 4.3). OCT4, SOX2, and 
NANOG were similarly downregulated between normoxic and hypoxic BMP4/SU 
treatment, indicating the loss of the pluripotent stem cell state (Fig. 4.3A). The 
upregulation of trophoblast transcription factor genes, CDX2, GATA2, GATA3, DLX3, 
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TFAP2A, TFAP2C, HAND1, ID2, and MSX2, in both normoxic and hypoxic BMP4/
SU treatment indicated that cells were differentiating into the trophoblast lineage 
(Fig. 4.3B). Expression of transcription factor CDX2 was most strongly  upregulated 
at 2 days, in both treatments, then dropped thereafter. In contrast, most of the other 
trophoblast transcription factors displayed further upregulation following the initial 
increase at day 2. Strikingly, ID2 expression showed downregulation at days 6 and 7 
when cultured at  20% oxygen, but  continued to remain upregulated at 3% oxygen, in 
line with the microarray analysis. 
The placental genes assayed include PGF and CGA, which showed the most 
remarkable increase in expression upon BMP4/SU treatment, with a significant jump 
between days 2 and 4 (Fig. 4.3B). Likewise, PGF expression profile demonstrates a 
similar significant increase between days 2 and 4. Keratin 18 (KRT18), a gene 
expressed in the placenta, and EPAS1 remains hugely increased throughout the 7 days 
of treatment, while HIF1A showed a small increase in gene expression in the first 4 
days, followed by  downregulation thereafter. These trends were similar across both 
oxygen conditions.
Overall, the BMP4/SU treatment in hypoxic conditions appeared to be as effective as 
that in normoxic conditions, in its ability  to effectively  induce the trophoblast lineage 
in vitro, as evidenced by the upregulation of trophoblast transcription factor genes as 
well as placental genes. Interestingly, upregulation of CDX2, GATA3, HAND1, and 
ID2, were significantly  stronger in BMP4/SU treatment at 3% oxygen than it was at 
20%. 
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Figure 4.1. Culture of hES and trophoblast-induced cells are comparable between 20% 
and 3% oxygen conditions. (A) Colony and cell morphology of untreated hESCs, cultured 
at 20% and 3% oxygen conditions, were found to be similar in early days. After several days, 
outgrowth of cells from colonies cultured at 20% oxygen was not uncommon (indicated by 
red arrow), but this was not observed in the 3%-oxygen cultures. (B) Trophoblast-induced 
cultures (BMP4/SU-treated) displayed cell differentiation beginning at colony periphery, and 
progressed radially toward the centre. Cells take on a flattened form, with increased cell area 
as well as increased cytoplasmic-nuclear ratio. 
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Figure 4.2. Venn analysis of upregulated genes. Through microarray analysis, 2,312 
genes were found commonly upregulated (>1.5 fold) upon 2-day treatment, while that of 6-
day treatment was 3,654 genes. Genes that were potentially upregulated as a result of 
hypoxia were subtracted; these genes were identified as upregulated in untreated/hESCs 
cultured at 3% oxygen conditions. 
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Figure 4.3. Expression of pluripotency markers as well as trophoblast markers and 
placental genes in BMP4/SU treatment at 20% and 3% oxygen conditions. Left column, 
gene expression profiles for cells treated with BMP4/SU at 20% oxygen concentration; right 
column, at 3% oxygen concentration. Genes were assayed at 2, 4, 6, and 7 days of 
treatment. (A) Pluripotency markers OCT4, SOX2, and NANOG are significantly 
downregulated in both 20% and 3% oxygen conditions. (B) Trophoblast transcription factors 
and placental genes are similarly upregulated between the two oxygen conditions, with the 
exception of CDX2, GATA3, HAND1, and ID2  (by studentʼs t-test, **p-value<0.05). The 
upregulation of these four genes are stronger in hypoxic conditions than in normoxic 
conditions. 
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4.3. EPAS1 targets by ChIP-Seq. 
Prior to ChIP, in vitro protein expression of EPAS1 was confirmed by  immuno-
staining (Fig. 4.4A). The fluorescence signal was strongest in the nuclei, with 
expression significantly  stronger in cultures kept  at 3% oxygen than that at  20% 
oxygen, suggestive of oxygen-dependent degradation. Western blot of nuclear lysates 
indicated that EPAS1/HIF2α protein was expressed upon BMP4/SU treatment at 3% 
oxygen (Fig. 4.4B). In contrast, HIF1α protein was present in untreated hESCs 
cultured at 3% oxygen, but  absent under the treatment. I included the post-
immunoprecipitation supernatant (IP S/N) alongside the INPUT fraction (pre-cleared 
nuclear lysate), to demonstrate antibody efficiency. The results show that the target 
protein was greatly  enriched in the INPUT fraction, and only  weakly detected in the 
IP S/N, indicating efficient capture by the antibody. 
As part of the quality  check for ChIP, size resolution of DNA fragments was 
determined by gel electrophoresis (Fig. 4.4C). The DNA smear indicated an 
acceptable range of sizes, ranging from 100bp to 500bp, with the strongest signal 
around 200-300bp. Additionally, prior to sequencing, the ChIP-DNA was validated 
by qPCR with primers for presently known HIF targets (Fig. 4.4D), with the caveat 
that none of these targets have previously been described in the trophoblast lineage. 
These targets include the promoter region of CA9, HRE of EGLN3, and a novel 
binding site designated BID17 (Lau et al., 2007; Schodel et  al., 2011). We also 
included a negative control, using primers designed to a region >1kbp upstream of 
the novel BID17 site. We found 4.9-fold enrichment for BID17, and 2.1-fold 
enrichment for EGLN3. However, CA9, like the negative control (-)BID17, did not 
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show enrichment, at 0.64-fold and 0.53-fold respectively. As an extra measure of 
confirmation that these values, since admittedly small, were real, I also conducted 
ChIP-qPCR on untreated hESCs kept at 3% oxygen. In all cases, the enrichment 
values derived from the untreated controls were <0.5-fold. 
With all quality checks passed, ChIP-DNA were processed for sequencing. Two 
libraries were prepared from 6-day BMP4/SU-treated cells grown in 3% oxygen; the 
INPUT for control (CHC015), and the EPAS1/HIF2α ChIP-bound fraction 
(CHC016). Samples were sequenced on two separate lanes, on the Illumina HiSeqTM 
Sequencing System, and mapped to reference genome Homo sapiens hg19 
(GRCh37).
While a more thorough analysis of this data set is pending, due to time limits here I 
only present a preliminary analysis of peaks identified by manual inspection. Visually 
scanning across the mapped ChIP-seq data on the UCSC Genome Browser I 
identified the 41 most  highly enriched locations in the EPAS1 data that lacked peaks 
in the control (Table 4.1). As often the most enriched locations are those that are also 
the most biological relevant I used this analysis to confirm the success of the ChIP-
seq. Seven, out of the 41 peaks have been recognized as HIF binding sites in a prior 
study in a breast cancer cell line, MCF-7 (Schodel et al., 2011); these sites have been 
associated with SLC2A3, BHLHE40, EGLN1, ALDOA, EGFR, ELF3, and EGLN3. 
Peaks were ranked according to strength (peak height), and several peaks are 
pictorially presented (Figs. 4.5-4.9). These peaks are marked by ENCODE-identified 
DNaseI hypersensitivity  clusters, which indicate the presence of regulatory elements, 
as well as histone acetylation (H3K27AC), indicating the presence of active 
enhancers at least  in the cell lines studied which includes undifferentiated human ES 
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cells (Figs. 4.5-4.9). Previously  identified transcription factor binding (ChIP-Seq 
from ENCODE) in close proximity to peaks are also illustrated on figures. 
The strongest peak (#1; peak height: 242) is found closest to SLC2A1, also known as 
GLUT1, a glucose transporter. The gene is located ~50kb upstream of the binding 
(peak) locus (Fig. 4.5). The next strongest peak (#2; peak height: 182) is located next 
to HIF1A, and overlaps with multiple other transcription factor binding sites (Fig. 
4.6). The gene is found immediately  upstream of the binding locus. #4 (peak height: 
142) is nearest to ARRDC3, and its region has been strongly identified for the 
H3K27AC mark (Fig. 4.7). #14 (peak height: 96) is found within 5’ UTR of EGLN1, 
and has been previously recognized as a HIF2α binding site (Fig. 4.8; Schodel et al., 
2011). #28 (peak height: 77) is found ~40kb downstream of FLT1 (Fig. 4.9).
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Figure 4.4. Identification of EPAS1/HIF2α in vitro. (A) Immuno-staining of EPAS1/HIF2α in 
BMP4/SU-treated cells kept at 3% vs.. 20% oxygen. EPAS1 shows nuclear localization in 
treated cells at 3% oxygen. (B) Western blot of nuclear lysates. EPAS1/HIF2α protein was 
not present in untreated hESCs cultured at 3% oxygen, but was present upon treatment at 
3% oxygen. In contrast, HIF1α was only present in hESCs. Lack of the protein band in IP S/N 
indicates clearing of the target protein, after capture by the respective antibody. (C) 
Sonicated DNA fragments, prior to IP, shows a smear of sizes ranging from 100-500bp, with 
strongest signal at 200-300bp. (D) Fold-enrichment of known HIF2α binding targets in 6-day 
treated BMP4/SU samples alongside hESCs, as determined by qPCR (**p-value<0.05).
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Table 4.1. Preliminary  analysis of EPAS1 binding sites. 41 peaks were identified and 
annotated for nearest gene, or known association with genes. Peaks were ranked according 
to peak height (see Figs. 4.6-4.10). Seven sites have previously been identified as HIF 
















































































































































































































































































































Figure 4.7. Peak #4 is nearest to ARRDC3. This binding region has been strongly identified 
for the H3K27AC mark, and has numerous transcription factor binding sites within its 
proximity. CHC015: INPUT; CHC016: EPAS1 ChIP.  
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Figure 4.8. Peak #14 is found within exon 1 of EGLN1, in the 5ʼ UTR. There are multiple 
overlaps with other transcription factor binding sites (ChIP-Seq on ENCODE). The peak 
region also coincides with DNaseI hypersensitivity clusters, as well as with histone 






































































































































4.4. In vitro & in vivo expression of EPAS1 binding targets.
From the global microarray analysis, genes upregulated in 2- and 6-day BMP4/SU-
treated cultures grown in 3% oxygen were obtained by comparison with gene 
expression in that grown in 20% oxygen. Out of the 41 targets from preliminary 
analysis, 13 genes were found upregulated in hypoxia (Fig. 4.10A); 12 after 6-day 
BMP4/SU-treatment at  3% oxygen, and one after 2 days. Since the ChIP samples 
were derived from 6-day treatment, I focused in vitro upregulation analysis to the 12 
genes (Fig. 4.10B). Of the 12 genes, EGFR and ELF3 are previously known HIF2 
targets (Schodel et al., 2011). 
Next, I assessed in vivo expression of genes associated with EPAS1 binding sites 
(Fig. 4.11A). With the exception of PKM2, all genes identified were expressed in the 
chorionic villus samples, whether pre- and/or post-flow. SLC28A1 was also expressed 
only minimally (<1 FPKM) in both pre- and post-flow samples. Most of the genes 
were downregulated post-flow, although only  seven were significant (p-value<0.001); 
LDHA, COX4I2, CGA, ADM, HIST1H1C, FLT1, and SLC2A1 (Fig. 4.11A). 
Individual expression of these genes in each of the in vivo samples is illustrated (Fig. 
4.11B). KISS1R is included as well, since expression in post-flow samples is minimal.
Overall, of the genes identified, seven were previously reported as HIF2 binding sites 
(Schodel et  al., 2011), 12 were upregulated in vitro under hypoxia, and eight were 
upregulated in vivo pre-flow (Fig. 4.12).
133
           
              
Figure 4.10. In vitro expression of EPAS1 targets. (A) Genes upregulated in 3% oxygen 
vs. 20% oxygen, after 2-day or 6-day BMP4/SU treatment respectively, are overlaid with 
identified EPAS1 targets. 12 genes associated with EPAS1 binding sites are upregulated in 
6d-BMP4/SU treatment at 3% oxygen. (B) Upregulation of the 12 genes associated with 
EPAS1 binding sites. EGFR and ELF3 have previously been identified as HIF2 targets. 
Horizontal axis: gene; vertical axis: fold change.
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Figure 4.11. In vivo expression of EPAS1 targets by  RNA-Seq. (A) Pre- vs. post-flow 
expression of genes associated with or nearest to EPAS1 binding regions (*** indicates p-
value<0.001). AVE PRE-FLOW: average expression in 7- to 9-week placentae; AVE POST-
FLOW: average expression in 13- to 15-week placentae; horizontal axis: gene; vertical axis: 
expression level in FPKM. (B) Individual expression of genes differentially expressed 
between pre- and post-flow (p-value<0.001). KISS1R is also included since post-flow 
expression is minimal. #: potentially novel isoform, with at least one splice junction shared 
with a reference transcript.
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Figure 4.12. 35 genes associated with EPAS1 binding sites. Seven were identified prior 
by Schodel et al. (2011), 12 were upregulated in vitro  under hypoxia, and eight were 
downregulated in vivo post-flow.
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4.5. Discussion. 
4.5.1. Establishing the trophoblast lineage in 3% oxygen. 
Here I have established entry into the trophoblast lineage in our hypoxic in vitro 
system, as evidenced by the upregulation of trophoblast transcription factors and 
accompanying downregulation of pluripotency markers OCT4, SOX2, and NANOG. 
The upregulation of trophoblast transcription factor genes appeared in a temporal 
fashion, where CDX2, a transcription factor marking the early trophoblast in the TE, 
was most strongly upregulated at  2 days of treatment, while that of the others, 
GATA2, GATA3, DLX3, TFAP2A, TFAP2C, HAND1, ID2, and MSX2, were further 
upregulated after 2 days. The other placental genes, CGA, KRT18, PGF, and EPAS1, 
were also further upregulated after 2 days.
The BMP4/SU protocol developed in our lab has successfully  demonstrated rapid 
upregulation of transcription factors associated with trophoblast emergence, including 
CDX2, GATA2, GATA3, HAND1, ID2, MSX2, and TFAP2A and TFAP2C (Luo, 2008). 
However, given the oxygen-sensitive nature of EPAS1/HIF2α, there was a need to 
keep  the in vitro system under hypoxia. There was thus a concern for BMP4/SU 
treatment efficacy since multiple studies have demonstrated that low oxygen tensions 
hinder differentiation in hESC cultures, and is preferential for the maintenance of a 
highly  proliferative, pluripotent population of hESCs (Ezashi et al., 2005; Forristal et 
al., 2010). Indeed, I observed higher tendency for spontaneous differentiation, by 
morphology, in hESCs cultured at 20% oxygen than at 3% oxygen, as evidenced by 
the outgrowth of cell masses from the centre of the cell colony (Fig. 4.1). 
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Nevertheless, it appeared that BMP4/SU-induction of the trophoblast lineage was 
effective even in hypoxic conditions (3% oxygen). Both microarray and qPCR 
analysis demonstrated the upregulation of trophoblast/placenta-associated genes, 
including transcription factors (Fig. 4.2 and 4.3). Gene expression profiles of these 
genes remained largely  similar between the two oxygen conditions, with the 
exception of CDX2, GATA3, HAND1, and ID2, showing surprisingly  greater 
upregulation in hypoxic BMP4/SU treatment. PGF and hCG genes were not 
represented in the microarray as upregulated at 2 days, and only emerged after 6 days, 
comparable to their qPCR expression profiles, which presented a significant increase 
after 2 days. Syncytin, or ERVWE1, as well as HLA-G, also only emerged as 
upregulated after 6 days, although this was not verified by qPCR. By microarray 
analysis, TFAP2C had dropped out of the upregulated genes list  in 6-day treatment at 
20% oxygen, but this was not mirrored in qPCR analysis; TFAP2C expression profile 
was comparable in 3% and 20% oxygen. 
CDX2 and GATA3 were more strongly  upregulated under hypoxic conditions than 
under normoxic conditions across all time-points. Since CDX2 is a well-known 
marker of the early trophectoderm (Kimber et al., 2008), which coincidentally 
develops in a low oxygen environment, the BMP4/SU treatment under hypoxia was 
conceivably more conducive for the emergence and maintenance of this early cell 
type. Similarly, GATA3, a CDX2-regulator also found abundantly  in trophectoderm 
(Home et al., 2009), has its expression beginning at the 4-cell embryo stage, within an 
environment of low oxygen. It is thus reasonable to say that while low oxygen 
preserves pluripotency, under a condition of induced or controlled differentiation, we 
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are mimicking the in vivo environment, which overall gives enhanced maintenance of 
the trophoblast progenitors. 
Interestingly, HAND1 and ID2 also showed stronger upregulation in hypoxic 
conditions. ID2 expression was in fact downregulated at 6 and 7 days in normoxic 
BMP4/SU treatment. Both of these genes have been postulated to be involved in early 
trophoblast differentiation and cytotrophoblast development (Knofler et al., 1998; 
Janatpour et al., 2000). While the exact mechanism of their function in the 
trophoblast cell type is yet to be fully understood, their expression patterns have 
provided clues to their possible roles. For example, ID2 expression was relatively 
increased in cases of compromised cytotrophoblast differentiation (Janatpour et al., 
2000). The authors also reported that cytotrophoblasts transduced to constitutively 
express ID2 retained characteristics of undifferentiated cells, displaying inhibited 
invasion capabilities. HAND1 expression, on the other hand, was undetectable in the 
villous trophoblast, but was abundantly expressed in cytotrophoblastic cell lines 
(Knofler et al., 1998). My observation of increased ID2 and HAND1 expression under 
hypoxic conditions, especially  when tied to the downregulation of ID2 under 
normoxic BMP4/SU treatment, indicates that the treatment in low oxygen appears to 
support the presence of the earlier cytotrophoblast. This is in line with the findings by 
Genbacev and colleagues (1997), in which they found that hypoxic culture (2% 
oxygen) supported the proliferation of cytotrophoblasts while normoxic culture (20% 
oxygen) promoted differentiation. Regardless, in this study, I do not attempt to make 
any definitive claims about the specific trophoblast cell sub-type achieved in our in 
vitro system. To that end, there is a separate project underway in the lab, which aims 
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to design an in vitro system capable of maintaining the syncytiotrophoblast and/or the 
cytotrophoblast.
Altogether, the gene expression assays indicates that BMP4/SU treatment under 
hypoxia was effective in repressing pluripotency markers and switching on 
trophoblast transcription factor genes, as well as in the production of placenta-
specific genes, such as CGA and PGF.
4.5.2. Verification of ChIP.  
Having ascertained mRNA and protein expression of EPAS1/HIF2α and HIF1α in our 
in vitro system, I confirmed that EPAS1/HIF2α was the dominant HIF protein in the 
trophoblast-induced culture, being upregulated to a greater extent than HIF1α, which 
additionally, was only  transiently  upregulated during treatment (Fig. 4.3B). This trend 
of EPAS1/HIF2α mRNA abundance over that of HIF1α, in the context  of the human 
placenta, was not unlike that which had previously  been reported by Su and 
colleagues (2002). This observation was supported by protein expression, in which 
EPAS1/HIF2α was markedly abundant upon treatment, but not in the case of HIF1α 
(Fig 4.4B).
Contrary  to recent reports linking HIF proteins and the maintenance of pluripotency 
in hESCs (Covello et  al., 2006; Forristal et al., 2010; Das et al., 2012), I found no 
significant nucleic presence of EPAS1/HIF2α in our hESC culture at 3% oxygen, 
which is likely due to the length of time the culture was kept in hypoxia. I conducted 
short-term cultures, where the cells were incubated in 3% oxygen for no longer than 7 
days, which is in stark contrast to the study  by Forristal et al. (2010), where they 
conducted long-term cultures of more than three passages. Even so, the authors 
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reported transient (<3 passages) nuclear localization of HIF1α in hESC culture at  5% 
oxygen, while EPAS1/HIF2α displayed an initial cytoplasmic localization, before 
translocating to the nucleus following long-term (>3 passages) culture at 5% oxygen. 
My observations of HIF protein expression in hESCs cultured at hypoxia were similar 
to theirs; I also report nuclear localization of HIF1α in short-term hypoxic culture, but 
am unable to confirm neither the cytoplasmic expression of EPAS1/HIF2α at short-
term nor the nuclear expression at long-term, since I only tested the nuclear lysates of 
short-term culture. 
Nevertheless, I confirmed EPAS1/HIF2α protein expression in vitro, with nuclear 
localization (Fig 4.4A). I first validated the ChIP, by qPCR using primers retrieved 
from previous studies (Lau et al., 2007; Schodel et al., 2011). These results, in fold-
enrichment, indicate the interaction of the DNA binding site with the antibody-
protein/ChIP complex; the higher the fold-enrichment, the stronger the affinity  of the 
protein for the binding site.  
The results of the ChIP-qPCR indicated that there was binding at the PHD3 and 
BID17 sites, but not at the CA9 and (-)BID17 sites. The primers used were designed 
to flank the hypoxia-responsive elements (HRE) of PHD3 and CA9 (Lau et al., 2007), 
while that of BID17 was designed against a novel binding site, whose corresponding 
gene is yet unclear (Schodel et al., 2011). For this reason, I designed yet another pair 
of primers, (-)BID17, for the region 1kbp  upstream of the identified BID17, as a 
negative control. 
Since the fold-enrichment values were not particularly high, I included a ChIP set 
conducted on untreated hESCs for comparison. The untreated hESCs represented a 
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null scenario, with no expression of target protein, and hence no binding, resulting in 
a <1 fold-enrichment. As evident in Fig. 4.4D, the fold-enrichment  in treated samples 
for PHD3 and BID17 were significantly  higher than that in untreated samples, 
indicating with conviction that  there was protein binding to these sites. In contrast, a 
HIF1β ChIP tested in the same manner resulted in non-significant fold-enrichment 
between treated and untreated samples (data not shown). 
The PHD3 gene has been demonstrated to be regulated by HIF proteins, through its 
HRE located in its first intron (Pescador et al., 2005). Preliminary results (#38; Table 
4.1) now indicate that  likewise, in our in vitro system, EPAS1/HIF2α also binds to the 
same HRE of PHD3, also known as EGLN3, the gene for one of the HIF prolyl 
hydroxylases (PHD). While PHDs are responsible for hydroxylation of HIFα 
proteins, targeting them for recognition and protein degradation under normal oxygen 
conditions, PHD3/EGLN3 is itself a HIF target and is markedly induced by hypoxia 
(Appelhoff et al., 2004; Aprelikova et al., 2004), suggesting that it may participate in 
a feedback loop to mitigate the HIF response in hypoxia (Minamishima et al., 2009). 
4.5.3. Assessment of EPAS1/HIF2α targets in the human trophoblast. 
Apart from EGLN3, through a preliminary manual analysis at the time of writing, 
ChIP-Seq of EPAS1/HIF2α ultimately derived 41 binding sites (Table 4.1). 35 known 
genes associated with, or nearest  to, the identified sites were deemed potential 
EPAS1/HIF2α regulatory targets (Fig. 4.12). Of these genes, seven had already been 
identified as HIF2 targets (Schodel et al., 2011), which I find a positive indicator of 
the results presented.
142
Twelve genes were found by global microarray  analysis to be upregulated in vitro, 
and coupled with ChIP identification of binding sites, this indicates possible active 
regulation by the bound EPAS1/HIF2α transcription factor. In contrast, the other 12 
genes identified by ChIP-Seq but not upregulated in vitro are likely  not under active 
regulation in the human trophoblast. Meanwhile, only  eight of the 35 potential targets 
were verified in vivo, indicated by significant change in expression under 
oxygenation (downregulated post-flow), and out of that eight, only CGA and 
HIST1H1C remained consistent between in vitro (upregulated in hypoxic culture) and 
in vivo pattern of regulation. Regardless, this does not mean that the other targets 
were inaccurately  identified. Rather, this reflects the disparity between cell types 
achieved in culture and that extracted from tissue samples. While the in vitro system 
manages to approximate the cell types found in the tissue, it might also boil down to 
activation of different targets during different phases of placental development, 
wherein the in vitro cells are less mature than that of the in vivo. 
This list of targets included proponents of energy metabolism, such as glucose 
transporters (SLC2A1 and SLC2A3), which serve to increase glucose availability for 
glycolysis. Glycolysis compensates for energy production in low oxygen, and 
correspondingly, glycolytic enzymes (ALDOA, GAPDH, LDHA, and PKM2) were 
also identified as prospective targets. Additionally, genes involved in angiogenesis, 
such as the vascular endothelial growth factor receptor (VEGFR/Flt1) and 
adrenomedullin (ADM), a vasodilator, were found.
As verified by  hypoxic upregulation in vitro, potential EPAS1/HIF2α targets in the 
trophoblast include EGFR, HIST1H1C, ELF3, MAPK4, KRT19, MID1, CGA, NANS, 
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ARRDC3, CLK3, AMOTL2, and IDH2 (Fig. 4.10B). EGFR and ELF3 were reported 
by Schodel et al. (2011) as HIF targets in MCF7 cells. In our hESC-derived 
trophoblast culture, EGFR was upregulated ~31-fold while ELF3 was upregulated 
~7-fold (Fig. 4.10B), confirming EPAS1/HIF2α-mediated activation in vitro. 
Meanwhile, examining pre-flow upregulation, where EPAS1 is expected to be active 
within the low oxygen placental environment of the first  trimester, CGA, HIST1H1C, 
LDHA, ADM, FLT1, SLC2A1 and KISS1R also emerge as potential EPAS1/HIF2α 
targets in the trophoblast (Fig. 4.11B). These genes represent strong contenders as 
they  were downregulated/unexpressed post-flow, in a presumably oxygen-rich 
environment, one in which EPAS1/HIF2α would be subject to oxygen-dependent 
degradation and have its activity compromised. For example, peak #35 was found 
right next to ADM, a gene significantly downregulated post-flow (4.11B). ADM 
expression is relatively  specific to the placenta (by  BioGPS; Su et al., 2002), and 
although it did not  emerge in our microarray  analysis as upregulated in vitro, it has 
been found to be induced by hypoxia in placental explant culture (Marinoni et al., 
2011). Altogether, this hypoxic induction, in vivo downregulation post-flow, and 
identification of EPAS1/HIF2α binding in proximity  to the gene, are evidence of 
ADM as a HIF2 target in the human trophoblast.  
On the other hand, COX4I2 (cytochrome c oxidase subunit IV isoform 2), was instead 
downregulated pre-flow. This gene codes for a subunit of cytochrome c oxidase 
(COX), the terminal enzyme of the mitochondrial respiratory chain (Huttemann et al., 
2001). Increased expression and function of COX in highly oxygenated tissue, like 
lung and trachea, has been tied to its protective function, in preventing oxidative 
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damage by  accelerating the final electron transport step, which decrease the available 
electrons for free radical formation (Huttemann et al., 2007). This thus might explain 
the increased expression of COX4I2 post-flow, upon perfusion and oxygenation of the 
placenta. 
Regulation of COX4I2 in hypoxic conditions is thought to be mediated either through 
a novel conserved oxygen-responsive element found in the promoter (Huttemann et 
al., 2007), or via HIF1 transcription activity (Fukuda et al., 2007). One of the HIF1-
targeted HREs (5’-CTGTGTGCACGTA-3’) on COX4I2 is found in intron 1 (Fukuda 
et al., 2007), and sits well within the ChIP-identified EPAS1/HIF2α binding locus. 
Interestingly, although verification at the protein level is necessary to prove 
corresponding changes in protein presence, the decreased expression of COX4I2 pre-
flow (low oxygen climate) might  suggest a transcriptional repressor role for EPAS1/
HIF2α.  
4.5.4. EPAS1 regulation and preeclampsia. 
Preeclampsia is a condition plagued by  placental insufficiencies, which ultimately 
results in inefficient  perfusion of the tissue, likely  leading to dysregulation of oxygen-
sensitive gene expression. Given the capacity  of EPAS1/HIF2α in mediating gene 
expression in the trophoblast, coupled with its oxygen-sensitive nature, it was logical 
to wonder if EPAS1/HIF2α is implicated in the dysregulation of gene expression 
during preeclampsia. 
FLT1, a gene notorious for its implication in placental development and 
preeclampsia, emerged as an EPAS1/HIF2α target in the human trophoblast. The 
binding region was found ~40kb away from the gene, and it  was also significantly 
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downregulated in post-flow placenta; average expression was 215.0 FPKM pre-flow 
and 13.6 FPKM post-flow. Additionally, LEP, a gene frequently  associated with 
preeclampsia, is found ~221kb away from peak #5 (Table 4.1). LEP is also 
significantly downregulated post-flow, indicating oxygen-sensitive regulation (see 
Chapter 5). It is thus not beyond reason to speculate if LEP expression in the placenta 
is also EPAS1/HIF2α-mediated. 
Since the analysis presented is preliminary, there are likely numerous other EPAS1/
HIF2α targets in the trophoblast yet to be identified, with the possibility  that more 
genes in that list are implicated in preeclampsia. More extensive and in-depth 
bioinformatics analysis is in progress to uncover those genes. Ultimately, it remains 
to be seen if EPAS1/HIF2α-mediated gene expression has an overreaching influence 
on genes associated with preeclampsia. At this juncture, this notion of EPAS1/HIF2α 
as a key player in gene dysregulation during preeclampsia is novel and altogether 
exciting. 
Nevertheless, in the next chapter, I explore global gene expression in the chorionic 
villus samples to uncover genes differentially expressed between pre- and post-flow, 
conditions which act as a measure of oxygen-mediated regulation, and their 
association with placental development and pregnancy health. 
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4.5. Concluding remarks. 
In this chapter, I presented the approach and results of identifying EPAS1/HIF2α 
transcription factor targets in the human trophoblast. Given the ethical concerns 
surrounding the use of, as well as, the limited accessibility  to healthy human placental 
tissue, we believe the best foreseeable method to elucidating the HIF-mediated 
response in the early  placenta is to maintain a simulated in vitro system, derived from 
pluripotent hESCs, that is capable of supporting the trophoblast cell type. To that  end, 
many regard the BMP4-driven/FGF2-inhibited hESC culture as a reliable model of 
trophoblast differentiation (Schulz et al., 2008; reviewed by  Ezashi et al., 2012). 
Using a hESC-derived trophoblast culture kept at hypoxia, EPAS1/HIF2α binding 
sites were established by ChIP-Seq. Associated genes were identified, and both in 
vitro and in vivo expression as well as regulation were assessed. 
At the time of writing, binding sites that had been sequenced were being 
computationally assessed by  CCAT (Xu et al., 2010) and MACS (Zhang et al., 2008) 
to derive a more comprehensive list  with 95% confidence (p-value<0.05). From this 
list, biologically-relevant targets will be identified using the strategy  described in this 
chapter; by  examining gene expression in the relevant conditions. Since we can 
simulate the conditions in which EPAS1/HIF2α is present and active (low oxygen 
culture; pre-flow placenta), as well as when EPAS1/HIF2α is not active (high oxygen 
culture; post-flow placenta), we are able to sidestep  the need for EPAS1/HIF2α 
knockout and over-expression. Moreover, such molecular manipulation drives the cell 
further from its biological context, possibly  leading to inaccurate identification or 
misrepresentation of targets. In addition, using the CCAT-/MACS-identified hits, de 
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novo motif analysis will be conducted, which could amount to a convincing 
assessment of the experiment, since the HIF-binding sequence has been identified and 
reviewed in the literature. 
As with all ChIP-based approaches to identifying transcription factor gene targets, 
further molecular validation is obligatory. One approach is by  mutagenesis of the 
HIF-bound sequence, followed by assessment of subsequent gene expression to 
ascertain the gene target tied to respective  EPAS1/HIF2α binding sites. At present 
analysis, association of gene with transcription factor binding site is by observation of 
proximity as well as previous gene annotations. 
It is hoped that from these attempts, we can glean the first insight to the HIF 
transcriptional network of genes responding to early  development in the placenta. 
Many previous studies have identified HIF gene targets in a variety  of tissue and cell 
types (Wang and Semenza, 1993; Forsythe et al., 1996; Kaluz et al., 2008; Schodel et 
al., 2011). The study by Schodel et al. (2011) identified 500 HIF-binding sites in a 
breast cancer cell line, and by overlapping with high-resolution mapping of DNase1 
hypersensitivity  sites, their results provide a comprehensive pan-genomic analysis of 
the HIF-mediated transcriptional response to hypoxia, at least in MCF7 cells. 
However, it  is essential to specify  these targets within a cell-specific or biological 
context, as evidence has shown that the HIF transcriptional network may or may not 
activate all of its targets, depending on the active HIF isoform present, its regulators, 
as well as as its co-activators (Semenza, 2003; Wenger et al., 2005). In this regard, it 
would also be prudent to identify  co-activators of EPAS1/HIF2α in the trophoblast 
cell type. Moreover, studying the HIF transcription network in the trophoblast cell 
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type would enhance our understanding of early  placental development, which begins 








Examination of the global transcriptomic landscape of the early  placenta offers 
insight into the biological processes occurring within the tissue. Genes being 
expressed are strong indicators of active pathways as well as cellular interactions 
ongoing in the tissue. Comparison across changing environments represents an 
excellent strategy to understand developmental and coping mechanisms which are 
activated during this window of change. During the transition from first to second 
trimester, a significant change takes place in the uterine environment. The placental 
vasculature, although fully  formed by the end of the first  trimester, is virtually devoid 
of maternal blood due to the presence of trophoblastic plugs in the spiral arteries 
(Hustin and Schaaps, 1987; Burton et al., 1999). During this time, which spans the 
entire embryonic period (up to 8 weeks) and the first few weeks of the fetal period, 
the embryo/fetus is undergoing extensive growth and virtually all organogenesis. 
Without  blood flow, nutrition is derived from secretions of the uterine glands, in what 
is known as histiotrophic nutrition (Burton et al., 2002). At approximately 12 weeks, 
the trophoblastic plugs are broken down, thus unleashing the flow of blood (Hustin 
and Schaaps, 1987; Jauniaux et al., 1992; Jauniaux et al., 1995; Jaffe et  al., 1997; 
Burton et al., 1999). The sudden presence of blood drastically modifies the uterine 
environment; the blood brings with it oxygenation, as well as hemotrophic nutrition, 
which is the exchange of blood-borne materials between the maternal and fetal 
circulations (Wooding and Flint, 1994).  
An analysis of pre-flow versus post-flow chorionic villi would provide an opportunity 
to explore transcriptional dynamics in response to oxygen within trophoblast under a 
151
physiological setting. With the abundance of expression of EPAS1 in chorionic villi 
(Apps et al., 2011), presumably this physiological response would be mediated, in 
part, through HIF2α. Through collaboration (Cheryl Lee, Andrew Sharkey, and 
Ashley Moffett), I was able to access two sets of RNA samples, derived from 
chorionic villus of normal pregnancies, one from near the end of the first trimester (7-
week to 9-week old; pre-flow), and the other from the start of the second trimester 
(13-week to 15-week old; post-flow). We achieved a comprehensive assessment of 
gene expression through massively parallel sequencing of poly-adenylated mRNA 
(i.e. mRNA-Seq). The changes evident in the expression of these genes, between pre-
flow and post-flow samples, therefore indicate the biological processes triggered by 
the onset of maternal blood flow, as well as processes actively taking place during 
this time of changing oxygen concentration in the placenta.
mRNA-Seq permits the accurate quantification of gene expression from read counts, 
as the number of RNA-Seq reads generated from a transcript is directly proportional 
to its relative abundance in the sample. However, the number of reads generated from 
a transcript is influenced by the length of the transcript. Therefore, to calculate the 
correct expression level of each transcript, reads that map to a particular transcript are 
tallied, and this count is then normalized by the length of that respective transcript. To 
compare the expression level of a transcript across runs, the counts must be 
normalized for the total yield of the machine. The commonly used quantifier 
‘fragments per kilobase of transcript per million mapped fragments’ (FPKM) 
incorporates these two normalization steps to ensure that expression levels for 
different genes and transcripts can be compared across runs (Trapnell et al., 2012). 
FPKM was used as opposed to ReadsPKM since we generated paired-end mRNA-Seq, 
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thus the fragment equates to counting of two reads, one from either end of the 
fragment.
We thus obtained the levels of gene expression, quantified as FPKM, in the placental 
samples. Comparing between pre-flow and post-flow, we determined a list of the 
genes which were differentially expressed across the two conditions (p-value<0.001). 
These genes were then screened, via gene ontology analysis, for their associations 
with, as well as function in, biological pathways and cellular interactions. Genes with 
the highest expression levels in the placenta were also identified. Additionally, 
amongst the differentially  expressed genes were numerous genes known to be 
implicated in preeclamptic pregnancies, a complication characterized by high blood 
pressure and proteinuria in the expectant mother.
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5.2 mRNA-seq data generation.
The samples were derived from placental biopsies in Cambridge, UK under local 
Institutional Review Board approval. Prior to the biopsy, gestational age was 
confirmed by ultrasound. The samples were from otherwise normal pregnancies that 
were being electively terminated. Biopsies were taken from the central region of the 
placenta through a chorionic villus sampling (CVS)-like procedure and immediately 
cryogenically preserved. Total RNA was isolated in Cambridge by  our collaborators 
and subsequently shipped on dry ice to Singapore.
In total, 15 samples were grouped into two subsets based on gestational age (Table 
5.1). The first subset comprises of 8 samples, collected from 7- to 9-week old 
placentae. The second subset comprises of 7 samples, collected from 13- to 15-week 
old placentae. Since maternal blood flow and the corresponding onset of oxygenation 
normally begins at 12 weeks, the first  subset is referred to as ‘pre-flow’, and the 
second as ‘post-flow’. All RNA Integrity Number (RIN) values as determined by the 
Agilent Bioanalyzer were 6.0 or greater. After paired-end library  construction and bar 
coding, the 15 samples were run across 5 lanes on the Illumina HiSeq 2000 with each 
lane generating 154 to 200 million 101-base paired-end reads per lane. For each 
sample, approximately  40-60 million paired reads were generated (Table 5.1). With 
each cDNA fragment sequenced 101 bases into either end, there would be 202 bases 
of sequence per fragment. Thus each RNA sample was sequenced to a depth of 
approximately 10 billion bases. Mapping to the genome was in the ~70-80% range 
(Table 5.1) which is consistent with other human mRNA-Seq experiments. 
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Left and right mapped reads were tallied, normalized, and presented as FPKM  values 
for each unique transcript, indicating strength of expression. The top  10% of all genes 
expressed in the tissue had an average expression (across all samples) of 14.7 - 
91,698.3 FPKM. To exemplify the use of this data set in interrogating gene 
expression, I will first outline the expression levels and profiles of some of the most 
highly expressed genes; the hCG genes (CGA and CGB).   
5.2.1.  Human chorionic gonadotropin genes.
CGA, the gene coding for the alpha subunit of hCG (Fiddes and Goodman, 1979), 
also gives rise to the alpha subunit of luteinizing hormone (LH), follicle-stimulating 
hormone (FSH), and thyroid-stimulating hormone (TSH). These glycoprotein 
hormones are heterodimeric, with their unique beta subunit  conveying their 
individual biological functions. The beta subunit of hCG is encoded by six highly 
similar genes, CGB, CGB1, CGB2, CGB5, CGB7, and CGB8, arranged in tandem and 
inverted pairs on chromosome 19 (Policastro et al., 1986; Talmadge et al., 1984; Bo 
and Boime, 1992).
When gene expression was ranked based upon average FPKM across samples, CGA, 
along with three CGB genes, turned up as the top  four (i.e. most abundantly 
expressed) genes in pre-flow placentae, while in post-flow placentae, they  placed 
within top 10 genes (Fig. 5.1). CGA was the gene most highly expressed in both pre- 
and post-flow conditions, and across all samples. In pre-flow samples, CGA yielded 
an average of 149,334.26 FPKM, that is, ~14.9% of all polyadenylated transcripts. 
Expression of CGB genes in pre-flow placentae stood as follows; CGB8 came in 
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second with 36,856.39 FPKM, followed by  CGB5 (36,272.68 FPKM), and CGB 
(28,500.73 FPKM).
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Figure 5.1. Expression of hCG genes. CGA and all six CGB genes were highly expressed 
in pre-flow placentae, with CGA, CGB8, CGB5, and CGB making up  the top  four genes. 
Average FPKM in pre-flow placentae: CGA, 149,334.26 FPKM; CGB8, 36,856.39 FPKM; 
CGB5, 36,272.68 FPKM; CGB, 28.500.73 FPKM. Horizontal axis: gene; vertical axis: FPKM.
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5.3. Differential analysis and gene ontology.
The transcriptomes of all samples were compared to identify differentially-expressed 
genes. The initial unsupervised clustering analysis of all 15 samples clearly clustered 
the majority of samples according to their pre-flow or post-flow nominal status. The 
one exception was RHM077 which clustered with the pre-flow samples. Flow was 
not measured in these placentae prior to CVS and the exact timing of trophoblast 
rupture is known to vary across a couple of weeks. RHM077 represents one of the 
earliest ‘post-flow’ samples (13 weeks + 0 days). Based on its clustering with pre-
flow, I assumed this sample represented the not totally  unexpected occurrence of a 
later onset trophoblast rupture. With its later staging but apparent pre-flow status, I 
chose to exclude this sample from all subsequent analysis.
The unsupervised clustering of all remaining samples, produced two subsets, aligning 
according to gestational age (Fig. 5.2). The first subset encompassed all samples of 
gestational age between 7 to 9 weeks (i.e. pre-flow), while the second subset  included 
all samples that were at  13 to 15 weeks gestation (i.e. post-flow). Between these two 
subsets, 681 genes were differentially expressed (FDR<0.001; Fig. 5.2; complete list 
included in Appendix, Supplementary Table 1). 
I then focused our gene ontology analysis based on this exclusive set of 681 genes, in 
order to examine gene sets representing major biological processes (Fig. 5.3). Blood 
coagulation pathways featured prominently across various databases (Complement 
and coagulation cascades, KEGG; Hemostasis, REACTOME; Blood coagulation, 
PANTHER; p-value<0.05). Cell surface receptors and interactions, as well as 
adhesion molecules, were also represented in the gene ontology analysis (Integrins 
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and other cell-surface receptors, BBID; CAMs, KEGG; ECM-receptor interaction, 
KEGG; p-value<0.05). Pathways of the immune system also emerged in the analysis 
(Signaling in immune system, REACTOME; Antigen processing and presentation, 
KEGG; p-value<0.05). The exhaustive list of genes is included in the Appendix 
(Supplementary  Table 2). The variation in expression of these genes therefore 
indicate the biological processes triggered by the onset of maternal blood flow, as 
well as processes actively  taking place during this time of changing oxygen 
concentration in the placenta.
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The hemoglobin genes HBZ (hemoglobin zeta subunit) and HBE1 (hemoglobin 
epsilon subunit 1) emerged as the two most differentially  expressed genes (p-values = 
4.74 x 10-32 and 1.42 x 10-29 respectively; Fig. 5.4A; Supplementary Table 1). Both 
genes were, on average, expressed approximately 230-times higher in pre-flow than 
in post-flow placental samples. This then prompted us to assess the expression of 
other hemoglobin genes. With the exception of the hemoglobin gene HBD (delta 
subunit), all five of the remaining known hemoglobin genes were found to be 
expressed in our samples (Fig. 5.5A); HBG1 (gamma subunit 1), HBG2 (gamma 
subunit 2), HBA1 (alpha subunit 1), HBA2 (alpha subunit 2), and HBB (beta subunit).
Hemoglobin genes encode the various polypeptide chains that make up the 
heterotetramer protein, with the specific combination of subunits defining the 
biological relevance and function of the hemoglobin protein (Collins and Weissman, 
1984; Karlsson and Nienhuis, 1985; Higgs et al., 1989). Adult hemoglobin (HbA, 
α2β2) comprises two alpha chains with two beta chains, fetal hemoglobin (HbF, α2γ2) 
constitutes two alpha chains and two gamma chains, while embryonic hemoglobin is 
predominantly made up of two epsilon chains and two zeta chains (ζ2ε2; Hecht et al., 
1966).
A secondary analysis determined contribution, by  expression, of each individual 
hemoglobin gene (Fig. 5.4B). Samples were analyzed individually, with expression of 
each hemoglobin gene charted as a percentage of total hemoglobin gene expression. 
A distinct trend of hemoglobin switching was observed; where in pre-flow placentae, 
HBZ and HBE1 make up the predominant hemoglobin gene expression, while in post-
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flow placentae, HBG2 alone makes up 40-60% of total hemoglobin gene expression, 
with no significant contribution by HBZ and HBE1. 
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Figure 5.4. Expression of hemoglobin genes indicates hemoglobin switching. (A) 
Scatter plots of hemoglobin genes expression. HBZ and HBE1 were differentially expressed 
between pre-flow and post-flow samples (*** indicates p-value<0.001). Horizontal axis: 
gestational age; vertical axis: FPKM. (B) Proportional analysis of hemoglobin gene 
expression, indicates that in pre-flow placentae, HBZ and HBE1 make up  the predominant 
hemoglobin gene expression, while in post-flow placentae, HBG2 alone makes up  40-60% of 
total hemoglobin gene expression, with no significant contribution by HBZ and HBE1. 
Contribution of HBB gene expression across all samples fall under 10%. 
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5.3.2. Blood coagulation. 
Several genes involved in the blood coagulation cascade were found differentially 
expressed between pre-flow and post-flow placentae. Three genes in particular, 
PROCR, TFPI, and TFPI2, were significantly downregulated in the post-flow subset, 
while another three, A2M, F3, and F13A1, were significantly upregulated (Fig. 5.5A).
The gene F3 (coagulation factor III) encodes tissue factor (TF; Morrissey et al., 1987; 
Spicer et al., 1987; Mackman et al., 1989), the cell surface glycoprotein which 
functions as the high-affinity receptor for factor VII, ultimately  forming the factor 
VIIa-TF complex (Konigsberg et  al., 2001). Briefly, the coagulation process begins 
with the formation of a factor VIIa-TF complex, which then activates additional 
proteases, factors IX and X, ultimately leading to the formation of a fibrin clot (Rao 
and Rapaport, 1987; Davie et al., 1991).
The F13A1 gene encodes the A1 polypeptide of the A subunit  of coagulation factor 
XIII, the last protease precursor to become activated in the blood coagulation cascade 
(Ichinose and Davie, 1988; Board et al., 1988). Factor XIII, a heterotetramer of 2 A 
and 2 B subunits, is activated upon cleavage by thrombin, yielding the active enzyme 
factor XIIIa (reviewed in Muszbek et al., 2011). This enzyme catalyzes the 
crosslinking between fibrin molecules, forming the stable fibrin clot (Adany and 
Bardos, 2003; Bereczky et al., 2005). 
TFPI (tissue factor pathway inhibitor) is implicated in the process through its role in 
inhibiting the activated factor X, forming the Xa-TFPI complex, which subsequently 
also inhibits the VIIa-TF complex (Broze and Miletich, 1987; Broze et al., 1988 and 
1990; Girard et al., 1989; Novotny et al., 1989).  
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Meanwhile, the TFPI2 gene was designated to a previously  known placental protein 
that was found to be homologous to TFPI (Sprecher et al., 1994; Petersen et al., 
1996). This protein, originally  isolated from the placenta, exhibits serine protease 
inhibitory activity  (Butzow et al., 1988; Miyagi et al., 1994). TFPI2 mRNA, along 
with evidence of protein synthesis (Seppala et al., 1983), has been identified in the 
syncytiotrophoblast from first trimester to term placenta (Udagawa et al., 1998), 
specifically on the surface of microvilli and the membrane of the endoplasmic 
reticulum (Udagawa et al., 2002). In contrast, TFPI is widely distributed in fetal and 
placental tissues such as syncytiotrophoblasts, cytotrophoblasts, extravillous 
trophoblasts and the vascular endothelium, while TFPI2 is abundant only in 
syncytiotrophoblasts (Edstrom et al., 2000; Udagawa et al., 2002; Aharon et al., 
2004).
Within the blood coagulation pathways, there are multiple other inhibitors that 
regulate the processes, including protein C (PROC), a serine protease that inactivates 
factors Va and VIIIa. PROC activity is enhanced when it binds its membrane-bound 
receptor (PROCR; Walker, 1981; Walker et al., 1987). However, PROCR also 
circulates in soluble form, and when it  binds activated PROC in this form, it inhibits 
PROC activity instead (Van de Wouwer et al., 2004). 
A2M (alpha-2-macroglobulin) also functions as an inhibitor of coagulation by 
blocking thrombin and factor Xa (Downing et  al., 1978; Ellis et al., 1982). It can 
conversely impede fibrinolysis by inhibiting plasmin (PLG) and kallikrein (KLK1B; 
Harpel, 1970 and 1977; Schapira et al., 1982; van der Graaf et al., 1983; Kaufman et 
al., 1991). A2M may additionally act as a carrier protein through its binding with 




Figure 5.5. Expression of genes involved in the blood coagulation cascade. (A) 
Expression levels determined by mRNA-Seq. PROCR, TFPI, and TFPI2, were significantly 
downregulated in the post-flow subset. A2M, F3, and F13A1, were significantly upregulated 
(*** indicates p-value<0.001). Horizontal axis: gene; vertical axis: FPKM. (B) KEGG  pathway 
for complement and coagulation cascades (complement cascade not shown). F3/F7: factor 
VIIa-TF complex; TFPI: tissue factor pathway inhibitor; F13: factor XIII; PROC/PROCR: 
endothelial protein C (receptor); F5: factor Vl; F8: factor VIII; A2M: alpha-2-macroglobulin; 
PLG: plasmin; KLK1B: kallikrein.
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 5.3.3. Complement system. 
Components of the complement cascade, C1QA, C1QB, C1QC, C1R, CFD, and C7, 
along with the complement receptor C3AR1, were upregulated, while inhibitors of the 
cascade, CD55 and CD59, were downregulated (Fig. 5.6). 
The complement cascade can be triggered by  three pathways; classical, alternative, or 
lectin pathway (reviewed in Janeway et al., 2001; Fig. 5.6B). The classical pathway is 
initiated by activation of the C1 complex, which comprises three subcomponents; 
C1q, C1r, and C1s. The genes C1QA, C1QB, and C1QC, make up the C1q 
subcomponent (Sellar et al., 1991), while C1R specifies the C1r subcomponent 
(Nguyen et al., 1988).
All three pathways converge at the C3-convertase stage. In the alternative pathway, 
CFD (complement factor D) facilitates the formation of C3-convertase (Fig. 5.6B). 
C3-convertase can be inhibited by DAF (delay accelerating factor), specified by  the 
CD55 gene (Lublin et al., 1987). Past this stage, the complement cascade forms a 
membrane attack complex (MAC), comprising C6, C7, C8, and multiple C9 
components, ultimately  leading to lysis of the pathogenic cell. MAC formation can be 
inhibited by CD59, a complement regulatory protein (Huang et al., 2006). 
Another inflammatory outcome is also possible, mediated by C3a, C4a, and C5a, 
which trigger chemotaxis as well as increase vascular permeability  and smooth 
muscle contraction (Janeway et al., 2001). This is facilitated by membrane receptors 




Figure 5.6. Expression of genes involved in the complement cascade. (A) Expression 
levels determined by mRNA-Seq. Components of the complement system, C1q (C1QA, 
C1QB, C1QC), C1R, CFD, and C7, are upregulated post-flow, while inhibitors CD55/DAF and 
CD59 are downregulated. C3AR1, a complement receptor, is also upregulated. (*** indicates 
p-value<0.001). Horizontal axis: gene; vertical axis: FPKM. (B) KEGG  pathway for 
complement and coagulation cascades (only complement cascade is shown). C1Q: q 
subcomponent of C1 complex; C1R: r subcomponent; C7: complement component 7; DF: 
complement factor D (CFD); DAF: delay accelerating factor/CD55; CD59: complement 
regulatory protein; C3AR1: complement component 3a receptor 1. 
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5.4. Genes most abundantly expressed in the placenta.
As a means to understand biological processes important in placental development, 
we also assessed genes that were most highly expressed in our samples. The top 30 
genes expressed in pre-flow samples ranged from 429.04 FPKM to 149,334.26 
FPKM (Table 5.2), and in post-flow ranged from 136.74 FPKM  to 14,850.41 FPKM 
(Table 5.3). 
5.4.1. Chorionic somatomammotropin hormone 1.
CSH1 (chorionic somatomammotropin hormone 1) was strongly expressed in pre-
flow placentae (4,757.77 average FPKM), and it was significantly  upregulated post-
flow (12,282.67 average FPKM; Fig. 5.7). Expression levels in post-flow samples 
were comparable to that of CGA and CGB, coming in second only  to CGA (Table 
5.3). 
Also known as human placental lactogen, the protein encoded by  CSH1 is a member 
of the somatotropin/prolactin family of hormones (Josimovich et al., 1963; Seeburg et 
al., 1977; Shine et al., 1977; Martial et al., 1979). CSH1 is expressed mainly in the 
placenta, playing an important role in growth control. It functions similarly  to the 
human growth hormone, modifying the metabolism of the mother during pregnancy, 
in order to facilitate supply  of energy  to the fetus (reviewed in Newbern and 
Freemark, 2011).
5.4.2. Growth differentiation factor 15.
GDF15 (growth differentiation factor 15) is abundantly expressed in both pre- 
(6,080.27 average FPKM) and post-flow (894.56 average FPKM) placentae, with 
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significant downregulation in post-flow samples (Fig. 5.7). In pre-flow placentae, 
expression of GDF15 was the highest after the family of hCG genes (Table 5.2). 
This gene is found abundantly  expressed in human placenta (Fairlie et al., 1999), with 
its expression dysregulated both in preeclampsia and in diabetic pregnancies (Sugulle 
et al., 2009). The product of the gene belongs to the transforming growth factor beta 
(TGFβ) superfamily, which has a role in regulating inflammatory and apoptotic 
pathways in injured tissues and during disease processes (Hsiao et al., 2000; Xu et al., 
2006). 
5.4.3. Peptidylprolyl isomerase B.
The average expression of PPIB (peptidylprolyl isomerase B) in pre-flow samples 
was 1,502.67 FPKM. This was significantly  downregulated (501.89 average FPKM) 
in the post-flow subset (Fig. 5.7). The protein encoded by the PPIB gene, also known 
as cyclophilin B (CypB), is mainly localized to the endoplasmic reticulum, 
extracellular space, and nucleus, with a role in secretory  pathways (Peddada et al., 
1992; Price et al., 1994). 
5.4.4. Epstein-Barr virus induced 3.
In our samples, the expression of EBI3 (Epstein-Barr virus induced 3) ranked 15th 
most abundant in the pre-flow subset (1,233.42 average FPKM; Table 5.2), but was 
downregulated in the post-flow subset (361.28 average FPKM; Fig. 5.7). EBI3 is a 
secreted glycoprotein, a member of the hematopoietin receptor family related to the 
p40-subunit of interleukin-12 (IL12). It  is found as a subunit  in two distinct 
heterodimeric cytokines, interleukin-27 (IL27) and -35 (IL35; Devergne et  al., 1997; 
Pflanz et al., 2002), and has a role in regulating cell-mediated immune responses. It is 
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expressed in the first  trimester placenta with localization to the syncytiotrophoblast 
layer (Coulomb-L'Herminé et al., 2007). Interestingly, the other subunit of IL27, 
specified by the gene IL27, is also downregulated in post-flow samples, although not 
significantly (data not shown).
5.4.5. Ferritin light polypeptide.
FTL (ferritin light polypeptide) expression was upregulated in post-flow samples 
(1,412.57 average FPKM), from 658.00 average FPKM in pre-flow (Fig. 5.7). The 
FTL gene encodes the light subunit of the ferritin protein, the major intracellular iron 
storage protein, keeping iron in a soluble and non-toxic state (Munro et al., 1988; 
Gasparini et al., 1997). Abnormal expression of the FTL gene has also been observed 
in fetuses conceived by assisted reproductive techniques, namely in vitro fertilization 
and intracytoplasmic sperm injection (Zhang et al., 2008). 
173




Table 5.3. Post-flow expression of genes. Average FPKM values of top  30 genes 
expressed in post-flow samples.
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Figure 5.7. Genes abundantly  expressed in the placenta. These genes were expressed 
abundantly in the placental samples, ranking within the top 30 in both pre-flow and post-flow 
subsets. CSH1  and FTL were upregulated post-flow, while the other three genes, GDF15, 
PPIB, and EBI3, were downregulated post-flow (*** indicates p-value<0.001). Horizontal axis: 
gene; vertical axis: FPKM.
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5.5. Genes associated with preeclampsia and other pregnancy complications.
We found at least seven genes known to be associated with preeclampsia, that were 
differentially expressed between pre- and post-flow placental samples. LEP, INHA, 
INHBA, and ENG were downregulated in post-flow placental samples, while SPP1, 
and HGF were upregulated (Fig. 5.8). A novel isoform of FLT1, not mapped to 
Ensembl transcripts, was also found downregulated, through a separate analysis of 
novel genes and/or isoforms expression (analysis by Dr. Li Juntao; refer to Fig. 4.11). 
These genes are early-onset placental genes, whose dysregulation have been 
implicated in unsatisfactory pregnancy outcomes.
5.5.1. Leptin.
The product  of the LEP (leptin) gene is an adipose-derived hormone that plays a key 
role in the regulation of energy intake and expenditure (Ingalls et al., 1950; Zhang et 
al., 1994; Isse et al., 1995; ). The major source of leptin is adipose tissue, but it can 
also be produced by syncytiotrophoblasts in the placenta and ovaries (Masuzaki et al., 
1995; Cioffi et al., 1997; Hassink et al., 1997; Masuzaki et al., 1997; Senaris et al., 
1997; Henson et al., 1998). Placental LEP expression is markedly augmented in 
preeclamptic pregnancies (Mise et al., 1998), as well as pregnancies complicated with 
diabetes mellitus (Lepercq et al., 1998; Lea et al., 2000).
5.5.2. Inhibin genes.
The INHA (inhibin, alpha) gene encodes the alpha subunit of inhibins A and B protein 
complexes, while the INHBA (inhibin, beta A) gene encodes the beta subunit of 
inhibin A (Stewart et al., 1986). The inhibin alpha subunit combines with either the 
beta A or beta B subunit to form a complex that negatively regulates follicle-
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stimulating hormone (FSH) secretion from the pituitary gland (Welt et al., 1997; 
Lahlou et al., 1999; Welt et al., 2003). Additionally, the beta A subunit forms a 
homodimer, known as activin A, and also heterodimerizes with the beta B subunit, 
forming activin AB, both of which stimulate FSH secretion (Ling et al., 1986; Vale et 
al., 1986). Inhibin A, the complex comprising INHA and INHBA, and activin A are 
glycoproteins secreted during pregnancy  (Schneider-Kolsky et al., 2002), circulating 
in higher amounts in women with gestational hypertension and/or preeclampsia, as a 
result of increased placental production (Manuelpillai et al., 2001; Florio et al., 2002; 
Casagrandi et al., 2003). 
5.5.3. Endoglin and fms-related tyrosine kinase 1.
ENG (endoglin), a cell surface receptor for TGF-β1 (Lastres et al., 1996), exhibits 
increased expression in preeclamptic pregnancies (Yang et  al., 2008; Tannetta et al., 
2013). ENG was also found to induce (in pregnant rats) vascular permeability and 
hypertension, mimicking maternal symptoms of preeclampsia (Venkatesha et al., 
2006). It is postulated to act in a concerted manner with sFlt1 to cause severe 
preeclampsia, with restriction of fetal growth (Maynard et al., 2003; Venkatesha et 
al., 2006).
FLT1 (fms-related tyrosine kinase 1) is a receptor tyrosine kinase belonging to the 
family of vascular endothelial growth factor receptors (VEGFR). It is involved in 
angiogenesis and vasculogenesis, and found expressed in vascular endothelial cells, 
placental trophoblasts (Helske et al., 2001) and peripheral blood monocytes 
(reviewed in Shibuya, 2006). Known isoforms include a full-length transmembrane 
receptor isoform, as well as a shortened, soluble isoform (i.e. sFlt1; Shibuya et al., 
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1990; Kendall and Thomas, 1993). Excess levels of the latter has been associated 
with the onset of preeclampsia (Koga et al., 2003; Maynard et  al., 2003; Levine et al., 
2004). 
5.5.4. Secreted phosphoprotein 1.
The SPP1 gene specifies secreted phosphoprotein 1 (SPP1), also known as 
osteopontin (OPN), a protein involved in bone mineralization (Kiefer et al., 1989; 
Reinholt et al., 1990; Choi et al., 2008). SPP1/OPN also upregulates expression of the 
pro-inflammatory cytokines, interleukin-12 (IL12) and interferon-gamma (IFN-γ), 
and reduces production of the anti-inflammatory  cytokine, interleukin-10 (IL10; 
Ashkar et al., 2000; Wang et al., 2008). SPP1 expression was found upregulated in 
preeclamptic placenta (Gabinskaya et al., 1998; Tsoi et al., 2003). 
5.5.5. Hepatocyte growth factor.
HGF (hepatocyte growth factor) regulates cell growth, cell migration, and 
morphogenesis by activating a tyrosine kinase signaling cascade (Bottaro et al., 1991; 
Naldini et al., 1991; Rubin et al., 1993). HGF is known to have a major role in 
embryonic organ development, adult  organ regeneration, and wound healing 
(reviewed in Skibinski, 2003). HGF gene expression was diminished in preeclampsia 
(Wolf et al., 1991; Kauma et al., 1997).
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Figure 5.8. Expression of genes implicated in preeclamptic pregnancies. LEP, INHA, 
INHBA, and ENG were downregulated in post-flow placental samples, while SPP1, and HGF 
were upregulated (*** indicates p-value<0.001). Horizontal axis: gene; vertical axis: FPKM.
A novel isoform of FLT1, not mapped to Ensembl transcripts, was also found downregulated.
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5.6. Discussion.
Through quantifiable transcriptomic analysis, we were afforded unique insight into 
human placental gene expression across a time frame of early  pregnancy 
development. This window traverses the earliest major environmental change in the 
site of gestation, triggered by the onset of maternal blood flow into the placenta, 
entailing a switch in oxygen conditions as well as mode of nutrition. 
We approached the study  by means of differential analysis, choosing to focus on 
genes whose expression levels were changing significantly between two selected time 
points. These time points are reflective of the changing uterine environment; the 
earlier time point was during the first trimester of pregnancy, prior to the flow of 
maternal blood into the placenta, while the later time point was at the beginning of 
the second trimester, just after the onset of maternal blood flow. Our rationale behind 
this approach was that given the altered conditions, fluctuations in gene expression 
would be indicative of biological processes and pathways activated or repressed, in 
wake of the introduction of maternal blood, responsible either for adaptation to the 
new environment, or perhaps even the commencement of the next phase of 
development. 
5.6.1. Hemoglobin switching by the placenta.
Our data has the potential to identify  genes that are changing significantly during this 
transition. The top two genes that emerged with the most significant difference in 
expression levels were the hemoglobin genes HBZ and HBE1. Upon assessment of 
the expression of other genes in the hemoglobin family, it  was evident that the 
expression levels reflected a switch from embryonic hemoglobin (ζ2ε2) to fetal 
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hemoglobin (HbF, α2γ2), at approximately 9th to 12th weeks of pregnancy. The zeta 
and epsilon chains, specified by  HBZ and HBE1 respectively, were no longer being 
expressed with any significance, falling to <1%, from the 13th week onwards. 
It was first postulated by Brinkman and colleagues (1934) that “human hemoglobin is 
changing from one form to the other”, and to date it is recognized that the first  major 
hemoglobin switch occurs as ζ- and ϵ-globin expression ceases, and α- and γ-globin 
synthesis begins, leading to production of HbF (Peschle et al., 1985; Ley et al., 1989). 
These events are coincident with the transition of the site of erythropoiesis from the 
yolk sac, in the early  embryo, to the fetal liver (Migliaccio et al., 1986). The second 
switch involves the perinatal decline of HbF synthesis coupled with the increased 
synthesis of the adult form of hemoglobin (HbA, α2β2). Unlike the well-studied fetal-
to-adult globin transition, little is understood about the control of the embryonic-to-
fetal globin transition. Nevertheless, multiple studies have indicated, by means of 
comparative globin gene expression, that the embryonic-to-fetal globin switch occurs 
after 10 weeks of gestation. One study found that the relative abundance of ϵ-globin 
mRNA transcripts in mid-gestational human fetal liver was less than 1% that of γ-
globin, and ζ-globin transcripts less than 5% that of α-globin (Ley et al., 1989). More 
recently, Al-Mufti and colleagues (2000) reported that 25% of erythroblasts express 
the ζ-chain at 10 weeks, but decreased exponentially with gestation to less than 1% 
by 17 weeks. Similarly, expression of the ϵ-chain decreased from 97% of 
erythroblasts at 10 weeks to less than 1% by 25 weeks. In contrast, expression of the 
γ-chain increased from about 30% at 10 weeks to 90% by 16 weeks. From our study 
meanwhile, we established that this switch happened as early as the 13th week of 
gestation. 
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The embryonic to fetal hemoglobin switch has never been associated with the pre- 
and post- flow placenta. Here I have shown that this switch tightly correlates with this 
trophoblast plug rupture-induced physiological change. As the major physiological 
change that the chorionic villi see is a switch from low oxygen to oxygen-rich 
maternal blood, it is intriguing to note that embryonic hemoglobins have a higher 
affinity for oxygen than do fetal or adult hemoglobins (Brittain, 2002) with 4, 12 and 
6 mm Hg for the three human embryonic proteins compared to 20 and 26 mm Hg for 
the human fetal and adult proteins. I would thus speculate that this embryonic to fetal 
hemoglobin switch is functionally linked to trophoblast plug rupture. With low 
oxygen prior to rupture, the placenta requires hemoglobin with higher affinity to 
capture oxygen compared to when oxygen-enriched maternal blood is in immediate 
contact with the syncytiotrophoblast.
Additionally, EPAS1 has been implicated in hemoglobin regulation (Beall et al., 
2010; Yi et al., 2010), although the exact molecular mechanism has not been 
elucidated. The presence of oxygen post-flow, and its subsequent  effect on EPAS1 
activity, could also likely mediate the changes seen in hemoglobin gene expression. 
However, because our hESC-derived trophoblast culture (see Chapter 4) does not 
express hemoglobin, we are unable to confirm if EPAS1 directly  targets hemoglobin 
genes, but this does not exclude the possibility  of EPAS1 regulating hemoglobin gene 
expression in chorionic villi. 
Overall, our results fully  corroborate the current understanding of hemoglobin 
switching. Our data reveals gene expression in chorionic villi of the placenta, 
admittedly comprising pooled populations of various cell types. Although the role of 
the placenta in erythropoiesis has yet  to be clearly established, recent studies have 
183
suggested that it has a broader role as a hematopoietic organ than previously 
appreciated, functioning as an integral component of both primitive (embryonic) and 
definitive (fetal/adult) hematopoiesis (Rhodes et al., 2008; Barcena et al., 2009a & 
2009b; Robin et al., 2009; van Handel et al., 2010). Barcena and colleagues (2009) 
successfully  isolated, from human placental chorionic villi, multipotent primitive 
hematopoietic progenitors as well as intermediate progenitors, which is indicative of 
active hematopoiesis. The population of these progenitor cells increased throughout 
early gestation, peaking at 5 to 8 weeks, then decreasing more than 7-fold from the 9th 
week onwards. Additionally, van Handel et al. (2010) identified ζ-globin+ primitive 
erythroid cells in placental villi between 5 to 7 weeks of development. Our findings 
are thus consistent with earlier studies, in which we found predominant expression of 
embryonic globin genes in human chorionic villi prior to 9 weeks of gestation. 
Moreover, the loss of ζ- and ϵ-globin expression from 13 weeks onwards was met 
with predominant expression of α- and γ-globin genes, signifying the onset of fetal 
hematopoiesis. Our results therefore provide evidence in support of the placenta as a 
hematopoietic organ. 
5.6.2. Changing state of the placenta: Anti-coagulatory to pro-coagulatory. 
We also report the emergence of genes involved in the blood coagulation cascade as 
candidates important during the transition from first to second trimester. In the case of 
PROCR, transcriptional data bears little insight to its activity  as it is the protein form 
that dictates its contribution to the coagulation process. As a protein, it could act 
either as an enhancer in its membrane-bound form (Walker, 1981; Walker et al., 
1987), or as a hindrance, in its soluble form (Van de Wouwer et al., 2004). 
184
Meanwhile, the upregulation of F3 and F13A1, components of the blood coagulation 
cascade (Morrissey  et al., 1987; Spicer et al., 1987; Mackman et  al., 1989; 
Konigsberg et al., 2001), as well as the downregulation TFPI and TFPI2, both 
inhibitors of the TF-dependent pathway of the cascade (Broze and Miletich, 1987; 
Girard et al., 1989; Novotny et al., 1989; Petersen et al., 1996; Udagawa et al., 2002), 
testifies to the increased activity of the blood coagulation cascade in the second 
trimester. F3, coding for tissue factor (TF), the potent initiator of the TF-dependent 
pathway, has also been found strongly expressed in syncytiotrophoblasts (Reverdiau 
et al., 1995; Aharon et al., 2004). Some suggest that this procoagulant tendency may 
reflect a physiological need for immediate inhibition of hemorrhage in the placental 
intervillous space (Lanir et al., 2003; Dusse et al., 2006). Moreover, the presence of 
coagulant activity  in the amniotic fluid during the second and third trimester is a well-
known phenomenon (Lockwood et al., 2000; Uszynski et al., 2001). Our data 
accordingly  indicates that second-trimester placental villi tend toward a procoagulant 
state, in response to the onslaught of maternal blood, likely in a bid to minimize risk 
of hemorrhage.
Conversely, in the first trimester, the upregulation of TFPI and TFPI2 reflects an anti-
coagulant environment during this time. Having previously  established the expression 
of TFPI2 in syncytiotrophoblasts (Udagawa et al., 1998), Udagawa and colleagues 
(2002) later examined the association between the presence of the 
syncytiotrophoblast layer and coagulation using clinical specimens, revealing that 
fibrin deposits were specifically observed in regions devoid of the 
syncytiotrophoblast layer in placental villi. Such local inhibitory  mechanisms limit 
coagulation and fibrin deposition, in favor of patency for intervillous blood flow 
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(Udagawa et al., 2002; Lanir et al., 2003). This anti-coagulant environment is 
composed in preparation for the onset of maternal blood flow, thus enhancing the 
flow of blood into the placenta. This phenomenon is well in agreement with 
endovascular trophoblast invasion and remodeling of the spiral artery into dilated 
inelastic tubes, reducing flow resistance and increasing uteroplacental perfusion to 
the fetus (Brosens et al., 1967; Robertson and Manning, 1974; Robertson, 1976; 
Hirano et al., 2002). 
The increased expression of the anti-protease A2M suggests a propensity toward the 
inhibition of the blood coagulation cascade in the second trimester, conflicting with 
the earlier justification of a procoagulant state. On the contrary  however, A2M, an 
anti-protease, inactivates a large variety of proteases, not exclusive to the components 
of the blood coagulation cascade alone. It also inhibits plasmin and kallikrein 
(Harpel, 1970 and 1977; Schapira et al., 1982; van der Graaf et al., 1983; Kaufman et 
al., 1999), hampering fibrinolysis, a process in which the fibrin clot, the product of 
coagulation, is broken down. In this regard, A2M is also a contributor to the 
procoagulant state of the second trimester placenta.
5.6.3. Complement system and pregnancy.
Complement system activation has been associated with pregnancy (Baines et al., 
1974; Hopkinson and Powell, 1992; Richani et al., 2005). Complement products are 
deposited on placental tissue, in both physiological as well as pathological pregnancy 
(Faulk et al., 1980; Weir, 1981; Tedesco et al., 1990). It has been postulated that the 
complement system plays a key role in protecting the fetus, at the feto-maternal 
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interface, from potential pathogens invading the uteroplacental unit (Girardi et al., 
2006; Girardi et al., 2011). 
Our data, beginning at  ~8 weeks and leading to ~14 weeks, indicates upregulation of 
the complement pathway during second trimester, indicated by the increased 
expression of complement components C1q, C1r and CFD, which culminate in the 
activation of C3-convertase through both alternative and classical pathways. At this 
juncture, we find downregulation of DAF/CD55, an inhibitor of C3-convertase, as 
well as upregulation of the C3a complement receptor. Further down the cascade, C7 
was also found upregulated, while the inhibitory  CD59 was downregulated (Fig. 5.6). 
Overall, our data suggests that activity of the complement system increases between 
first and second trimester, coinciding with the onset of maternal blood. The activation 
of the complement system during this time could likely provide immuno-protection 
from potential pathogens found in maternal circulation.
However, this increased activity  has to be properly  controlled and/or limited, as 
excessive complement activation in the placenta has been associated with 
unsatisfactory pregnancy outcomes (Sinha et al., 1984; Shamonki et al., 2007; Lynch 
et al., 2008; Buurma et al., 2012). Trophoblasts express complement regulatory 
proteins, such as DAF/CD55 and CD59, from at least 6 weeks of gestation until term, 
likely serving to regulate the complement pathway (Holmes et al., 1992; Xu et al., 
2000). Dysregulation of the complement pathway has been associated with 
preeclampsia, IUGR, and fetal rejection (Sinha et al., 1984; Tedesco et  al., 1990; 
Girardi et  al., 2006; Lynch et al., 2008; Buurma et  al., 2012), although the origins of 
dysregulation remain unknown. Sinha et  al. (1984) found increased deposition of 
C1q, C3d, and C9 in preeclamptic tissue. Similarly, Wang et al. (2012) demonstrated 
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elevated C3 deposition in preeclamptic placentae, and also reported that complement 
3a receptor activation is a key mechanism to sFlt1 secretion and subsequent 
decreased angiogenesis. An earlier study had also linked complement activation with 
increased sFlt1, a potent anti-angiogenic protein associated with placental 
dysfunction (Girardi et al., 2006). Buurma et al. (2012) found upregulated mRNA 
expression of complement regulatory proteins CD55 and CD59 in preeclampsia. It 
was postulated that  complement regulatory proteins were upregulated in response to 
excessive complement activation, but their regulatory capacity  may nevertheless be 
overwhelmed, leading to development of pathological pregnancy (Denny et al., 
2012). 
In conclusion, there is evidence for increased classical pathway activation and altered 
complement regulation in preeclampsia, leading to angiogenic factor imbalance. 
These data indicate that immunological mechanisms are operating within the 
chorionic villi of the placenta during preeclampsia, suggesting that among other 
mechanisms, immune processes may  be operative in the pathophysiology of this 
disease (Sinha et al., 1984).
5.6.4. Recognizing important placental genes. 
In our study, we next chose to focus on genes that were highly expressed in the 
placenta, with the understanding that the magnitude of expression is reflective of their 
role in the development and maintenance of pregnancy. These include the hCG genes, 
a family well known and equally well studied for their involvement in pregnancy, as 
well as five other genes, CSH1, GDF15, PPIB, EBI3, and FTL. 
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It was no surprise that genes specifying the human chorionic gonadotropin hormone 
(hCG) emerged as most abundant. hCG is essential to pregnancy  success, by  playing 
a part in the production of steroid hormones and other growth factors in the corpus 
luteum (Jaffe et al., 1969; Hay and Lopata, 1988; Rao, 2001), in the modulation of 
blastocyst implantation as well as human trophoblast differentiation and fusion 
(Srisuparp et al., 2001; Yang et al., 2003; Handschuh et al., 2007), in uterine 
vascularization and angiogenesis (Zygmunt et al., 2002; Berndt et al., 2006; Bourdiec 
et al., 2012), and uterine quiescence and immunological adaptation during pregnancy 
(Toth et al., 2001).
hCG is synthesized by the trophoblast shortly after fertilization, and later, by 
placental tissue (Ruddon et al., 1981; Hay, 1988; Hay and Lopata, 1988). Levels of 
hCG in maternal serum rise rapidly during early gestation, peaking at 10 to 12 weeks, 
declining steadily thereafter (Diczfalusy, 1953; Midgley and Jaffe, 1968). In the third 
and final trimester, hCG level rises in a gradual, yet significant, manner until term 
(Boothby et al., 1983; Hay, 1988). Multiple studies have reported that placental levels 
of hCG-β peak at 9 to 10 weeks of pregnancy, and fall thereafter up to the 16th week 
(Bo and Boime, 1992; Jameson and Hollenberg, 1993; Miller-Lindholm et al., 1997). 
Our results show a general trend of increasing levels of hCG expression as gestational 
age approaches 9 weeks, and at 13 weeks onward, indicate a decrease in expression 
levels, across CGA and all CGB genes, well in accordance with previously observed 
patterns.
Similarly, we established expression profiles for five other genes whose respective 
expressions were highest in the placental samples. These genes include those that 
have long been known to be expressed during pregnancy, such as CSH1 and FTL, as 
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well as more recent discoveries of placental genes, like GDF15 and EBI3. The effects 
of CSH1 work in parallel, increasing maternal food intake, and at the same time 
promoting maternal beta-cell expansion and insulin production to defend against 
development of gestational diabetes mellitus (Mannik et al., 2012). Based on our 
results, CSH1 expression in the placenta increased as pregnancy entered the second 
trimester, in keeping with the metabolic demands of the growing fetus, which is thus 
in line with its known functions (reviewed in Newbern and Freemark, 2011; Mannik 
et al., 2012). Likewise, our results show that the expression of FTL increased with 
gestational age, thereby increasing cellular iron stores to meet  the demands of the 
growing fetus (Scholl, 2005). The FTL expression identified in our samples 
represents placental isoferritin, the intracellular iron storage protein found in the 
cytoplasm of placental syncytiotrophoblasts (Li et al., 2008). Levels of placental 
isoferritin in circulation have been correlated with pregnancy outcome. Multiple 
studies reported that elevated levels of placental isoferritin during the second 
trimester were predictive of early  spontaneous preterm delivery (Goepel et al., 1988; 
Maymon et al., 1989; Goldenberg et al., 1996; Tamura et al., 1996), although this was 
likely a reflection of an acute-phase reaction to subclinical infections, which are 
closely associated with premature delivery (Tamura et al., 1996).
Meanwhile, for GDF15, although its expression has been identified in the placenta 
(Fairlie et al., 1999; Herse et al., 2007; Sugulle et al., 2009), its biological role during 
pregnancy has yet to be understood. Nevertheless, it is known to promote 
angiogenesis, under hypoxic conditions, in human umbilical vein endothelial cells, by 
modulating HIF1α signaling (Song et al., 2012). It thus stands to reason that GDF15 
could likely be a contributor to angiogenesis in placental development during first 
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trimester, when oxygen is low. Moreover, its dysregulation in preeclamptic, as well as 
diabetic, pregnancies signifies its importance in a successful and healthy pregnancy 
(Herse et al., 2007; Sugulle et al., 2009). 
EBI3 too is highly expressed in placental cells during pregnancy (Devergne et  al., 
2001), and also differentially expressed in preeclamptic placentae (Enquobahrie et al., 
2008; Kang et al., 2011; Mayor-Lynn et  al., 2011; Nishizawa et al., 2011). 
Interestingly, EBI3 and IL27, which together make up  the heterodimeric cytokine 
IL27, were both more lowly expressed post-flow, although the change in the latter 
was not significant. IL27 has a regulatory  role in the adaptive immune response, 
which is responsible for recognizing foreign antigens (Janeway et al., 2001). In 
pregnancy, the maternal immune system faces a major challenge in the tolerance of 
fetal allo-antigens, encoded by  paternal genes. The downregulation of EBI3, could 
therefore likely  help maintain maternal immune tolerance toward the fetus (Coulomb-
L’Hermine et al., 2007; Louwen et al., 2012).  
Additionally, our study  also demonstrated potential in identifying novel genes 
important in pregnancy. Our findings revealed the expression of genes previously  not 
recognized during pregnancy, for example PPIB. The PPIB gene thus far is only 
postulated to be implicated in pregnancy through its function as a chaperone for the 
nuclear transport and action of the somatotropin/prolactin hormone family (Rycyzyn 
et al., 2000; Fang et al., 2010). Given the integral position of this hormone family in 
pregnancy, it stands to reason that  its regulator would emerge as an essential gene 
transcribed during pregnancy. 
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5.6.5. Influence of the uterine environment on preeclampsia pathogenesis.
Of the genes already discussed, three are known to be implicated in pregnancy 
complications; GDF15 expression is dysregulated in preeclampsia and diabetic 
pregnancies (Sugulle et al., 2009), PROCR mutations have been associated with late 
fetal loss (Franchi et al., 2001), and factor XIII (F13A1) deficiencies can result in 
recurrent spontaneous miscarriage (Ichinose et al., 2005; Asahina et al., 2007). Our 
differential analysis unveiled at least six other genes associated with preeclampsia, 
revealing the influence of the uterine environment on their regulation. 
Firstly, LEP, INHA, INHBA, ENG, and FLT1 (albeit a novel isoform) were 
downregulated in the second trimester. While the placental expression of LEP has 
been widely  demonstrated (Hassink et  al., 1997; Masuzaki et al., 1997; Senaris et al., 
1997; Henson et al., 1998), no study thus far has tracked its expression levels 
throughout the course of pregnancy. Regardless, LEP expression is markedly 
augmented in preeclamptic placenta in comparison to gestational age-matched 
healthy controls (Mise et  al., 1998). Multiple studies also suggest a close correlation 
between fetal growth restriction and elevated LEP levels found in maternal serum 
(Schubring et al., 1996; Mise et  al., 1998; Lepercq et al., 1999; Ong et al., 1999). 
Overall, LEP is postulated to be involved in the regulation of fetal growth, placental 
angiogenesis, and mobilization of maternal fat (Wauters et al., 2000; Hoggard et al., 
2001), implying that dysregulation of leptin metabolism and/or leptin function in the 
placenta would result in the pathologies of pregnancy disorders, such as gestational 
diabetes, IUGR, and preeclampsia (Bajoria et al., 2002; Sagawa et al., 2002). 
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Interestingly, in a study done to elucidate the mechanisms for augmented placental 
production of leptin in preeclampsia, the authors found that  leptin secretion was 
enhanced in extended hypoxic conditions (Mise et al., 1998). The authors thus 
proposed that placental insufficiencies, which plague preeclampsia, lead to chronic 
hypoxia of the trophoblast cells, therefore resulting in augmented LEP production. In 
this scenario, the same placental insufficiencies also result in chronic disturbance of 
nutrient and oxygen supply to the fetus, thereby leading to IUGR. Our study offers 
support to their hypothesis in the form of oxygen-regulated expression of placental 
LEP; we observed downregulation of LEP in the second trimester, following 
perfusion of the placenta by oxygenated maternal blood. Whether or not increased 
oxygen levels directly triggered this change however remains to be seen, since LEP 
expression is also induced by hCG (Maymo et al., 2012), which we found 
downregulated as well. 
INHA and INHBA, together make up inhibin A, while a homodimer of INHBA forms 
activin A (Stewart et al., 1986). Several studies have showed that levels of inhibin A 
peaked at 8 to 10 weeks gestation, declining thereafter, but rose gradually  again 
throughout the third trimester (Muttukrishna et al., 1995; Illingworth et al., 1996; 
Birdsall et al., 1997). Our data demonstrates a similar trend for the expression of 
INHA and INHBA in the first and second trimester. While inhibins and activins have 
been shown to regulate gonadotropin-releasing hormone, hCG, and progesterone 
secretion from cultured human placental cells (Petraglia et al., 1989), the biological 
role of activin A and inhibin A in early pregnancy however remain unclear. 
Nevertheless, further in vivo studies have revealed that activin A is capable of 
inducing cell migration and invasion, thus regulating human cytotrophoblast 
193
differentiation (Caniggia et al., 1997; Bearfield et al., 2005). However, evidence has 
shown elevated placental expression of both inhibin A and activin A in preeclampsia 
(Jackson et al., 2000; Manuelpillai et al., 2001; Florio et al., 2002; Casagrandi et al., 
2003; Yu et al., 2012), which is inconsistent with the invasion-promoting effect of 
activin A, given the restricted invasive properties of trophoblast cells in preeclamptic 
placenta (Yu et al., 2012). On the other hand, Yu and colleagues (2012) recently 
demonstrated that high levels of activin A, acting via Nodal signaling, induce 
apoptosis in trophoblast cells (Munir et al., 2004; Nadeem et al., 2011), which could 
conceivably lead to the preeclamptic outcome. Yet, it might be prudent to note that it 
is not fully understood if activin A and inhibin A play a role in the pathology of 
preeclampsia, or if their expression is merely a manifestation of the disease. To that 
end, an understanding of their regulation would be necessary to elucidate the 
underlying mechanism of their function. Our findings mark the first step, in which we 
can begin to understand how the uterine environment regulates their expression, and 
how this might go awry in a condition like preeclampsia. 
Endoglin (ENG) and sFlt1 are both endogenous anti-angiogenic factors (Park et al., 
1994; Toporsian et al., 2005). Endoglin, expressed in vascular endothelial cells and 
placental trophoblasts, is a surface receptor for TGF-β1 (Lastres et  al., 1996), and in 
this manner it impairs binding of TGF-β1 to its other receptors, thus leading to 
dysregulation of TGF-β1 signaling and subsequent effect on vasodilation (Yang et al., 
2008). sFlt1 meanwhile binds to VEGF and placental growth factor (PGF), blocking 
their angiogenic effect  on vascular tissue (Park et al., 1994; Shibuya, 2006; Yang et 
al., 2008). PGF plays an important role in enhancing VEGF-driven angiogenesis; the 
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loss of which impairs angiogenesis, wound healing, and inflammatory  responses 
(Autiero et al., 2003; Nagy et al., 2003). 
Our data demonstrates the downregulation of endoglin and sFlt1 in the second 
trimester, which in preeclamptic pregnancies, were upregulated in both placenta and 
serum (Koga et al., 2003; Maynard et al., 2003; Venkatesha et al., 2006; Yang et  al., 
2008). Excess levels of endoglin and sFlt1 may offset VEGF, PGF, and TGF-β1 
activity, impairing maternal vascular endothelial functions and inducing glomerular 
endotheliosis (Maynard et al., 2003; Venkatesha et al., 2006), both of which have 
been implicated as major components in the pathogenesis of preeclampsia (Levine et 
al., 2004; Levine et al., 2006). Moreover, Yang et al., (2008) also demonstrated that 
trophoblast cultures from preeclamptic placentae produced more endoglin and sFlt1 
than those from healthy placentae, and that additionally, hypoxic conditions promoted 
endoglin and sFlt1 production. In the context of preeclampsia, with its concomitant 
placental insufficiencies, the hypoxic conditions may only  exacerbate the 
pathogenesis.
Interestingly, thrombin, a mediator of blood coagulation, has been associated with 
sFlt1 regulation (Lockwood et  al., 2007; Zhao et al., 2012). We report that the 
placental environment undergoes a switch from anti- to pro-coagulatory state, 
implying the increase in activity of thrombin between first  and second trimesters. 
Although this is not reflected in gene expression, the precursors to thrombin and its 
inhibitors are accordingly regulated, facilitating the switch to a pro-coagulatory 
environment. Thrombin has been found to promote sFlt1 expression in decidual cells 
(Lockwood et al., 2007) as well as trophoblasts (Zhao et al., 2012), and with the 
decreased activity/presence of thrombin in first trimester, this indicates that sFlt1 is 
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adherently  regulated and not found in excess. This sits well with the development of 
the placenta, as during this time, the activity of the anti-angiogenic sFlt1 would be 
detrimental. It would otherwise promote preeclampsia by  interfering with local 
vascular transformation. This exemplifies the interconnectedness between 
components of the biology of pregnancy, and thus the need for holistic regulation, as 
dysregulation of one component (i.e. blood coagulation) has far-reaching 
repercussions (i.e. angiogenesis, which is outside of blood coagulation) that may 
affect the health of the entire system (i.e. pregnancy). Moreover, the increased 
activity of the coagulation cascade in the second trimester would promote sFlt1 
expression, and it is thus also necessary for fine regulation to ensure that sFlt1 is not 
produced in excess, as the placenta continues to grow and remodel throughout 
pregnancy. This regulation, which we postulate to be oxygen-mediated EPAS1 
regulation of FLT1, is implied in our findings as even with increased activity  of blood 
coagulation, sFlt1 expression is downregulated. 
Secondly, our study demonstrates the upregulation of SPP1 and HGF in the second 
trimester. The SPP1/OPN protein is an extracellular matrix protein implicated in cell 
adhesion, spreading, and invasion (Franzen and Heinegard, 1985; Fisher et al., 1987; 
Johnson et  al., 2003). It is expressed in the placenta, with evidence for its role in 
regulation of placental invasiveness (Young et al., 1990; Gabinskaya et  al., 1998; 
Briese et al., 2005). In first trimester placenta, SPP1/OPN was present in the villous 
trophoblast, with strongest expression in the cytotrophoblast. Briese and colleagues 
(2005) also reported that SPP1/OPN presented strong expression in EVTs at  the 
invasion front of normal placenta, colocalizing with CEACAM1 (carcinoembryonic 
antigen-related cell adhesion molecule 1). Both SPP1/OPN and CEACAM1 interact 
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with integrin β3, playing an important  role in the implantation and invasion process 
(Brummer et al., 2001; Damsky et al., 1994). SPP1/OPN however is not expressed in 
the syncytial trophoblast (Daiter et al., 1996). 
Our results show an upregulation of SPP1 from the 13th week onwards, upon 
perfusion of the placenta, which indicate an affinity  for invasiveness in the presence 
of oxygenated maternal blood, therein implying the ability of the trophoblast in 
oxygen sensing and in response, placental remodeling. While the mechanism 
employed by trophoblast cells for oxygen sensing is yet to be fully understood 
(Hunkapiller and Fisher, 2010), an investigation of the effect of oxygen on 
trophoblast invasion, both endovascular and interstitial trophoblast invasion were 
reduced in arteries at 3% oxygen, compared to arteries at 17% oxygen (Crocker et al., 
2005). Logically then, the presence of oxygen accompanying maternal blood flow 
into the placenta would elicit an increase in invasion-mediating proteins in response. 
HGF expression has been found in the syncytial and extravillous trophoblasts, as well 
as the mesenchyme cells of the villous core, while the expression of its receptor Met 
was localized mainly  to cytotrophoblasts (Wolf et al., 1991; Kauma et al., 1997). 
Thus it was postulated that placental HGF acts in a paracrine manner on trophoblasts 
expressing Met. HGF, by nature of its potential in stimulating the invasion of multiple 
epithelial cell types (Tsarfaty et al., 1994; Kalluri and Neilson, 2003), is also thought 
to regulate placental trophoblast invasion. In fact, HGF-knockout mice were found to 
be embryonic-lethal due to abnormal placental development (Uehara et al., 1995). A 
study done by Kauma et al. (1999) showed that HGF expression was diminished in 
placentae from preeclamptic pregnancies, in line with the inadequate trophoblast 
invasion that is characteristic of this condition. The authors thus proposed that 
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decreased placental production of HGF in preeclampsia provides a potential 
mechanism for shallow trophoblast invasion that is seen in this pregnancy disorder 
(Kauma et al., 1999). Our findings demonstrate the upregulation of HGF at the 
beginning of the second trimester, and as with the case of SPP1, increased HGF 
during this time indicates invasiveness on the part  of the trophoblast for placental 
remodeling, in response to the presence of maternal blood. 
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5.7. Concluding remarks.
Like our study, two other studies have sought to understand the dynamic regulation of 
genes throughout pregnancy (Mikheev et al., 2008; Sitras et al., 2012). Sitras and 
colleagues (2012) juxtaposed placental gene expression between late first  trimester 
(9-12 weeks) and that at term, while Mikheev and colleagues (2008) compared 
expression at mid-first trimester (6-8 weeks) and second trimester (approximately  16 
weeks). Our study is notable in that we characterized gene expression across the 
shortest time period (7-9 weeks vs.. 13-15 weeks), capturing the changing biology 
occurring during the most drastic transformation of the uterine environment - 
placental perfusion and oxygenation. 
In summary, our study derived a set of genes showing significant change in 
expression level between late first trimester and early  second trimester of pregnancy, 
two time points which were chosen to contrast the situation prior to and after the 
perfusion of the placenta by maternal blood. Of the genes identified, we found six 
genes implicated in the blood coagulation cascade, and nine associated with the 
complement cascade. Additionally, we were able to determine the first-to-second 
trimester expression profile of multiple genes known to be important in pregnancy. 
Many of these genes also have prior implications in preeclampsia and other 
pregnancy complications, including gestational diabetes and IUGR. 
The data set from this study  stands strongly and independently as a tool to further 
understand the intrauterine environment and its concomitant changes throughout 
pregnancy. From our assessment of differential gene expression, we postulate that the 
blood-devoid first trimester placenta is placed in an anti-coagulant state, later 
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switching to a pro-coagulant state during the second trimester in the presence of 
maternal blood. The former setting facilitates entry of blood into the placenta, 
allowing a smooth undisturbed flow, while in the latter, the placenta readies itself to 
limit blood loss, due to trauma or otherwise. In addition, our data unveiled the 
production of hemoglobin genes, by cells of the chorionic villi, switching from 
embryonic to fetal globin between first and second trimester, supporting the role of 
the placenta as a hematopoietic organ. We were also able to analyze the expression of 
a well known set of pregnancy-associated genes, the hCG family, and in doing so, 
identified the expression profiles of respective genes throughout the transition 
between first and second trimester. 
Our findings highlighted the top  most highly  expressed genes in the placenta that 
were differentially expressed across this transition. Four of these genes, CSH1, 
GDF15, EBI3, and FTL, have already  been recognized as important in pregnancy, 
while the last, PPIB, is a novel finding on our part. We postulate that the increased 
expression of CSH1 and FTL in the second trimester was in keeping with the 
metabolic demands of the growing fetus. GDF15 and EBI3, both recently identified 
in the placenta, remain unresolved with regard to their biological role in pregnancy, 
but with our data outlining their downregulation in second trimester, we gain an 
insight to their response to placental perfusion, and clues to their roles in the placenta. 
Likewise for PPIB, the question of its role and regulation persists. Admittedly, our 
study uncovers as many  questions as it resolved to answer, as with many other 
instrumental studies. 
Lastly, our data also shed light on the placental expression of genes known to be 
dysregulated in preeclampsia. Based on what is known of respective genes, our study 
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substantiates the standing hypotheses for the function and roles they play in the 
pathogenesis of preeclampsia. A preliminary look indicates that many genes which 
were downregulated post-flow (i.e. higher in first trimester: GDF15, PROCR, LEP, 
INH, INHA, ENG, FLT1, CD55, and CD59) have been implicated in preeclampsia, 
with augmented expression observed in the preeclamptic as compared to healthy 
placenta. This suggests an incomplete switch on the part of the placental cells from 
the pre-flow state to post-flow, with insufficient downregulation of those genes, 
which could be attributed to inadequate trophoblast  invasion during placental 
development, and thus ineffective perfusion. 
Multiple studies have proposed the use of select  molecules as predictors of 
preeclampsia (Lynch et al., 2008; Lopez-Novoa, 2007; Leanos-Miranda et al., 2013), 
but we propose that a more extensive and comprehensive list of contributors to the 
pathogenesis of preeclampsia be considered. More pertinently, the genes that have so 
far been associated with the pathogenesis of preeclampsia also emerge in our 
analysis, as being differentially expressed between pre- and post-flow. Apart  from 
signifying the potential of our list in identifying indicators of preeclampsia, this also 
suggests that regulation during this stage of placental development (trophoblast plug 
rupture, and the transition from pre- to post-flow and its accompanying change in 
oxygen), is crucial to determining the health of the pregnancy, and if preeclampsia 
develops. 
The pinnacle of this study would be to derive a comprehensive set of gene markers, 
measured from maternal serum, which exhibit dynamic expression between two time 
points (i.e. pre- and post-flow), that are reflective of the physiological changes 
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occurring in the uteroplacental unit. This set  of markers would thus be used as the 





Due to ethical restrictions, the only  means of studying the human placenta is by 
surveying and interrogating discarded tissue. Even then, access to such material is 
limited. Animal models, although useful in the right context, bear stark differences in 
reproductive physiology. As such, there is a scarcity of appropriate in vivo models for 
the trophoblast  lineage. Inevitably, in vitro systems become the popular choice, and 
by manipulating growth conditions, including oxygen, efforts remain to capture and 
maintain various trophoblast cell types, and subsequently study  their progression of 
differentiation down the lineage. 
Exploiting the in vitro system, we investigated the role of a key transcription factor 
in the trophoblast by  identifying its gene targets within a biological context. With this 
work, we are starting to see the EPAS1-regulated pathways in the trophoblast, and 
this finding is set  to expand with the more comprehensive list currently being 
analyzed. In conjunction with the data obtained from the human placental 
transcriptome, it would be most intriguing to study how EPAS1-regulated genes are 
changing across first and second trimester placenta, tying it in with hypoxia and the 
reproductive success the Tibetans are observing despite their low oxygen habitat. 
While we anticipate further verification, we were fortunate enough to gain access to 
human tissue samples, which overall led to a two-pronged approach to studying 
oxygen-mediated gene regulation in the placenta. The information laid out in this 
thesis is only  the tip of the iceberg. With access to the placental transcriptome across 
a crucial developmental milestone, we can not only begin to understand the changes 
in the early  placenta, we can then apply this understanding to address pregnancy 
complications, such as preeclampsia. The work achieved in this dissertation presents 
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a novel and rich resource useful not only  for human reproduction and developmental 
biologists, but also for more niche fields like hematopoiesis. 
The vast expanse of information extracted from the global transcriptomic analysis 
will lead to countless options for further data mining; one of which, presently 
underway in the lab, is the search for novel genes and/or isoforms expressed in the 
early placenta. Given the sample design, we are also able to track how the expression 
levels of these novel sequences change with progression into the second trimester, 
thereby presenting with the first means of understanding their role and association 
with the placenta. Ideally, the secondary layer of analysis would then be to compare 
against the diseased or compromised tissue.
Bearing in mind the complexity, coupled with the transience of the placenta as an 
organ, the pace at which it forms and then performs its multitude of tasks is 
remarkable. The effort to fully  understand the placenta will be no less than a dizzying 
maze of information and postulations. We believe, and we hope, the evidence and 
ideas presented in this dissertation will go a long way to this cause.
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Forward Reverse Amplification of:
GGAGAGGAGGAAGGAGAA GCTTGGTGAATAGGAAGT EPAS1 exons 2 to 7
TTCCCATCCTTCCACATC GTTCAGTTCCACACCTTT SNP site
ACCTGCCCCTCACTCCACCCCC GCGGCTGACTGTGGGGTGTCC CA9 binding site 
AGTGTCCGTTCCCAGCTCAG TAGGCACAGTAAACAGGCCC PHD3 binding site
GGGTGAAGGTGACAGCAAGT ACACAGACTCAACGTGCCA BID17 binding site 






















































































































































































































































































































































































































































































































































































































































































































































































































    
Supplementary Table 2. List of pathways and genes from gene ontology analysis.
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